SRAX (SRAX) 10-K 31 Mar 21 2020 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2020	Mar. 29, 2021	Jun. 30, 2020
Cover [Abstract]
Entity Registrant Name	SRAX, Inc.
Entity Central Index Key	0001538217
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 32,811,898
Entity Common Stock, Shares Outstanding		22,884,030
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2020

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	$ 451,000	$ 32,000
Accounts receivable, net	2,608,000	805,000
Prepaid expenses	367,000	715,000
Marketable securities	8,447,000	83,000
Other current assets		306,000
Total current assets	11,873,000	1,941,000
Notes receivable	893,000
Property and equipment, net	118,000	191,000
Goodwill	23,351,000	15,645,000
Intangible assets, net	2,409,000	1,966,000
Right of use assets	366,000	456,000
Other assets	3,000	35,000
Total assets	39,013,000	20,234,000
Current liabilities
Accounts payable and accrued expenses	3,561,000	2,442,000
Derivative liability		4,397,000
Other current liabilities	8,711,000	537,000
Payroll protection loan - current portion	747,000
OID notes payable - current portion	6,016,000
Total current liabilities	19,035,000	7,376,000
Right of use liability - long term	243,000	352,000
Payroll protection loan - long term	379,000
Deferred Tax Liability	131,000
Total liabilities	19,788,000	7,728,000
Commitments and contingencies (Note 16)
Stockholders' equity
Preferred stock
Class A common stock, authorized 250,000,000 shares, $0.001 par value, 16,145,778 and 13,997,452 shares issued and outstanding, respectively	16,000	14,000
Additional paid in capital	69,551,000	48,129,000
Accumulated deficit	(50,342,000)	(35,637,000)
Total stockholders' equity	19,225,000	12,506,000
Total liabilities and stockholders' equity	$ 39,013,000	$ 20,234,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares issued
Preferred stock, shares outstanding
Class A Common stock, shares authorized	250,000,000	250,000,000
Class A Common stock, par value	$ 0.001	$ 0.001
Class A Common stock, shares issued	16,145,778	13,997,452
Class A Common stock, shares outstanding	16,145,778	13,997,452

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenues	$ 8,647,000	$ 3,584,000
Cost of revenue	2,589,000	1,680,000
Gross profit	6,058,000	1,904,000
Operating expense
Employee related costs	7,895,000	8,656,000
Marketing and selling expenses	2,675,000	2,454,000
Platform costs	1,667,000	1,738,000
Depreciation and amortization	1,303,000	1,164,000
General and administrative expenses	4,115,000	5,750,000
Total operating expense	17,655,000	19,762,000
Loss from operations	(11,597,000)	(17,858,000)
Other income (expense)
Financing costs	(12,150,000)	(725,000)
Interest income		9,000
Gain on sale of SRAXmd, net	7,873,000	658,000
Exchange gain		12,000
Gains from marketable securities	874,000	(6,000)
Change in fair value of derivative liabilities	321,000	1,045,000
Total other income (expense)	(3,082,000)	999,000
Loss before provision for income taxes	(14,679,000)	(16,859,000)
Provision for income taxes	(26,000)
Net loss	$ (14,705,000)	$ (16,859,000)
Net loss per share, basic and diluted	$ (1)	$ (1.36)
Weighted average shares outstanding, basic and diluted	14,649,788	12,377,851

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2018		$ 10,000	$ 32,870,000	$ (18,778,000)	$ 14,102,000
Balance, shares at Dec. 31, 2018		10,109,530
Share based compensation			935,000		935,000
Sale of common stock and warrants for cash		$ 3,000	12,194,000		12,197,000
Sale of common stock and warrants for cash, shares		3,412,821
Common stock issued for exercise of warrants		$ 1,000	1,195,000		$ 1,196,000
Common stock issued for exercise of warrants, shares		342,000
Loss on repricing of warrants			342,000		$ 342,000
Common stock issued for services			374,000		374,000
Common stock issued for services, shares		75,000
Shares issued for settlement of original issue discount			219,000		219,000
Shares issued for settlement of original issue discount, shares		58,101
Net loss				(16,859,000)	(16,859,000)
Balance at Dec. 31, 2019		$ 14,000	48,129,000	(35,637,000)	12,506,000
Balance, shares at Dec. 31, 2019		13,997,452
Share based compensation			1,710,000		1,710,000
Relative fair value of warrants issued with notes payable			4,331,000		4,331,000
Shares issued for extension agreement			71,000		71,000
Shares issued for extension agreement, shares		36,700
Shares issued for debt extinguishment			181,000		181,000
Shares issued for debt extinguishment, shares		100,000
Conversion of debt to equity			434,000		434,000
Conversion of debt to equity, shares		411,626
Common stock issued for the acquisition of subsidiary		$ 2,000	4,262,000		4,264,000
Common stock issued for the acquisition of subsidiary, shares		1,600,000
Reclassification of warrants from liability to equity			4,076,000		4,076,000
Premium on debt extinguishment			46,000		46,000
Beneficial conversion feature			6,311,000		$ 6,311,000
Common stock issued for exercise of warrants, shares
Net loss				(14,705,000)	$ (14,705,000)
Balance at Dec. 31, 2020		$ 16,000	$ 69,551,000	$ (50,342,000)	$ 19,225,000
Balance, shares at Dec. 31, 2020		16,145,778

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Net loss	$ (14,705,000)	$ (16,859,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	1,852,000	1,167,000
Change in fair value of marketable securities	(874,000)	6,000
Gain on sale of SRAXmd	(7,873,000)	(658,000)
Change in fair value of derivative liabilities	(321,000)	(1,045,000)
Amortization of debt issue costs	9,128,000
Loss on extinguishment of debt	1,103,000
Loss on repricing of warrants		342,000
Additional value for Red Diamond		219,000
Provision for bad debts	64,000	482,000
Depreciation expense	73,000	74,000
Amortization of intangibles	1,230,000	1,089,000
Right of use of asset	90,000
Changes in operating assets and liabilities
Accounts receivable	(1,837,000)	1,638,000
Prepaid expenses	277,000	(106,000)
Other current assets	306,000	81,000
Accounts payable and accrued expenses	1,149,000	(2,214,000)
Right of use liability	(109,000)
Other current liabilities	3,042,000	434,000
Net cash used in operating activities	(13,489,000)	(15,350,000)
Cash flows from investing activities
Proceeds from the sale of securities held for sale	916,000
Proceeds from sale of SRAXmd	7,000,000	570,000
Acquisition of LD Micro, net of cash acquired	(697,000)	(73,000)
Development of software	(1,205,000)	(1,292,000)
Other assets	32,000
Net cash used in investing activities	(6,046,000)	(795,000)
Cash flows from financing activities
Proceeds from OID notes payable, less issuance costs	11,988,000
Redemption of OID notes payable	(6,070,000)
Proceeds from issuance of short-term notes payable less issuance costs	960,000
Repayment of short-term notes payable	(100,000)
Proceeds from payroll protection program	1,084,000
Proceeds from the issuance of notes payable	2,130,000
Repayment of notes payable	(2,130,000)
Proceeds from the issuance of common stock units		12,197,000
Proceeds from the exercise of warrants		1,196,000
Net cash provided by financing activities	7,862,000	13,393,000
Net increase / (decrease) in cash and cash equivalents	419,000	(2,752,000)
Cash and cash equivalents, Beginning of year	32,000	2,784,000
Cash and cash equivalents, End of year	451,000	32,000
Supplemental schedule of cash flow information
Cash paid for interest	176,000	140,000
Cash paid for taxes
Supplemental schedule of noncash financing activities
Common stock received in lieu of cash for account received	8,406,000	50,000
Record right to use assets		(526,000)
Record operating lease liability		526,000
Vesting of common stock award	94,000
Relative fair value of warrants issued with term loan	83,000
Derivative liabilities transferred to equity	4,076,000
Shares of common stock issued for extension agreement	71,000
Fair value of BCF for debt financings	6,311,000
Fair value of warrants issued for debt financings	4,248,000
Premium on debt financings	46,000
Original issue discount recorded on OID convertible debentures	1,931,000
Common stock issued to settle liability	181,000	219,000
Convertible notes converted into shares	434,000
Shares issued for the acquisition of a subsidiary	$ 4,264,000

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1 – ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization We are a technology firm focused on enhancing communications between public companies and their shareholders and investors. We currently have two distinct business units: ● Our unique SaaS platform, Sequire provides users many features which allow issuers to track their shareholders’ behaviors and trends, then use data-driven insights to engage with shareholders across marketing channels. ● Through LD Micro, we organize and host investor conferences within the micro and small- cap space, and plan to create several more niche events for the investor community. Our endeavor provides our clients an integrated investor and shareholder analytics platform drove us to develop this platform, acquire LD Micro, and begin cultivating the Sequire Community. Each SRAX business unit delivers valuable insights that assist our clients with their investor relations and communications initiatives. We are headquartered in Westlake Village, California but work as a distributed virtual Company. Liquidity and Going Concern The Company has incurred significant losses since its inception and has not demonstrated an ability to generate sufficient revenues from the sales of its goods and services to achieve profitable operations. In addition, the Company’s operations and specifically, the continued operation of BIGToken will require significant additional financing. As of December 31, 2020, the Company had cash and cash equivalents of $451,000 which is not sufficient to fund the Company’s planned operations through one year after the date the consolidated financial statements are issued, and accordingly, these factors create substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position, our cash flow and cash usage forecasts, and obligations and debts. Although management has a long history of successful capital raises, the analysis used to determine the Company’s ability as a going concern does not include cash sources outside the Company’s direct control that management expects to be available within the next 12 months. We expect that our existing cash and cash equivalents as of December 31, 2020, will not be sufficient to enable us to fund our anticipated level of operations through 2021. As discussed in Note 22 Subsequent events, the Company has raised approximately $16 million in net proceeds through the sale of equity securities and the exercise of warrants. We anticipate raising additional capital through the private and public sales of our equity or debt securities and selling our marketable securities or a combination thereof. Although management believes that such capital sources will be available, there can be no assurance that financing will be available to us when needed in order to allow us to continue our operations, or if available, on terms acceptable to us. If we do not raise sufficient capital in a timely manner, among other things, we may be forced to scale back our operations or cease operations altogether. During the year ended December 31, 2020, the Company was able to raise net cash proceeds (net of debt repayments, commissions, and fees) of approximately $7,900,000. The Company’s capital-raising efforts are ongoing and the Company has undertaken the following to raise capital and reduce its cash burn rate: (i) received a PPP Loan from the Small Business Administration for funding under the Payroll Protection Program, in the amount of $1,084,000 (ii) entered into an “At the Market” sales agreement for the sale of up to $3,125,000 of our equity securities, (iii) sold OID convertible debentures for proceeds of $13,268,000. Additionally, the Company sold its remaining position in TI Health (f/k/a SRAXmd) for a total of $8,000,000. Substantially, all of these proceeds were used to redeem a portion of our outstanding OID convertible debentures. The ultimate impact of the COVID-19 pandemic on the Company’s operations continues to be unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material impact on our business, financial condition and results of operations. The significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact. Management continues to monitor the business environment for any significant changes that could impact the Company’s operations. The Company has taken proactive steps to manage costs and discretionary spending, such as remote working and reducing facility related expenses. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of the Company and its subsidiaries from the acquisition date of majority voting control of the subsidiary. Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has two operating segments BIGToken and Sequire. Business Combinations For all business combinations (whether partial, full or step acquisitions), the Company records 100% of all assets and liabilities of the acquired business, including goodwill, generally at their fair values; contingent consideration, if any, is recognized at its fair value on the acquisition date and, for certain arrangements, changes in fair value are recognized in earnings until settlement and acquisition-related transaction and restructuring costs are expensed rather than treated as part of the cost of the acquisition. Use of Estimates The consolidated financial statements have been prepared in conformity with generally accepted accounting principles accepted in the United States of America (“GAAP”) and requires management of the Company to make estimates and assumptions in the preparation of these consolidated financial statements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and assumptions. The most significant areas that require management judgment and which are susceptible to possible change in the near term include the Company’s revenue recognition, allowance for doubtful accounts and sales credits, stock-based compensation, income taxes, borrowing rate considered for operating lease right-of-use asset and related operating lease liability, purchase price for acquisition, goodwill, other intangible assets, put rights and valuation of other assets and liabilities. Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist us in determining fair value, as appropriate. Although the Company believes that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values. The Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and accrued expenses, are carried at historical cost. At December 31, 2020 and 2019, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. The Company measures certain non-financial assets, liabilities, and equity issuances at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and goodwill for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations. Cash and Cash Equivalents The Company considers all short-term highly liquid investments with a remaining maturity at the date of purchase of three months or less to be cash equivalents. Accounts Receivable Credit is extended to customers based on an evaluation of their financial condition and other factors. Management periodically assesses the Company’s accounts receivable and, if necessary, establishes an allowance for estimated uncollectible amounts. Accounts determined to be uncollectible are charged to operations when that determination is made. The Company usually does not require collateral. Allowance for doubtful accounts was approximately $491,000 and $530,000 as of December 31, 2020 and 2019, respectively. Concentration of Credit and Significant Customer Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited with financial institutions within the United States. The balances maintained at these financial institutions are generally more than the Federal Deposit Insurance Corporation insurance limits. The Company has not experienced any loss on these accounts. As of December 31, 2020, the Company had two customers with accounts receivable balances of approximately 20.0% and 10.4%. As of December 31, 2019, the Company had three customers with accounts receivable balances of approximately 23.7%, 15.0%, and 13.7%. For the year ended December 31, 2020, the Company had one customer that account for approximately 18.1% of total revenue. For the year ended December 31, 2019, the Company had two customers that accounted for 17.7% and 12.9%. Long-lived Assets Management evaluates the recoverability of the Company’s identifiable intangible assets and other long-lived assets when events or circumstances indicate a potential impairment exists. Events and circumstances considered by the Company in determining whether the carrying value of identifiable intangible assets and other long-lived assets may not be recoverable include, but are not limited to: significant changes in performance relative to expected operating results; significant changes in the use of the assets; significant negative industry or economic trends; a significant decline in the Company’s stock price for a sustained period of time; and changes in the Company’s business strategy. In determining if impairment exists, the Company estimates the undiscounted cash flows to be generated from the use and ultimate disposition of these assets. If impairment is indicated based on a comparison of the assets’ carrying values and the undiscounted cash flows, the impairment loss is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairments have been recorded regarding its identifiable intangible assets or other long-lived assets during the years ended December 31, 2020 or 2019, respectively. Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets of three to seven years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment. Intangible assets Intangible assets consist of intellectual property, a non-compete agreement, and internally developed software and are stated at cost less accumulated amortization. Amortization is provided for on the straight-line basis over the estimated useful lives of the assets of five to six years. Costs incurred to develop computer software for internal use are capitalized once: (1) the preliminary project stage is completed, (2) management authorizes and commits to funding a specific software project, and (3) it is probable that the project will be completed and the software will be used to perform the function intended. Costs incurred prior to meeting the qualifications are expensed as incurred. Capitalization of costs ceases when the project is substantially complete and ready for its intended use. Post-implementation costs related to the internal use computer software, are expensed as incurred. Internal use software development costs are amortized using the straight-line method over its estimated useful life which ranges up to three years. Software development costs may become impaired in situations where development efforts are abandoned due to the viability of the planned project becoming doubtful or due to technological obsolescence of the planned software product. For the years ended December 31, 2020, and 2019 there has been no impairment associated with internal use software. For the years ended December 31, 2020, and 2019, the Company capitalized software development costs of $1,172,000 and $1,292,000, respectively. During 2016, the Company began capitalizing the costs of developing internal-use computer software, including directly related payroll costs. The Company amortizes costs associated with its internally developed software over periods up to three years, beginning when the software is ready for its intended use. The Company capitalizes costs incurred during the application development stage of internal-use software and amortize these costs over the estimated useful life. Upgrades and enhancements are capitalized if they result in added functionality which enable the software to perform tasks it was previously incapable of performing. Software maintenance, training, data conversion, and business process reengineering costs are expensed in the period in which they are incurred. Right of Use Assets and Lease Obligations The Right of Use Asset and Lease Liability reflect the present value of the Company’s estimated future minimum lease payments over the lease term, which may include options that are reasonably assured of being exercised, discounted using a collateralized incremental borrowing rate. Typically, renewal options are considered reasonably assured of being exercised if the associated asset lives of the building or leasehold improvements exceed that of the initial lease term, and the sales performance of the restaurant remains strong. Therefore, the Right of Use Asset and Lease Liability may include an assumption on renewal options that have not yet been exercised by the Company. As the rate implicit in leases are not readily determinable, the Company uses an incremental borrowing rate to calculate the lease liability that represents an estimate of the interest rate the Company would incur to borrow on a collateralized basis over the term of a lease within a particular currency environment. Goodwill Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment for its reporting units on an annual basis, or when events occur or circumstances indicate the fair value of a reporting unit is below its carrying value. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that implied fair value of the goodwill within the reporting unit is less than its carrying value. The Company performed its most recent annual goodwill impairment test as of December 31, 2020 using market data and discounted cash flow analysis. Based on this analysis, it was determined that the fair value exceeded the carrying value of its reporting units. The Company concluded the fair value of the goodwill exceeded the carrying value accordingly there were no indicators of impairment for the years ended December 31, 2020 and 2019. The Company had historically performed its annual goodwill and impairment assessment on December 31 st When evaluating the potential impairment of goodwill, management first assess a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company’s products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company’s reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the impairment testing methodology primarily using the income approach (discounted cash flow method). We compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized. When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results. Derivatives The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, Distinguishing Liabilities From Equity Derivatives and Hedging The Company has adopted ASU 2017-11, Earnings per share (Topic 260), provided that when determining whether certain financial instruments should be classified as liability or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. If a down round feature on the conversion option embedded in the note is triggered, the Company will evaluate whether a beneficial conversion feature exists, the Company will record the amount as a debt discount and will amortize it over the remaining term of the debt. If the down round feature in the warrants that are classified as equity is triggered, the Company will recognize the effect of the down round as a deemed dividend, which will reduce the income available to common stockholders. Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statements of operations. The fair value of the warrants issued by the Company has been estimated using a Black-Scholes option pricing model, at each measurement date. Debt Discounts The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options Revenue Recognition The Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers ASC Topic 606 is a comprehensive revenue recognition model that requires revenue to be recognized when control of the promised goods or services are transferred to our customers at an amount that reflects the consideration that we expect to receive. Application of ASC Topic 606 requires us to use more judgment and make more estimates than under former guidance. Application of ASC Topic 606 requires a five-step model applicable to all product offering revenue streams as follows: Identification of the contract, or contracts, with a customer A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit or financial information pertaining to the customer. Identification of the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. When a contract includes multiple promised goods or services, we apply judgment to determine whether the promised goods or services are capable of being distinct and are distinct within the context of the contract. If these criteria are not met, the promised goods or services are accounted for as a combined performance obligation. Determination of the transaction price The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods or services to our customer. We estimate any variable consideration included in the transaction price using the expected value method that requires the use of significant estimates for discounts, cancellation periods, refunds and returns. Variable consideration is described in detail below. Allocation of the transaction price to the performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative Stand-Alone Selling Price (“SSP,”) basis. We determine SSP based on the price at which the performance obligation would be sold separately. If the SSP is not observable, we estimate the SSP based on available information, including market conditions and any applicable internally approved pricing guidelines. Recognition of revenue when, or as, we satisfy a performance obligation We recognize revenue at the point in time that the related performance obligation is satisfied by transferring the promised goods or services to our customer. Principal versus Agent Considerations When another party is involved in providing goods or services to our customer, we apply the principal versus agent guidance in ASC Topic 606 to determine if we are the principal or an agent to the transaction. When we control the specified goods or services before they are transferred to our customer, we report revenue gross, as principal. If we do not control the goods or services before they are transferred to our customer, revenue is reported net of the fees paid to the other party, as agent. Our evaluation to determine if we control the goods or services within ASC Topic 606 includes the following indicators: We are primarily responsible for fulfilling the promise to provide the specified good or service. When we are primarily responsible for providing the goods and services, such as when the other party is acting on our behalf, we have indication that we are the principal to the transaction. We consider if we may terminate our relationship with the other party at any time without penalty or without permission from our customer. We have risk before the specified good or service have been transferred to a customer or after transfer of control to the customer. We may commit to obtaining the services of another party with or without an existing contract with our customer. In these situations, we have risk of loss as principal for any amount due to the other party regardless of the amount(s) we earn as revenue from our customer. The entity has discretion in establishing the price for the specified good or service. We have discretion in establishing the price our customer pays for the specified goods or services. Contract Liabilities Contract liabilities consist of customer advance payments and billings in excess of revenue recognized. We may receive payments from our customers in advance of completing our performance obligations. We record contract liabilities equal to the amount of payments received in excess of revenue recognized, including payments that are refundable if the customer cancels the contract according to the contract terms. Contract liabilities have been historically low historically recorded as current liabilities on our consolidated financial statements when the time to fulfill the performance obligations under terms of our contracts is less than one year. We have no long-term contract liabilities which would represent the amount of payments received in excess of revenue earned, including those that are refundable, when the time to fulfill the performance obligation is greater than one year. Practical Expedients and Exemptions We have elected certain practical expedients and policy elections as permitted under ASC Topic 606 as follows: ● We applied the transitional guidance to contracts that were not complete at the date of our initial application of ASC Topic 606 on January 1, 2018. ● We adopted the practical expedient related to not adjusting the promised amount of consideration for the effects of a significant financing component if the period between transfer of product and customer payment is expected to be less than one year at the time of contract inception; ● We made the accounting policy election to not assess promised goods or services as performance obligations if they are immaterial in the context of the contract with the customer; ● We made the accounting policy election to exclude any sales and similar taxes from the transaction price; and ● We adopted the practical expedient not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. Cost of Revenue Cost of revenue consists of payments to media providers and website publishers that are directly related to a revenue-generating event and project and application design costs. The Company becomes obligated to make payments related to media providers and website publishers in the period the advertising impressions, click-throughs, actions or lead-based information are delivered or occur. Such expenses are classified as cost of revenue in the corresponding period in which the revenue is recognized in the accompanying consolidated statements of operations. Stock-Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation – Stock Compensation We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded in accordance with ASC 718 on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at t

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Acquisitions	NOTE 2 – ACQUISITIONS On September 15, 2020 (“Closing Date”), an Agreement and Plan of Merger (the “Agreement”) is entered into by and among SRAX, Inc. a Delaware corporation (“Parent”), Townsgate Merger Sub 1, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Parent (“Merger Sub 1”), LD Micro, Inc., a Delaware corporation and a direct wholly-owned subsidiary of Parent (“Merger Sub 2”), LD Micro, Inc., a California corporation (the “Acquiree”, “LD Micro”), and Christopher Lahiji, the sole stockholder of the Acquiree (the “Stockholder”). Merger Sub 1 and Merger Sub 2 are sometimes collectively referred to as “Merger Sub.” The parties intend that Merger Sub 1 will be merged with and into the Acquiree (the “First Merger”), with the Acquiree surviving the First Merger, and then the Acquiree will be merged with and into Merger Sub 2 (the “Second Merger,” and together with the First Merger, the “Merger”), with Merger Sub 2 surviving the Second Merger. As consideration, the Company will pay cash payable as follows: (i) $1,000,000 at the Closing, (ii) $1,000,000 on January 1, 2021, (iii) $1,000,000 on April 1, 2021, and (iv) $1,000,000 on July 1, 2021 and subject to adjustment or off-set. Additionally, the Company issued 1,600,000 shares of its Class A common stock. The total consideration to be paid by the Company is $7,610,000, as adjusted, as follows: Calculation of the purchase price: Fair value of stock at closing $ 4,264,000 Cash at closing 1,000,000 Deferred payments 2,771,000 Less cash received (303,000 ) Transaction expenses 10,000 Working capital adjustment (132,000 ) Purchase price $ 7,610,000 The transaction was accounted for using the acquisition method. Accordingly, goodwill has been measured as the excess of the total consideration over the amounts assigned to the identifiable assets acquired and liabilities assumed. The deferred payments of $3,000,000 were discounted using the yield on a CCC rated corporate debt for 3-month, 6-month and 9-month maturities, respectively. The implied discount is approximately $229,000, which will be amortized over the term on the payments. The purchase price includes working capital adjustments that are based on our preliminary estimates and assumptions that are subject to change. The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed: Accounts receivable, net $ 30,000 Intangibles 468,000 Goodwill 7,706,000 Accounts payable and accrued liabilities (324,000 ) Payroll protection loan (42,000 ) Other current liabilities (97,000 ) Deferred tax liability (131,000 ) Net assets acquired $ 7,610,000 Intangible assets consisted of the following: Fair Value Life in Years Trademark $ 271,000 Indefinite Domain name 3,000 Indefinite Noncompete 8,000 5 years Customer list 186,000 3 years $ 468,000 The estimated fair values for the trademark and domain name were determined by using the relief-from-royalty method. The estimated fair value for the customer list and noncompete were determined using the excess earnings and differential method of comparing having an asset in-place versus not having the asset in place, respectively. The Company has estimated the preliminary purchase price allocations based on historical inputs and data as of September 15, 2020. The preliminary allocation of the purchase price is based on the best information available and is pending, amongst other things: (i) the finalization of the valuation of the fair values and useful lives of tangible assets acquired; (ii) the finalization of the valuations and intangible assets acquired; (iii) finalization of the valuation of accounts payable and accrued expenses; and (iv) finalization of the fair value of non-cash consideration. During the measurement period (which is the period required to obtain all necessary information that existed at the acquisition date, or to conclude that such information is unavailable, not to exceed one year), additional assets or liabilities may be recognized, or there could be changes to the amounts of assets or liabilities previously recognized on a preliminary basis, if new information is obtained about facts and circumstances that existed as of the acquisition date that, if known, would have resulted in the recognition of these assets or liabilities as of that date. The amounts of revenue and earnings of the Acquiree since the acquisition date included in the consolidated statements of operations for the year ended December 31, 2020 follows: Revenues $ - Net income (loss) (51,000 ) The following pro forma information presents the combined results of operations as if the acquisitions had been completed on January 1, 2019. The pro forma results include the amortization associated with the preliminary estimates for the acquired intangible assets. The pro forma results do not reflect any cost saving synergies from operating efficiencies, or the effect of the incremental costs incurred in integrating the two companies. Accordingly, these pro forma results are presented for informational purpose only and are not necessarily indicative of what the actual results of operations of the combined company would have been if the acquisition had occurred at the beginning of the period presented, nor are they indicative of future results of operations. Pro Forma Consolidated Statements of Operations For the Year ended December 31,2020 SRAX, Inc. LD Micro, Inc. Pro Forma Adjustment Pro Forma Combined Revenues $ 8,647,000 $ 937,000 $ - $ 9,584,000 Cost of revenues (2,589,000 ) (98,000 ) - (2,687,000 ) Operating expenses (17,655,000 ) (858,000 ) 171,000 (18,342,000 ) Other expense (3,082,000 ) (1,000 ) - (3,083,000 ) Provision for income taxes (26,000 ) - - (26,000 ) Net loss $ (14,705,000 ) $ (20,000 ) $ 171,000 $ (14,554,000 ) Pro Forma Consolidated Statements of Operations For the Year ended December 31,2019 SRAX, Inc. LD Micro, Inc. Pro Forma Adjustment Pro Forma Combined Revenues $ 3,584,000 $ 1,142,000 $ - $ 4,726,000 Cost of revenues (1,680,000 ) (188,000 ) - (1,868,000 ) Operating expenses (19,762,000 ) (1,037,000 ) (58,000 ) (20,857,000 ) Other income 999,000 8,000 - 1,007,000 Net loss $ (16,859,000 ) $ (75,000 ) $ (58,000 ) $ (16,992,000 ) The following summarizes the pro forma adjustments made for the years ended December 31: 2020 2019 Amortization of intangibles acquired $ 64,000 64,000 Employee related costs (235,000 ) (235,000 ) Financing costs - 229,000 Net income (loss) $ (171,000 ) $ 58,000 Amortization relates to the acquired noncompete and customer list amounting to $2,000 plus $62,000 for the years ended December 31, 2020 and 2019, respectively. Employee related cost are contracted cost amounting to $235,000 for the years ended December 31, 2020 and 2019, respectively. Financing cost relates to amortization of the discount related to the $3,000,000 deferred payments.

Sale of Accounts Receivable

Sale of Accounts Receivable	12 Months Ended
	Dec. 31, 2020
Credit Loss [Abstract]
Sale of Accounts Receivable	NOTE 3 – SALE OF ACCOUNTS RECEIVABLE On January 22, 2020 and January 30, 2020, the Company entered into financing agreements, with a single unrelated purchaser to sell, with full recourse, certain accounts receivable with a face value of $454,000 and $75,000, respectively, for a purchase price of $454,000 and $56,000, respectively. Transactions under these agreements were accounted for as financing of accounts receivable and the related accounts receivable was not removed from our consolidated balance sheet at the time of the sales transactions, a liability was recorded for the proceeds received. The terms of the agreements are as follows: Pursuant to the initial purchase agreement, commencing on March 24, 2020, the purchaser may, at its sole discretion, exercise a put option, to cause the Company to purchase from purchaser, any of the outstanding January 22, 2020 receivables which were not collected by the purchaser. Effective April 9, 2020, the put option was extended until June 23, 2020. The purchase price payable by Company to the Purchaser for the receivables upon exercise of the Put Option shall be equal to one hundred and thirty six percent (136%) of the then remaining outstanding balance of the applicable receivables. Upon the occurrence of a payment made on the applicable receivables, the Company is required to pay a true up amount as follows: a. ten percent (10%) of the portion of the receivables which are paid on or before the 30th day following the effective date of the agreement; b. twenty percent (20%) of the portion of the receivables which are paid after the 30 th th c. thirty six percent (36%) of the portion of the receivables which are paid after the 60 th In order to secure performance by the Company, the purchaser was granted a security interest in: (i) 239,029 shares of the Company’s Class A common stock in connection with the sale of the $454,000 receivable and (ii) 29,519 shares of the Company’s Class A common stock in connection with the sale of the $75,000 receivable. The shares have been issued and are being held by the Company’s transfer agent. Since the shares are not outstanding, the Company has treated them as shares reserved for collateral. Since the purchaser of the receivables has recourse, the Company accounted for the purchase price as a liability. Upon the purchaser’s election of the put option or the true up, as applicable the Company will treat the put option price or the true up amounts as interest. On April 9, 2020 the Company entered into an agreement to amend the January 22 and 30 accounts receivable agreements. The purchaser agreed to amend the put option date as described above to June 23, 2020 and June 30, 2020 for the sale of receivables originating on January 22, 2020 and January 30, 2020, respectively. As consideration for the extension the Company agreed to issue the purchaser 32,668 and 4,032 shares of Class A common stock for the receivable sale originating on January 22 , On June 30, 2020, the Purchaser converted the payable of $510,000 and accrued interest of $184,000 (“Old Debt”) into approximately $788,000 of the OID Convertible Notes payable (“Debentures”) (See Note 15 - OID Convertible Debentures). The conversion was treated as an extinguishment of debt as prescribed by ASC 470-50 – Debt Modification and Extinguishment. At the date of issuance, the Debenture had a fair market value of approximately $815,000. The transaction created a loss on extinguishment of approximately $546,000, which consisted of (i) the difference of value between the Old Debt and the fair value of the new debt of approximately $95,000, (ii) the difference between the face value of the debenture and the fair value of the Debenture of approximately $27,000 and (iii) $424,000 for fair value of warrants issued with the Debenture. Also, since the Debenture was convertible into the Company’s common stock, a $27,000 premium associated with the conversion feature was recorded as additional paid in capital. Since the purchaser of the receivables has recourse, the Company accounted for the purchase price as a liability. Upon the purchaser’s election of the put option or the true up, as applicable the Company will treat the put option price or the true up amounts as interest. In December 2020, the Company entered into an agreement with PIPE Technologies, Inc. whereby it sold the Company’s right to future subscription revenues of $570,000 for net proceeds of $528,000. Under the terms of the agreement, the Company may borrow funds collateralized by the right to the revenues from Sequire platform contracts. PIPE receives a discount on the amount sold and remits the net amount to the Company. The Company bears the risk of credit loss on the contracts. These transactions are accounted for as secured borrowing arrangements and not as a sale of financial assets. The amount of borrowings outstanding was approximately $570,000 as of December 31, 2020 and none at December 31, 2019, respectively.

Marketable Securities

Marketable Securities	12 Months Ended
	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Marketable Securities	NOTE 4 – MARKETABLE SECURITIES During the second quarter of 2020, the Company began offering customers of its Sequire segment who purchase services on the Company’s proprietary SaaS platform the option to pay the contract price in securities issued by the Customer which could be a common stock, preferred stock or convertible debentures. The customer’s securities must be trading on a United States securities exchange and the Company must be a fully reporting entity pursuant to SEC Regulation S-X. In accordance with ASC 606 - Revenue Recognition, the Company will value the shares received at the fair market value of the date the contract is executed. The shares received will be accounted for in accordance with ASC 320 – Investments – Debt and Equity Securities, as such the shares will be classified as available-for-sale securities and will be measured at each reporting period at fair value with the unrealized gain or (loss) as a component of other income (expense). Upon the sale of the shares, the Company will record the gain or (loss) in the consolidated statement of operations as a component of net income (loss). The movement in this account is as follows: Balance as of December 31, Common Convertible 2020 Stock Debentures Balances at beginning of year $ 83,000 $ 83,000 $ — Additions 8,406,000 7,496,000 910,000 Sale of marketable securities (916,000 ) (916,000 ) — Change in fair value 874,000 1,101,000 (227,000 ) Balances at end of year $ 8,447,000 $ 7,764,000 $ 683,000 Balance as of December 31, Common Convertible 2019 Stock Debentures Balances at beginning of year $ 39,000 $ 39,000 $ — Additions 50,000 50,000 — Sale of marketable securities — — — Change in fair value (6,000 ) (6,000 ) — Balances at end of year $ 83,000 $ 83,000 $ — The Company’s sales of securities year ended December 31, 2020 were approximately $916,000, with a book basis of approximately $303,000 which represented a gain of $613,000, which the Company recorded as other income included in the gains from marketable securities. The Company recorded as a component of other income (expense) the realized and unrealized gain (loss) on marketable securities as follows: 2020 2019 Unrealized gain (loss) $ 261,000 $ (6,000 ) Realized gain 613,000 - Change in fair value of marketable securities $ 874,000 $ (6,000 ) The Company accounts for its investments in equity securities in accordance with ASC 321-10 Investments - Equity Securities. The equity securities may be classified into two categories and accounted for as follows: ● Equity securities with a readily determinable fair value are reported at fair value, with unrealized gains and losses included in earnings. Any dividends received are recorded in interest income, the fair value of equity investments with fair values is primarily obtained from third-party pricing services. ● Equity securities without a readily determinable fair value are reported at their cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer and their impact on fair value. Any dividends received are recorded in interest income. For equity investments without readily determinable fair values, when an orderly transaction for the identical or similar investment of the same issuer is identified, we use the valuation techniques permitted under ASC 820 Fair Value Measurement to evaluate the observed transaction(s) and adjust the fair value of the equity investment

Notes Receivable

Notes Receivable	12 Months Ended
	Dec. 31, 2020
Receivables [Abstract]
Notes Receivable	NOTE 5 – NOTES RECEIVABLE On October 30, 2020, a unit redemption agreement was entered into by and between the Company and Haylard MD, LLC (“Haylard”). The Company owns 10,000,000 Class A Units of Haylard. The Company desires to sell and transfer to Haylard, and Haylard desires to redeem and purchase from the Company. The price to be paid for all of the Units shall be $6,718,000 at closing and $960,000 upon the earlier of (a) the third anniversary of the closing and (b) a Sale of Haylard, for a total consideration of $7,678,000, provided that if Haylard consummates a Sale of Haylard within one hundred and eighty (180) calendar days after the closing, and the amount to be paid in respect of a Class A Unit in connection with such transaction after taking into account all fees, costs, expenses, escrows, indemnities, purchase price adjustments, repayments of indebtedness and other holdbacks as reasonably determined and calculated in good faith by Haylard is greater than $0.7677543, then Haylard shall pay to the Company an amount equal to such excess for each Unit redeemed and purchased hereunder by wire transfer of immediately available funds to the account specified by the Company. On October 30, 2020, a unit redemption agreement was entered into by and between the Company and MD CoInvest, LLC, (“CoInvest”). The Company owns 420,000 Units of CoInvest. The Company desires to sell and transfer to CoInvest, and CoInvest desires to redeem and purchase from the Company. The price to be paid for all of the Units shall be $282,000 at closing and $40,000 upon the earlier of (a) the third anniversary of the closing and (b) a Sale of CoInvest, for a total consideration of $322,000, provided that if CoInvest consummates a Sale of CoInvest within one hundred and eighty (180) calendar days after the closing, and the amount to be paid in respect of a Class A Unit in connection with such transaction after taking into account all fees, costs, expenses, escrows, indemnities, purchase price adjustments, repayments of indebtedness and other holdbacks as reasonably determined and calculated in good faith by CoInvest is greater than $0.7677543, then CoInvest shall pay to the Company an amount equal to such excess for each Unit redeemed and purchased hereunder by wire transfer of immediately available funds to the account specified by the Company. The deferred payments of $960,000 and $40,000 were discounted using the yield on a CCC rated corporate debt for 3-year maturity. The implied discount is approximately $107,000, which will be amortized over 3 years. Notes receivable as of December 31, 2020 amounted to $893,000.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 6 – PROPERTY AND EQUIPMENT Property and equipment consist of the following as of December 31: 2020 2019 Office equipment $ 406,000 $ 406,000 Accumulated depreciation (288,000 ) (215,000 ) Property and equipment, net $ 118,000 $ 191,000 Depreciation expense for the years ended December 31, 2020 and 2019 was $73,000 and $74,000, respectively.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	NOTE 7 – INTANGIBLE ASSETS Intangible assets consist of the following as of December 31: 2020 2019 Internally developed software $ 4,028,000 $ 2,856,000 Non-compete agreement 1,258,000 1,250,000 Intellectual property 756,000 756,000 Acquired Software 617,000 617,000 Trademark 271,000 - Customer list 186,000 - Domain name 36,000 - Total cost 7,152,000 5,479,000 Accumulated amortization (4,743,000 ) (3,513,000 ) Intangible assets, net $ 2,409,000 $ 1,966,000 Amortization expense was $1,024,000 for internally developed software and $206,000 acquired software for the year ended December 31, 2020. Amortization expense was $151,000 for intellectual property, $732,000 for internally developed software and $206,000 for acquired software for the year ended December 31, 2020. The estimated future amortization expense for the years ended December 31, are as follows: 2021 $ 1,180,000 2022 666,000 2023 247,000 2024 6,000 2025 and thereafter 3,000 $ 2,102,000 The following table summarizes the carrying amount of intangible assets not subject to amortization as of December 31, 2020: Trademark $ 271,000 Domain name 36,000 $ 307,000 The following table summarizes the carrying amount of goodwill as of December 31, 2020: Segment Sequire BigToken Total Balance as of January 1, 2020 $ 10,200,000 $ 5,445,000 $ 15,645,000 Goodwill acquired during the year (LD Micro) 7,706,000 7,706,000 Balance as of December 31, 2020 $ 17,906,000 $ 5,445,000 $ 23,351,000

Right to Use Asset

Right to Use Asset	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Right to Use Asset	NOTE 8 – RIGHT TO USE ASSET We adopted ASU No. 2016-02, Leases Operating leases are included in the right-of-use lease assets, other current liabilities and long-term lease liabilities on the Consolidated Balance Sheet. Right-of-use assets and lease liabilities are recognized at each lease’s commencement date based on the present values of its lease payments over its respective lease term. When a borrowing rate is not explicitly available for a lease, our incremental borrowing rate is used based on information available at the lease’s commencement date to determine the present value of its lease payments. Operating lease payments are recognized on a straight-line basis over the lease term. We had no financing leases as of December 31, 2020. We have operating leases for office space. Our leases have remaining lease terms of approximately 2.75 years. We consider renewal options in determining the lease term used to establish our right-of-use assets and lease liabilities when it is determined that it is reasonably certain that the renewal option will be exercised. As of December 31, 2020, there were no material variable lease costs or sublease income. Cash paid for operating leases are classified in operating expenses and were $192,000 and $304,000 for the years ended December 31, 2020 and 2019, respectively. The following tables summarize the lease expense for the year ended December 31: 2020 2019 Operating lease expense $ 163,000 $ 150,000 Short-term lease expense 29,000 154,000 Total lease expense $ 192,000 $ 304,000 The below table summarizes these lease asset and liability accounts presented on our accompanying Consolidated Balance Sheets for the year ended December 31: Operating Leases* Consolidated Balance Sheet Caption 2020 2019 Operating lease right-of-use assets - non-current Right of use asset $ 366,000 $ 456,000 Operating lease liabilities - current Other current liabilities $ 109,000 $ 91,000 Operating lease liabilities - non-current Right to use liability - long term 243,000 352,000 Total operating lease liabilities $ 352,000 $ 443,000 Components of Lease Expense We recognize lease expense on a straight-line basis over the term of our operating leases, as reported within “selling, general and administrative” expense on the accompanying consolidated statement of operations. Weighted Average Remaining Lease Term and Applied Discount Rate Weighted Average Remaining Lease Term Weighted Average Discount Rate Operating leases as of December 31, 2020 2.75 years 18 % Future Contractual Lease Payments as of December 31, 2020 The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments for the years ending December 31: Operating Leases - future payments 2021 163,000 2022 163,000 2023 123,000 Total future lease payments, undiscounted 449,000 Less: Implied interest (97,000 ) Present value of operating lease payments 352,000

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses	NOTE 9 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses as of December 31, are comprised of the following: 2020 2019 Accounts payable, trade $ 2,631,000 $ 1,708,000 Accrued expenses 605,000 335,000 Accrued compensation 238,000 270,000 Accrued commissions 80,000 129,000 Accrued interest 7,000 - Accounts payable and accrued expenses $ 3,561,000 $ 2,442,000

Derivative Liability

Derivative Liability	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liability	NOTE 10 – DERIVATIVE LIABILITY On June 30, 2020, the Company entered into an agreement to amend the warrants underlying the warrant liabilities instruments classified as Liabilities as of December 31, 2019. The amended agreement removed the embedded features that cause the warrants to be accounted for as liabilities. Pursuant to ASC 815 and ASC 480, the Company has reclassified these warrants as additional paid in capital as of June 30, 2020, due to the existence of a fundamental transaction clause the precluded equity classification. On June 30, 2020, each of the holders of warrants issued by the Company in 2017 and 2018 agreed to irrevocably waive their rights to a cash settlement due too in the event the Company has a fundamental transaction. As a result, this derivative liability was reversed to Nil and reclassified into stockholders equity under Additional Paid-In Capital. As consideration for the amendment, the Company issued contingent consideration in the form of warrants linked to the value of BIGtoken should it be transferred to a third-party purchaser. The form of the consideration issued is a warrant to purchase up to approximately 0.35% of BIGtoken’s acquiring entity on a fully-diluted basis. The exercise price of the warrants will be calculated by imputing a $10 million pre-money valuation on the acquiring entity. The form of the warrant is to be substantially similar to the warrants issued in conjunction with the OID Convertible Debentures. The Due to the uncertainty around the transfer of the BIGtoken business to a third-party the Company has determined that the warrant is a contingent consideration, therefore the value will be determined on the date the transaction occurs and will be recorded as a transactional expenses at that time. The Derivative Warrant Instruments have been accounted for utilizing ASC 815 “Derivatives and Hedging”. The Company identified embedded features in the Derivative Warrant Instruments which caused the warrants to be classified as a liability. These embedded features included the right for the holders to request for the Company to cash settle the Warrant Instruments from the Holder by paying to the Holder an amount of cash equal to the Black-Scholes value of the remaining unexercised portion of the Derivative Warrant Instruments on the date of the consummation of a fundamental transaction. The accounting treatment of derivative financial instruments requires that the Company treat the whole instrument as liability and record the fair value of the instrument as a derivative as of the inception date of the instrument and to adjust the fair value of the instrument as of each subsequent balance sheet dates. The Warrant derivative liability is comprised of the following warrant instruments (collectively, the “Derivative Liabilities”): 1. In January 2017, the Company issued Series A Warrants in Our registered direct and concurrent private placement; 2. In April and October 2017, the Company issued the Series A1 Warrants and Series A2 Warrants in connection with the private placement of secured convertible debentures; and 3. In November 2018, the Company issued the Series B1 Warrants upon redemption of the outstanding convertible debentures issued in April and October 2017, pursuant to the terms of such debentures. Series Number of Warrants Series A warrants 267,535 Series A1 warrants 471,667 Series A2 warrants 813,364 Series B1 warrants 1,090,863 Leapfrog warrants 350,000 Total 2,993,429 Series A Warrants The Series A Warrants are exercisable for five years commencing 6 months from the date of closing. The exercise price of the Series A Warrants is subject to full ratchet adjustment in certain circumstances, subject to a floor price of $1.20 per share. The adjustment provisions under the terms of the Series A Warrants will be extinguished at such time as our Class A common stock trades at or above $10.00 per share for 20 consecutive trading days, subject to the satisfaction of certain equity conditions. In addition, if there is no effective registration statement covering the shares issuable upon the exercise of the Series A Warrants, the warrants are exercisable on a cashless basis. If we fail to timely deliver the shares underlying the warrants, we will be subject to certain buy-in provisions. As a result of the sale of the debentures in April 2017, the exercise price of the Series A Warrants issued to investors in our January 2017 private offering were reset to $2.245 per share. The Series A Warrants fair value as of December 31, 2019 was estimated to be $368,000, based on a risk-free interest rate of 1.62, an expected term of 2 years, an expected volatility of 100% and a 0% dividend yield. The Series A Warrants were reclassified to equity as of June 30, 2020. The fair value was estimated to be $334,000 based on a risk-free interest rate ranging from 1.62 to 0.18, an expected term of 1.5 years, an expected volatility of 100% and a 0% dividend yield. Series A1 Warrant The Series A1 Warrants are initially exercisable at $3.00 per share and, if at any time after the six-month anniversary of the issuance the underlying shares of our class A common stock are not covered by an effective resale registration statement, the Series A1 Warrants are exercisable on a cashless basis. The conversion price of the Debentures and the exercise price of the Series A1 Warrants are subject to adjustments upon certain events, including stock splits, stock dividends, subsequent equity transactions (other than specified exempt issuances), subsequent rights offerings, and fundamental transactions, subject to a floor of $1.40 per share. If we fail to timely deliver the shares of our class A common stock upon any conversion of the Series A1 Debentures or exercise of the Series A1 Warrants, we will be subject to certain buy-in provisions. Pursuant to the terms of the Series A1 Debentures and Series A1 Warrants, a holder will not have the right to convert any portion of the Series A1 Debentures or exercise any portion of the Series A1 Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of class A common stock outstanding immediately after giving effect to such conversion or exercise, as such percentage ownership is determined in accordance with the terms of the Series A1 Debentures and the Series A1 Warrants; provided that after the Shareholder Approval Date, as defined below, at the election of a holder and notice to us such percentage ownership limitation may be increased or decreased to any other percentage, not to exceed 9.99%; provided that any increase will not be effective until the 61 st In accordance with the Nasdaq Marketplace Rules, until such time as our stockholders have approved the Securities Purchase Agreements and the transactions thereunder (the “Shareholder Approval Date”), we were not obligated to issue any shares of our class A common stock upon any conversion of the Series A1 Debentures and/or exercise of the Series A1 Warrants, and the holders had no right to receive upon conversion and/or exercise thereof any shares of our Class A common stock, to the extent the issuance of such shares of Class A common stock would exceed 20% of our outstanding Class A common stock prior to the transaction. We held a special meeting of the shareholders on June 23, 2017 whereby we obtained approval of the Securities Purchase Agreements and the transactions thereunder. We agreed to file a registration statement registering the resale of the shares of our Class A common stock underlying the Series A1 Debentures and the Series A1 Warrants. Under the terms of the Securities Purchaser Agreements, we also granted the Purchasers of the Series A1Debentures the right to purchase an additional $3,000,000 of Series A1 Debentures upon the same terms and conditions for a period beginning on the Shareholder Approval Date and expiring on earliest of the date that (a) the initial registration statement has been declared effective by the SEC, (b) all of the underlying shares have been sold pursuant to Rule 144 or may be sold pursuant to Rule 144 without the requirement for our company to be in compliance with the current public information required under Rule 144 and without volume or manner-of-sale restrictions, (c) following the one year anniversary of the closing date provided that a holder of the underlying shares is not an affiliate of the Company or (d) all of the underlying shares may be sold pursuant to an exemption from registration under Section 4(a)(1) of the Securities Act. The shares underlying the Series A1 Debentures and Series Warrants were included in a resale registration statement on Form S-3 that was declared effective by the SEC in June 2017. The Series A1 Warrants fair value as of December 31, 2019 was estimated to be $618,000 based on a risk-free interest rate ranging from 1.62% to 2.46%, an expected term ranging from 2.38 to 3.38, an expected volatility ranging from 100% to 164% and a 0% dividend yield. During the year ended December 31, 2019, we recorded a decrease in the fair value of the warrant derivative liability of $284,000. This was recorded as a gain on change in fair value of derivative liability. The Series A1 Warrants were reclassified to equity as of June 30, 2020. The fair value was estimated to be $555,700 based on a risk-free interest rate ranging from 1.62% to 0.18%, an expected term of 1.875 years, an expected volatility of 100% and a 0% dividend yield. Series A2 Warrants The Series A2 Warrants have an exercise price of $3.00 per share, subject to adjustment and contain anti-dilution protection for subsequent financings and have an exercise price floor of $1.40 per share. The Series A2 Warrants fair value as of December 31, 2019 was estimated to be $1,142,000 based on a risk-free interest rate ranging from 1.62 to 2.46, an expected term ranging from 2.88 to 3.88 years, an expected volatility ranging from 100% to 158% and a 0% dividend yield. During the year ended December 31, 2019, we recorded the decrease in the fair value of the warrant derivative liability of $303,000. This was recorded as a gain on change in fair value of derivative liability. The Series A2 Warrants were reclassified to equity as of June 30, 2020. Prior to the reclassification, we recorded the decrease in the fair value of the warrant derivative liability of $303,000. The fair value was estimated to be $555,570 based on a risk-free interest rate ranging from 1.62 to 0.18, an expected term ranging from 2.38 to 1.875 years, an expected volatility of 100% and a 0% dividend yield. Series B1 Warrants The Series B1 Warrants have a term of five (5) years from the date in which each of the redeemed Debenture were issued. Accordingly, of the Series B1 Warrants: (i) 277,500 have an expiration date of April 21, 2022, and (ii) 813,362 have an expiration date of October 27, 2022. The Series B1 Warrants are initially exercisable at $3.00 per share and, are subject to cashless exercise after six (6) months from the issuance date if the shares underlying the warrants are not subject to an effective registration statement. The Series B Warrants also contain anti- dilution protection for subsequent equity sales for a price lower than the then applicable exercise price, with a floor of $1.40. The exercise price of the Series B1 Warrants is subject to adjustment upon certain events, including stock splits, stock dividends, subsequent equity transactions (other than specified exempt issuances), subsequent rights offerings, and fundamental transactions, subject to the $1.40 floor described above. If we fail to timely deliver the shares of our Class A common stock (“Common Stock”) upon any exercise of the Series B Warrants, we will be subject to certain buy-in provisions. Additionally, the Series B Warrants contained certain beneficial ownership limitations. The Series B1 Warrants fair value at December 31, 2019 was estimated to be $1,786,000 based on a risk-free interest rate of 1.62, an expected term of 3.91, an expected volatility of 100%, and a 0% dividend yield. During the year ended December 31, 2019, we recorded a decrease, in the fair value of the warrant derivative liability of $224,000. This was recorded as a loss on change in fair value of derivative liability. The Series BI Warrants were reclassified to equity as of June 30, 2020. The fair value was estimated to be $1,700,445 based on a risk-free interest rate ranging from 1.62 to 0.18, an expected term ranging from 2.38 to 1.875 years, an expected volatility of 100% and a 0% dividend yield. Leapfrog Warrants The Leapfrog Warrants fair value at December 31, 2019 was estimated to be $480,000 based on a risk-free interest rate of 1.62, an expected term of 2.63, expected volatility of 100% and a 0% dividend yield. During the year ended December 31, 2019, we recorded a decrease in the fair value of the warrant derivative liability of $142,000. This was recorded as a loss on change in fair value of derivative liability. The Leapfrog Warrants were reclassified to equity as of June 30, 2020. The fair value was estimated to be $438,000 based on a risk-free interest rate ranging from 1.62 to 0.18, an expected term ranging from 2.38 to 2.13 years, an expected volatility of 100% and a 0% dividend yield. The Warrant liabilities are comprised of the following at December 31: Debenture Warrant Liabilities Leapfrog Warrant Liability Derivative Total Balance December 31, 2018 $ 4,324,000 $ 622,000 $ 496,000 $ 5,442,000 Adjustment to fair value (775,000 ) (142,000 ) (128,000 ) (1,045,000 ) Balance December 31, 2019 $ 3,549,000 $ 480,000 $ 368,000 $ 4,397,000 Debenture Warrant Liabilities Leapfrog Warrant Liability Derivative Total Balance December 31, 2019 $ 3,549,000 $ 480,000 $ 368,000 $ 4,397,000 Adjustment to fair value (245,000 ) (42,000 ) (34,000 ) (321,000 ) Transfer to Equity (3,304,000 ) (438,000 ) (334,000 ) (4,076,000 ) Balance December 31, 2020 $ − $ − $ − $ −

Other Current Liabilities

Other Current Liabilities	12 Months Ended
	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Other Current Liabilities	NOTE 11 – OTHER CURRENT LIABILITIES The following table summarizes the composition of other current liabilities presented on our accompanying Consolidated Balance Sheets: December 31, 2020 December 31, 2019 Contract liabilities $ 4,842,000 $ - BIGToken point liability 452,000 446,000 Operating lease liabilities - current 109,000 91,000 Other current liabilities 3,308,000 - Total other current liabilities $ 8,711,000 $ 537,000 Contract liabilities Contract liabilities are unearned revenues arising from the Company’s Sequire segment customers who are given the option to pay the contract price in securities issued which could be a common stock, preferred stock or convertible debentures. The customer’s securities must be trading on a United States securities exchange and the Company must be a fully reporting entity pursuant to SEC Regulation S-X. Contract liabilities amounted to $4,842,000 and nil as of December 31, 2020 and 2019, respectively. BIGToken Point liability In 2019, the Company launched the BIGToken consumer data management platform, where registered users are rewarded for undertaking actions and sharing data within the platform. The business is currently based on a platform of registered users, developed as a direct to consumer data marketplace where users are paid for their data. During the year ended December 31, 2019 the Company instituted a policy that allows BIGToken users to redeem outstanding BIGToken points for cash if their account and point balances meet certain criteria. As of December 31, 2020 and 2019, the Company has estimated the future liability for point redemptions to be $452,000 and $446,000, respectively. The Company considered the total number of points outstanding, the conversion rate in which points are redeemable for cash, and each user’s redemption eligibility The Company utilizes an account scoring system that evaluates a number of factors in determining an account’s redemption eligibility. These factors include an evaluation of the following: the infrastructure utilized by the user when engaging with BIGToken’s systems, the user’s geographical associations, consistency, and verifiability of the user’s data. Other current liabilities Other current liabilities mainly consist of the deferred consideration amounting to $2,735,000 million payable for the LD Micro acquisition. The remaining balance of $573,000 pertains to a short term financing.

Paycheck Protection Program Loa

Paycheck Protection Program Loan	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Paycheck Protection Program Loan	NOTE 12 - PAYCHECK PROTECTION PROGRAM LOAN On April 17, 2020, we entered into a promissory note evidencing an unsecured approximately $1,084,000 loan under the Paycheck Protection Program (PPP). The loan is being made through Cross River Bank. The term of the loan is two years with an interest rate of 1%, which shall be deferred for the first six months of the term of the loan. The promissory note evidencing the loan contains customary events of default relating to, among other things, payment defaults, breach of representations and warranties, or provisions of the promissory note. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, and/or filing suit and obtaining judgment against the Company. On September 15, 2020, $42,000 of the payroll protection loan of LD Micro was assumed in connection with the acquisition. This amount is expected to be forgiven, otherwise the Company will be reimbursed by Sellers of LD Micro. This is classified under current assets. As of December 31, 2020, the short-term and long-term balances were $747,000 and $379,000, respectively.

Short Term Promissory Notes

Short Term Promissory Notes	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Short Term Promissory Notes	NOTE 13 – SHORT TERM PROMISSORY NOTES In February 2020, the Company entered into three separate short-term promissory notes with an aggregate principal value of $450,000 (the “Notes”), of which $100,000 was borrowed from the Company’s Chief Financial Officer. The notes are due and payable on May 12, 2020 (“Maturity Date”). The notes will accrue interest as follows: (i) on the origination date, ten percent (10%) of the principal amount was added to each note, (ii) on March 12, 2020, an additional ten percent (10%) of the principal amount was added to each note, and (iii) on April 12, 2020, an additional sixteen percent (16%) of the principal amount was added to each notes. The note holders were granted security interests (in amounts equal to the face value of their investments on a dollar for share basis) in an aggregate of 450,000 shares of the Company’s Class A common stock (“Security Shares”). The shares have been issued and are being held by the Company’s transfer agent. Since the shares are not outstanding, the Company has treated them as shares reserved for collateral. The interest imputed on the origination date was treated as an original issue discount with the $45,000 amortized over the term of the Notes. On each of the interest date, the Company accrued and expensed the related interest. On the Maturity Date, one of the Note’s was amended to (i) extend the maturity date to December 31, 2020 and (ii) to release 100,000 shares of the Security Shares. The modification was treated as an extinguishment of debt as prescribed by ASC 470-50 – Debt Modification and Extinguishment. Based on the amended terms the fair value of the amended note approximated the book value of the old Note. The fair value of the Security Shares was approximately $181,000, which was expensed as a loss on the extinguishment. On June 30, 2020, the short-term note payable to the Company’s Chief Financial Officer in the amount of approximately $136,000 was repaid from the proceeds of the OID Convertible Notes Payable. On June 30, 2020, the two remaining Note Holders converted the Notes of approximately $350,000 and accrued interest of approximately $126,000 (“Old Debt”) into approximately $541,000 of the OID Convertible Debentures (See Note 15 - OID Convertible Debentures). The conversion was treated as an extinguishment of debt as prescribed by ASC 470-50 – Debt Modification and Extinguishment. At the date of issuance, the Debentures had a fair market value of approximately $560,000. The transaction created a loss on extinguishment of approximately $375,000, which consisted of (i) the difference of value between the Old Debt and the fair value of the Debentures of approximately $65,000, (ii) the difference between the face value of the debenture and the fair value of the Debenture of approximately $19,000 and (iii) $291,000 for fair value of warrants issued with the Debenture. Also, since the Debenture was convertible into the Company’s common stock, a $18,000 premium associated with the conversion feature was recorded as additional paid in capital. As of December 31, 2020, there is no outstanding loan balance on this account.

Term Loan Note

Term Loan Note	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Term Loan Note	NOTE 14 – TERM LOAN NOTE On February 28, 2020, the Company entered into a term loan and security agreement with a BRF Finance Co. LLC as lender. Pursuant to the loan agreement, the Company can borrow up to $5,000,000, subject to the conditions described below. Under the loan: (i) the Company received an initial draw of $2,500,000 on February 28, 2020 and (ii) the Company is eligible to receive an additional $2,500,000 loan within (30) days of the Company entering into an at the market sales agreement with the lender and the filing of an at the market offering on Form S-3 with the SEC registering the shares to be sold pursuant to the at the market sales agreement. The Company agreed to file the ATM by May 1, 2020. Additionally, the Company will be required to increase the dollar amount authorized under the at the market sales agreement each time additional capacity of at least $1,000,000 is available under our shelf registration statement. The loan is secured by substantially all of the assets of the Company pursuant to the loan agreement and the intellectual property security agreement entered into in connection with the transaction. The loan bears interest at ten percent (10%) per annum and has a maturity date of March 1, 2022. Beginning on August 1, 2020, and continuing on the first day of each month thereafter until the maturity date, the Company will make monthly payments of principal and interest on an eighteen (18) month straight line amortization schedule, based on the principal outstanding on July 31, 2020. Additionally, the Company will have the option of a one (1) time payment-in-kind payment for a monthly required payment of principal and interest, which will defer such payments and result in a recalculation of the amortization schedule. In the event that the Company is late on any payments under the Loan, a late charge of three percent (3%) of the amount of the payment due will be assessed. At origination the Company paid lender: (i) an origination fee of $300,000, (ii) $35,000 in attorneys’ fees reimbursement, and (iii) certain other costs and expenses associated with the completion of the loan, including but not limited to escrow fees and recording fees. Accordingly, the Company received net proceeds of approximately $2,164,000 as of May 1, 2020. The Loan may be prepaid in whole or in part at any time at the discretion of the Company. The loan also provides for mandatory prepayments of all of the net cash received upon (i) a sale of the company’ assets, (ii) raising additional capital through the issuance of equity or debt securities, or (iii) sales under the at the market sales agreement described above. As part of the loan the Company agreed to issue to Lender: (i) 500,000 Common Stock purchase warrants on the date of the origination date and (ii) 500,000 Common Stock purchase warrants on the date of the second drawdown. The warrants have an exercise price equal to a 25% premium of the closing price of the Common Stock on their respective date of issue (provided that the exercise price of the warrants cannot be less than $2.50 per share, subject to adjustment contained therein). The initial warrant has an exercise price of $3.60. The warrants will expire on October 31, 2022. The warrants allow for cashless exercise in the event that they are not subject to a registration statement on the six (6) month anniversary of their respective issuances. The warrants do not contain any price protection or non-standard anti-dilution provisions. In accordance with ASC 470 - Debt The Company evaluated the loan and warrant agreements in accordance with ASC 815 Derivatives and Hedging. On June 30, 2020, the principal and interest of approximately $2,585,000 was paid from the proceeds from the OID Convertible Debentures. As of December 31,2020, there is no outstanding loan balance on this account.

OID Convertible Debentures

OID Convertible Debentures	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
OID Convertible Debentures	NOTE 15 – OID CONVERTIBLE DEBENTURES On June 25, 2020, the Company entered into a definitive securities purchase agreement (the “Securities Purchase Agreement or Transaction”) with certain accredited and institutional investors (the “Purchasers”) for the purchase and sale of an aggregate of: (i) $16,101,000 in principal amount of Original Issue Discount Senior Secured Convertible Debenture (the “Debentures”) for $14,169,000 (representing a 12% original issue discount) (“Purchase Price”) and (ii) warrants to purchase up to 6,440,561 shares of the Company’s Class A common stock (the “Warrants”) in a private placement (the “Offering”). The Purchase Price consists of (a) $13,000,000 in cash and (b) the cancellation of $1,169,000 in outstanding debt, consisting of the accounts receivable loans of $510,000 with accrued interest of $184,000, and the short-term promissory notes of $350,000 with accrued interest of $125,000. The Debentures, which mature on December 31, 2021, pay interest in cash at the rate of 12.0% per annum commencing on June 30, 2021, with such interest payable quarterly, beginning on October 1, 2021. Commencing after the six month anniversary of the issuance of the Debentures, the Company will be required to make amortization payments (“Amortization Payments”) with each Purchaser having the right to delay such Amortization Payments by a six month period up to three separate times (each, an “Extension”) in exchange for five percent in principal being added to the balance of such applicable Debenture on each such Extension. Accordingly, upon a Purchaser exercising three Extensions, such Purchaser’s Debenture will mature and be due and payable on June 30, 2023. Beginning on the date that the first Amortization Payment is due, and on a monthly basis thereafter, the Company will be required to pay one hundred fifteen percent of the value of one-twelfth of the outstanding principal plus any additional accrued interest due. In the event a Purchaser converts a portion of its Debenture into shares of the Company’s Common Stock, such amount will be deducted from the next applicable Amortization Payment. In the event such conversion exceeds the next applicable Amortization Payment, such excess amount will be deducted, in reverse order, from future Amortization Payments. The Company’s obligations under the Debentures are secured by substantially all of the assets of the Company pursuant to a security agreement (the “Security Agreement”). The Debentures are convertible at the option of the holder into shares of the Company’s common stock at an initial conversion price of $2.69 per share, subject to adjustment in the event of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata distributions, and (iv) certain fundamental transactions, including but not limited to the sale of the Company, business combinations, and reorganizations. The Debentures do not have any price protection or price reset provisions with respect to future issuances of securities. Subject to the Company’s compliance with certain equity conditions, upon ten trading days’ notice to the Purchasers, the Company has the right to redeem the Debentures in cash at 115% of their outstanding principal, plus accrued interest. Additionally, in the event that (i) the Company sells or reprices any securities (each, a “Redemption Financing”), or (ii) the Company disposes of assets (except those sold or transferred in the ordinary course of business) (each, an “Asset Sale”), then the Purchasers shall have the right to cause the Company (a) in the event of a Redemption Financing at a price per Common Stock equivalent of $2.50 or less per share, the Purchasers may mandate that 100% of the proceeds be used to redeem the Debentures (b) in the event of a Redemption Financing at a price per Common Stock equivalent of greater than $2.50 per share, the Purchasers may mandate that up to 50% of the proceeds be used to redeem the Debentures, and (c) in the event of an Asset Sale, the Purchasers may mandate that up to 100% of the proceeds be used to redeem the Debentures. The Debentures also contain certain customary events of default provisions, including, but not limited to, default in payment of principal or interest thereunder, breaches of covenants, agreements, representations or warranties thereunder, the occurrence of an event of default under certain material contracts of the Company, failure to register the shares underlying the Debentures in Warrants (as described below), changes in control of the Company, delisting of its securities from its trading market, and the entering or filing of certain monetary judgments against the Company. Upon the occurrence of any such event of default, the outstanding principal amount of the Debenture plus liquidated damages, interest and other amounts owing in respect thereof through the date of acceleration, shall become, at the Purchaser’s election, immediately due and payable in cash. The Company is also subject to certain negative covenants (unless waived by 67% of the then outstanding Purchasers, and including the lead Purchaser) under the Debentures, including but not limited to, the creation of certain debt obligations, liens on Company assets, amending its charter documents, repayment or repurchase of securities or certain debt of the Company, or the payment of dividends. The Warrants are initially exercisable at 2.50 per share and, are subject to cashless exercise after six months if the shares underlying the Warrants are not subject to an effective resale registration statement. The Warrants are also subject to adjustment in the event of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata distributions, and (iv) certain fundamental transactions, including but not limited to the sale of the Company, business combinations, and reorganizations. The Warrants do not have any price protection or price reset provisions with respect to future issuances of securities. Pursuant to the terms of the Debentures and Warrants, a Purchaser will not have the right to convert any portion of the Debentures or exercise any portion of the Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99% (at the Purchaser’s option) of the number of shares of Common Stock outstanding immediately after giving effect to such conversion or exercise, as such percentage ownership is determined in accordance with the terms of the Debentures and the Warrants; provided that at the election of a holder and notice to us such percentage ownership limitation may be increased to 9.99%; provided that any increase will not be effective until the 61st day after such notice is delivered from the holder to the Company. The Company also agreed to use proceeds from the Offering to pay (i) $2,500,000 in outstanding principal plus accrued interest pursuant to the Company’s Term Loan and Security Agreement entered into on February 28, 2020 with BRF Finance Co., LLC (the “Term Loan”) and (ii) $136,000 in outstanding short-term promissory notes and accrued interest (collectively, the “Debt Repayments”). In connection with Securities Purchase Agreement, the Company will issue to the Placement Agent (as defined below), an aggregate of 478,854 Common Stock purchase warrants (“PA Warrants”). The PA Warrants are substantially similar to the Warrants, except that the PA Warrants have an exercise price of $3.3625 per share. The fair value of the PA Warrants at issuance was estimated to be $360,000 based on a risk-free interest rate of .11%, an expected term of 2.417 years, an expected volatility of 96% and a 0% dividend yield. Pursuant to a registration rights agreement (“Registration Rights Agreement”), the Company has agreed to file a registration statement registering the resale of the shares of the common stock underlying the Debentures and the Warrants within forty-five days from the date of the Registration Rights Agreement. The Company also agrees to have the registration statement declared effective within 90 days from the date of the Registration Rights Agreement and keep the registration statement continuously effective until the earlier of (i) the date after which all of the securities to be registered thereunder have been sold, or (ii) the date on which all the securities to be registered thereunder may be sold without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 under the Securities Act. The Company is also obligated to pay the Investors, as partial liquidated damages, a fee of 2.0% of each Purchaser’s subscription amount per month in cash upon the occurrence of certain events, including our failure to file and(or) have the registration statement declared effective within the time periods provided. Bradley Woods & Co. Ltd. (“Placement Agent”) acted as the placement agent, in connection with the sale of the securities pursuant to the Securities Purchase Agreement. Pursuant to an engagement agreement entered into by and between the Company and the Placement Agent, the Company agreed to pay the Placement Agent a cash commission of $1,040,000. Pursuant to the discussion above, the Company also issued an aggregate of 478,854 PA Warrants to the Placement Agent. The Company has agreed to include the shares of our common stock underlying the PA Warrants to be included in the registration statement to be filed. Additionally, upon the exercise of Warrants issued in the Offering, the Placement Agent will be entitled to eight percent (8%) of the cash proceeds received from such exercises. The Transaction closed on June 30, 2020 (the “Closing Date”), with approximately $3,800,000 cash proceeds received prior to Closing date, $4,200,000 received on the closing date and $5,000,000 received after the closing date. The gross proceeds received from the Offering were approximately $13,000,000 and net proceeds of approximately $9,100,000 after deducting the Placement Agent fees, the Debt Repayments and other offering expenses. Also, the Company reimbursed the lead Purchaser $75,000 for legal fees, which was deducted from the required subscription amount to be paid. The Company evaluated all of the associated financial instruments in accordance with ASC 815 Derivatives and Hedging. In accordance with ASC 470 - Debt During the year ended December 31, 2020, the Company recognized amortization expense of $5,639,000. During the year ended December 31, 2020, holders of debenture principal converted $1,118,000 debenture into 411,626 shares of the Company’s class A common stock. As a result of these conversions and issuance of common stock, the Company wrote-off debt discount and increased additional paid in capital by $434,000 . During the year ended December 31, 2020, majority of the debenture holders exercise their rights to delay amortization payment by six months in exchange for 5% additional principal. Total additional principal due to extension amounted to $472,000. The table below summarizes the transactions during the year: Principal Debt discount Net book value Issuance during the year $ 16,101,000 $ (12,731,000 ) $ 3,370,000 Extension 472,000 - 472,000 Redemption (6,069,000 ) 3,037,000 (3,032,000 ) Conversion (1,118,000 ) 685,000 (433,000 ) Amortization - 5,639,000 5,639,000 Total $ 9,386,000 $ (3,370,000 ) $ 6,016,000 As of December 31, 2020, the Company has classified the debt as current liability because management intends to redeem the remaining convertible debentures within the following 12 months.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 16 – COMMITMENTS AND CONTINGENCIES Other Commitments In the ordinary course of business, the Company may provide indemnifications of varying scope and terms to customers, vendors, lessors, business partners, and other parties with respect to certain matters, including, but not limited to, losses arising out of the Company’s breach of such agreements, services to be provided by the Company, or from intellectual property infringement claims made by third parties. In addition, the Company has entered indemnification agreements with its directors and certain of its officers and employees that will require the Company to, among other things, indemnify them against certain liabilities that may arise due to their status or service as directors, officers or employees. The Company has also agreed to indemnify certain former officers, directors and employees of acquired companies in connection with the acquisition of such companies. The Company maintains director and officer insurance, which may cover certain liabilities arising from its obligation to indemnify its directors and certain of its officers and employees, and former officers, directors and employees of acquired companies, in certain circumstances. It is not possible to determine the maximum potential amount of exposure under these indemnification agreements due to the limited history of prior indemnification claims and the unique facts and circumstances involved in each agreement. Such indemnification agreements may not be subject to maximum loss clauses. Employment agreements We have entered employment agreements with key employees. These agreements may include provisions for base salary, guaranteed and discretionary bonuses and option grants. The agreements may contain severance provisions if the employees are terminated without cause, as defined in the agreements. Litigation From time to time, the Company may become subject to legal proceedings, claims and litigation arising in the ordinary course of business. In addition, the Company may receive letters alleging infringement of patent or other intellectual property rights. The Company is not currently a party to any material legal proceedings, nor is the Company aware of any pending or threatened litigation that would have a material adverse effect on the Company’s business, operating results, cash flows or financial condition should such litigation be resolved unfavorably. Business Interruption The Company may be impacted by public health crises beyond its control. This could disrupt its operations and negatively impact sales of its products. The Company’s customer and, suppliers may experience similar disruption. In December 2019, a novel strain of the Coronavirus, COVID-19, was reported to have surfaced in Wuhan, China, which has evolved into a pandemic. This situation and preventative or protective actions that governments have taken to counter the effects of the pandemic have resulted in a period of business disruption, including delays in shipments of products and raw materials. COVID-19 has spread to over 175 countries, including the United States, and efforts to contain the spread of COVID-19 have intensified. To the extent the impact of COVID-19 continues or worsens, the demand for the Company’s products may be negatively impacted. COVID-19 has also impacted the Company’s sales efforts as its ability to make sales calls is constrained. The Company’s ability to promote sales through promotional activities has also been constrained. Trade shows and sales conferences, major events used to introduce and sell the Company’s products, have been postponed indefinitely. The length and severity of the pandemic could also affect the Company’s regular sales, which could in turn result in reduced sales and a lower gross margin.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2020
Equity [Abstract]
Stockholders' Equity	NOTE 17 – STOCKHOLDERS’ EQUITY Authorized Shares Preferred Stock We are authorized to issue 50,000,000 of preferred stock, par value $0.001, of which 200,000 shares were designated as Series 1 Preferred Stock. Our board of directors, without further stockholder approval, may issue preferred stock in one or more series from time to time and fix or alter the designations, relative rights, priorities, preferences, qualifications, limitations and restrictions of the shares of each series. The rights, preferences, limitations and restrictions of different series of preferred stock may differ with respect to dividend rates, amounts payable on liquidation, voting rights, conversion rights, redemption provisions, sinking fund provisions and other matters. Our board of directors may authorize the issuance of preferred stock, which ranks senior to our common stock for the payment of dividends and the distribution of assets on liquidation. In addition, our board of directors can fix limitations and restrictions, if any, upon the payment of dividends on both classes of our common stock to be effective while any shares of preferred stock are outstanding. Common Stock We are authorized to issue an aggregate of 259,000,000 shares of common stock. Our certificate of incorporation provides that we will have two classes of common stock: Class A common stock (authorized 250,000,000 shares, par value $0.001), which has one vote per share, and Class B common stock (authorized 9,000,000 shares, par value $0.001), which has ten votes per share. Any holder of Class B common stock may convert his or her shares at any time into shares of Class A common stock on a share-for-share basis. Otherwise, the rights of the two classes of common stock are identical. As of December 31, 2020, the Company had 16,145,778 shares issued and outstanding. As of December 31, 2019, the Company had 13,997,452 shares issued and outstanding. In April 2019, the Company sold 1,687,825 shares of the Company’s common stock for gross proceeds of $6,751,300, or $4.00 per share. The net proceeds after the placement agent fees, of approximately $523,000, was approximately $6,229,000. In conjunction with this offering, the Company entered into a placement agent agreement, which provided for the placement agent to receive a cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of the shares of common stock, warrants to purchase up to 101,270 shares of Common Stock at an exercise price of $5.00 per share and reimbursement of up to $50,000 for offering related expense. In July 2019, we issued a 75,000 share of the Company’s common stock as compensation. On the date of grant the fair value of the shares was $374,000. The fair value is be expensed over a one-year service period. For the twelve months ended December 31, 2019, the compensation expense was $235,000. In August 2019, the Company entered into a settlement agreement with a lender. Based on the settlement agreement, the lender and the Company agreed to cancel the 220,000 shares of common stock issued as collateral. As of the settlement date, the Company owed the lender $150,000 for the original issue discount. The Company issued 58,101 shares of the Company’s common stock as payment for the original issue discount issue. The fair value of the shares on the date of issuance was $219,000. On August 12, 2019, the Company sold 1,525,000 shares of the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) and Series A warrants (“Series A Warrants”) to purchase 965,500 shares of Common Stock at a purchase price per share of $3.60 (the “Registered Direct Offering”) resulting in gross proceeds to the Company of $5,490,000 and net proceeds of $4,968,000 after cash payments to the placement agents and legal fees. Concurrently with the offering the Company also issued the Investors in a private placement (“Private Placement”) (i) Series B warrants (“Series B Warrants”) to purchase an aggregate of 1,525,000 shares of Common Stock and (ii) Series C warrants (“Series C Warrants”) to purchase an aggregate of 965,500 shares of Common Stock (collectively, the Series B Warrants and Series C Warrants are referred to herein as the “Private Warrants”). The Series A Warrants are immediately exercisable upon issuance, have a term of ninety (90) days from the date of issuance, and have an exercise price of $3.60 per share. The Series B Warrants and Series C Warrants are not exercisable for a period of six (6) months following the issuance date, have an exercise price of $4.00 per share, and expire on October 1, 2022. Additionally, the Series C Warrants vest ratably from time to time in proportion to such Investor’s exercise of the Series A Warrants. The 1,525,000 shares of Common Stock and Series A Warrants to purchase 965,500 shares of Common Stock sold in the Registered Direct Offering were offered and sold by the Company pursuant to an effective “shelf” registration statement on Form S-3 (File No. 333-214644), which was declared effective on November 28, 2016. The Private Warrants and the Placement Agent Warrants (as defined below) were sold and issued without registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under applicable state laws. In connection with the Registered Direct Offering and the Private Placement, the Company entered into engagement agreements (the “PA Agreements”) with The Special Equities Group, LLC, a division of Bradley Woods & Co. Ltd., and WestPark Capital, Inc. (the “Placement Agents”) on August 11, 2019 and August 9, 2019, respectively. Pursuant to the PA Agreements, the Placement Agents received (i) aggregate cash fees of 7.0% for one Placement Agent or 8.0% for the other Placement Agent, of their respective portions of the gross proceeds received by the Company from the sale of the securities, (ii) approximately $60,000 for certain expenses, and (iii) warrants to purchase up to 59,668 shares of Common Stock (the “Placement Agent Warrants”), representing 6.0% of the Common Stock and Series B Warrants sold by one of the Placement Agents in the Registered Direct Offering. The Placement Agent Warrants have substantially the same terms as the Series B Warrants, except that the exercise price of the Placement Agent Warrants is $4.50 per share and has a four (4) year term beginning one (1) year after issuance. Additionally, upon the exercise of up to 1,027,778 Series A Warrants, 650,701 Series B Warrants, and 1,027,778 Series C Warrants sold Registered Direct Offering and Private Placement, we have agreed to pay one of the Placement Agents a cash fee of 8% of proceeds from the exercise of such warrants exercised within 120 days following the closing of this offering or a cash fee of 5% of the proceeds from the exercise of such warrants after such 120 day period following the closing of this offering. One of the Placement Agents will be entitled to the foregoing cash commission and fee in the previous sentence with respect to certain investors if such investors provide capital to us in any future private or public offering, or other financing or capital-raising transaction during the six (6) months following the expiration or termination of our engagement of such Placement Agent. In January 2020, we sold non-performing receivables in the aggregate amount of $529,000 for a purchase price of $510,000 whereby in the event of payment on the receivables being received, we agreed to provide a true-up to the purchaser of the receivable of between 10% and 36% depending on the payment date. In the event of nonpayment of the receivables by March 24, 2020 and March 30, 2020, as applicable to the receivables, the purchaser may require us to purchase any outstanding portion of the receivables for 136% of its outstanding balance (“Payment Date”). In order to secure our performance to repurchase the receivables, we pledged 239,029 shares of our Class A common stock. The purchaser and Company agreed to extend the Payment Date until June 23 and June 30, 2020, as applicable, in exchange for an aggregate of 36,700 Class A common shares. In February 2020, we sold a series of short-term notes with a total principal amount of $450,000. These short-term notes have maturities of 90 days from the date of sale. The notes are redeemable by the Company at any time prior to maturity at face value plus a fee determined by the number of days the notes are outstanding. These fees range from 10% to 36% of the face value. The notes are collateralized by a total of 450,000 shares of the Company’s Class A common stock, subject to certain adjustments. In connection with our June 2020 Offering, the notes were exchanged for securities in the June 2020 Offering, except for 100,000 Class A shares which were issued to a note holder in exchange for an extension of the maturity date and waiver of interest under the notes. On September 4, 2020, pursuant to an agreement and plan of merger (“Merger Agreement”), we acquired LD Micro, Inc. as a wholly owned subsidiary in exchange for the following compensation paid to LD Micro’s stockholders: (i) four million dollars ($4,000,000) payable as follows (collectively, the “Cash Payment”): (a) $1,000,000 at the closing, (b) one million dollars ($1,000,000) on January 1, 2021, (c) one million dollars ($1,000,000) on April 1, 2021, and (d) one million dollars ($1,000,000) on July 1, 2021; and (ii) one million six hundred thousand (1,600,000) shares of Class A common stock issued at the closing. During the year ended December 31, 2020, holders of debenture principal converted $1,118,000 debenture into 411,626 shares of the Company’s class A common stock. As a result of these conversions and issuance of common stock, the Company wrote-off debt discount and increased additional paid in capital by $434,000.

Stock Options, Awards and Warra

Stock Options, Awards and Warrants	12 Months Ended
	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Stock Options, Awards and Warrants	NOTE 18 – STOCK OPTIONS, AWARDS AND WARRANTS 2012, 2014 and 2016 Equity Compensation Plans In January 2012, our board of directors and stockholders authorized the 2012 Equity Compensation Plan, which we refer to as the 2012 Plan, covering 600,000 shares of our Class A common stock. On November 5, 2014, our board of directors approved the adoption of our 2014 Equity Compensation Plan (the “2014 Plan”) and reserved 600,000 shares of our Class A common stock for grants under this plan. On February 23, 2016, our board of directors approved the adoption of our 2016 Equity Compensation Plan (the “2016 Plan”) and reserved 600,000 shares of our Class A common stock for grants under this plan. The purpose of the 2012, 2014 and 2016 Plans is to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to our employees, directors and consultants and to promote the success of our company’s business. The 2012, 2014 and 2016 Plans are administered by our board of directors. Plan options may either be: ● incentive stock options (ISOs), ● non-qualified options (NSOs), ● awards of our common stock, ● stock appreciation rights (SARs), ● restricted stock units (RSUs), ● performance units, ● performance shares, and ● other stock-based awards. Any option granted under the 2012, 2014 and 2016 Plans must provide for an exercise price of not less than 100% of the fair market value of the underlying shares on the date of grant, but the exercise price of any ISO granted to an eligible employee owning more than 10% of our outstanding common stock must not be less than 110% of fair market value on the date of the grant. The plans further provide that with respect to ISOs the aggregate fair market value of the common stock underlying the options which are exercisable by any option holder during any calendar year cannot exceed $100,000. The exercise price of any NSO granted under the 2012, 2014 or 2016 Plans is determined by the Board at the time of grant but must be at least equal to fair market value on the date of grant. The term of each plan option and the manner in which it may be exercised is determined by the board of directors or the compensation committee, provided that no option may be exercisable more than 10 years after the date of its grant and, in the case of an incentive option granted to an eligible employee owning more than 10% of the common stock, no more than five years after the date of the grant. The terms of grants of any other type of award under the 2012, 2014 or 2016 Plans is determined by the Board at the time of grant. Subject to the limitation on the aggregate number of shares issuable under the plans, there is no maximum or minimum number of shares as to which a stock grant or plan option may be granted to any person. Transactions involving our stock options for the years ended December 31, 2020 and 2019, respectively, are summarized as follows: In March 2019, 685,000 common stock options having an exercise price of $3.42 per share with an option value as of the grant date of $1,513,137 calculated using the Black-Scholes option pricing model were granted to several employees and members of our management team. This expense associated with this option award will be recognized in operating expenses ratably over the vesting period. In April 2019 the Company issued 11,252 options to purchase the Company’s common stock at a price of $5.49 to our non-executive directors. Each of our four non-executive directors received 2,813 options that vest 1/4 th In April 2020 the Company issued 36,172 options to purchase the Company’s common stock at a price of $1.95 to our non-executive directors. Each of our four non-executive directors received 9,043 options that vest 1/4 th In August 2020, 430,000 common stock options having an exercise price of $2.70 per share with an option value as of the grant date of $859,000 calculated using the Black-Scholes option pricing model were granted to several employees and members of our management team. The expense associated with this option award will be recognized in operating expenses ratably over the vesting period of five years. In November 2020, 300,000 common stock options having an exercise price of $2.97 per share with an option value as of the grant date of $649,000 calculated using the Black-Scholes option pricing model were granted to an employee. The expense associated with this option award will be recognized in operating expenses at date of grant. Number of Shares Weighted Average Strike Price/Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Weighted Average Grant Date Fair Value Outstanding — December 31, 2018 547,662 $ 5.94 2.73 $ — $ — Granted 696,252 3.45 2.34 — 2.25 Exercised — — — — — Forfeited (51,395 ) 6.92 — — 3.37 Outstanding — December 31, 2019 1,192,519 4.14 2.17 — — Vested and exercisable — December 31, 2019 355,083 5.63 2.22 — 3.98 Unvested and non-exercisable - December 31, 2019 837,436 3.49 2.15 — 2.29 Outstanding — December 31, 2019 1,192,519 4.14 2.17 — — Granted 766,172 2.77 3.00 521,000 2.72 Exercised — — — — — Forfeited (316,367 ) 5.14 — — 3.14 Outstanding — December 31, 2020 1,642,324 3.30 2.81 — — Vested and exercisable — December 31, 2020 844,742 3.54 2.62 333,000 3.54 Unvested and non-exercisable - December 31, 2020 797,582 $ 2.81 3.00 $ 207,000 $ 2.09 During the years ended December 31, 2020 and 2019, we recorded compensation expense of $1,852,000 and $1,167,000, respectively, related to stock-based compensation. As of December 31, 2020, compensation cost related to the unvested options not yet recognized was approximately $1,667,000. The weighted average period over which the $1,667,000 will vest is estimated to be 3 years. Transactions involving our common stock awards for the years ended December 31, 2020 and 2019, respectively, are summarized as follows: On May 13, 2019 the Company entered into a consulting agreement with a contractor for services related to BIGToken. The agreement provides for 300,000 warrants with vesting conditions based on BIGToken user growth in Asia. The warrants were valued using the Black Scholes option pricing model at a total of $1,138,332 based on the five-year term, implied volatility of 101%, a risk-free equivalent yield of 1.8% and stock price of $4.99. Number of Shares Weighted Average Strike Price/Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Weighted Average Grant Date Fair Value Outstanding — December 31, 2018 4,325,423 $ 5.05 2.85 $ — $ - Granted 3,885,442 3.99 2.21 94,910 1.60 Exercised (342,000 ) 3.50 — — 4.79 Forfeited (1,631,435 ) 5.14 — — 1.97 Outstanding — December 31, 2019 6,237,430 3.57 2.68 — — Vested and exercisable — December 31, 2019 5,937,430 3.51 2.60 — 2.34 Unvested and non-exercisable - December 31, 2019 300,000 4.75 4.43 — 3.88 Outstanding — December 31, 2019 6,237,430 3.57 2.68 — — Granted 7,421,054 2.63 1.82 3,929,000 1.38 Exercised — — — — — Forfeited (1,073,201 ) — — — — Outstanding — December 31, 2020 12,585,283 2.98 1.78 4,460,000 1.38 Vested and exercisable — December 31, 2020 12,285,283 2.94 1.74 4,460,000 1.38 Unvested and non-exercisable - December 31, 2020 300,000 $ 4.75 3.37 $ — $ —

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 19 – INCOME TAXES Income tax expense from continuing operations for the year ended December 31, 2020 consisted of the following: Current Deferred Total Federal $ — $ — State 26,000 — 26,000 Subtotal 26,000 — 26,000 Valuation allowance — — — Total $ 26,000 $ — $ 26,000 Income tax (benefit) expense from continuing operations for the year ended December 31, 2019 consisted of the following: Current Deferred Total Federal $ — $ (3,198,000 ) $ (3,198,000 ) State — (920,000 ) (920,000 ) Subtotal — (4,118,000 ) (4,118,000 ) Valuation allowance — 4,118,000 4,118,000 Total $ — $ — $ — A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate is as follows: 2020 2019 Taxes calculated at federal rate 21.0 % 21.0 % Stock based compensation (2.7 )% (1.4 )% Permanent Differences (13.1 )% - % Change in Valuation Allowance (2.5 )% (23.7 )% Fair market adjustment derivatives 0.5 % 1.3 % Prior year True-ups (3.3 )% 3.0 % Other adjustments (0.1 )% (0.2 )% Provision for income taxes (0.2 )% — % The tax effects, rounded to thousands, of temporary differences that give rise to significant portions of the deferred tax assets and liabilities at December 31, are presented below: 2020 2019 Deferred Tax Assets Net operating loss carryforwards $ 9,040,000 $ 6,621,000 Bad debt expense 136,000 111,000 Fixed assets 9,000 - Accrued interest - 492,000 Stock based compensation 567,000 431,000 Interest expense limitation carryover 629,000 - Contribution carryover 5,000 - Lease liability 97,000 - Other accruals 192,000 84,000 Total Deferred Tax Assets 10,675,000 7,739,000 Deferred Tax Liabilities Fixed assets - (39,000 ) Right-of-use asset (101,000 ) - Unrealized gain on marketable securities (72,000 ) - Intangibles (690,000 ) (327,000 ) Prepaid expenses (17,000 ) (20,000 ) Total Deferred Tax Liabilities (880,000 ) (386,000 ) Net Deferred Tax Assets 9,795,000 7,353,000 Valuation Allowance (9,795,000 ) (7,353,000 ) Net deferred tax / (liabilities) $ — $ — Deferred tax assets and liabilities are computed by applying the federal and state income tax rates in effect to the gross amounts of temporary differences and other tax attributes, such as net operating loss carry-forwards. In assessing if the deferred tax assets will be realized, the Company considers whether it is more likely than not that some or all of these deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the period in which these deductible temporary differences reverse. During the years ended December 31, 2020 and 2019, the valuation allowance increased by $2,442,000 and $4,283,000, respectively. The increase for both years was attributable to the increase in our net operating loss carryforwards. The total valuation allowance results from the Company’s estimate of its inability to recover its net deferred tax assets. At December 31, 2020, the Company has federal and state net operating loss carry forwards, which are available to offset future taxable income, of approximately $31,439,000 and $36,679,000, respectively, both of which begin to expire in 2032 and 2032 respectively. These carry forwards may be subject to an annual limitation under Section 382 and 383 of the Internal Revenue Code of 1986, and similar state provisions if the Company experienced one or more ownership changes which would limit the amount of NOL and tax credit carryforwards that can be utilized to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382 and 383, results from transactions increasing ownership of certain stockholders or public groups in the stock of the corporation by more than 50 percentage points over a three-year period. The Company has not completed an IRC Section 382/383 analysis. If a change in ownership were to have occurred, NOL and tax credit carryforwards could be eliminated or restricted. If eliminated, the related asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the Company’s effective tax rate. The Company files income tax returns in the United States and various state jurisdictions. Due to the Company’s net operating loss posture all tax years are open and subject to income tax examination by tax authorities. The Company’s policy is to recognize interest expense and penalties related to income tax matters as tax expense. As of December 31, 2020 and 2019, there are no unrecognized tax benefits, and there are no significant accruals for interest related to unrecognized tax benefits or tax penalties. The Company is in the process of analyzing their NOL and has not determined if the company has had any change of control issues that could limit the future use of NOL. NOL carryforwards that were generated after 2017 of approximately $20.1 million may only be used to offset 80% of taxable income and are carried forward indefinitely.

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 20 – FAIR VALUE OF FINANCIAL INSTRUMENTS The carrying amounts of certain financial instruments, including cash and cash equivalents and accounts payable and accrued expenses, approximate their respective fair values due to the short-term nature of such instruments. Assets and Liabilities Measured at Fair Value on a Recurring Basis The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant judgments to be made. The Company had the following financial assets and liabilities as of December 31, 2020 and 2019: Quoted Prices in Significant Other Significant Balance as of Active Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2020 (Level 1) (Level 2) (Level 3) Marketable securities $ 8,447,000 $ 7,764,000 $ 683,000 $ — Total assets $ 8,447,000 $ 7,764,000 $ 683,000 $ — F-38 Quoted Prices in Significant Other Significant Balance as of Active Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2019 (Level 1) (Level 2) (Level 3) Marketable securities $ 83,000 $ 83,000 $ — $ — Total assets $ 83,000 $ 83,000 $ — $ — Debenture warrant liability $ 3,549,000 $ — $ — $ 3,549,000 Leapfrog warrant liability 480,000 — — 480,000 Derivative liability 368,000 — — 368,000 Total liabilities $ 4,397,000 $ — $ — $ 4,397,000 A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the years ended December 31: 2019 Outstanding, beginning of the period $ 5,442,000 Change in fair value (1,045,000 ) Warrant liabilities $ 4,397,000

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Segment Reporting	NOTE 21 – SEGMENT REPORTING The Company reorganized its operating units into two reporting segments, Sequire and BIGToken. As part of the reorganization, the Company was required to allocate the goodwill between the two reporting segments. Of the $15,645,000 of aggregate goodwill, $10,200,000 and $5,445,000 was allocated to Sequire and BIGToken, respectively. The goodwill was allocated to the two reporting units based on the relative fair value of each reporting unit as of June 30, 2020. The relative fair values of Sequire and BIGToken were determined using the discounted cash flow method, which is a form of the income approach. The discounted cash flow method (“DCF”) utilized discrete financial forecasts and other financial assumptions developed by management. The determination of fair value requires significant management judgment including estimating future sales, cost of sales, changes in working capital, investments in property and equipment and the selection of an appropriate discount rate. Additionally, we corroborate the conclusions of our discounted cash flow analyses by examining the trading multiples of similar publicly traded companies that operate within our industry vertical and compared the implied trading multiples of our DCF analysis with our publicly traded company group as a test for reasonableness. The Company has three operating units and two reportable segments: (i) Investor data analysis technologies (Sequire) and (ii) Consumer based marketing services and data technologies (BIGToken ). Our Chief Operating Decision Maker (CODM) does not evaluate operating segments using asset or liability information. The following table presents revenues and gross profits by reportable segment. For the Years Ended December 31, SEQUIRE BIGToken Corporate and Other Consolidated 2020 2019 2020 2019 2020 2019 2020 2019 Sequire platform revenue $ 5,781,000 $ 87,000 $ - $ - $ - $ - $ 5,781,000 $ 87,000 Conference revenue 503,000 - - - - - 503,000 - BIGtoken revenue - - 2,168,000 3,228,000 - - 2,168,000 3,228,000 Other - - - - 195,000 269,000 195,000 269,000 Total Revenue 6,284,000 87,000 2,168,000 3,228,000 195,000 269,000 8,647,000 3,584,000 Cost of Revenue 1,783,000 7,000 800,000 1,613,000 6,000 60,000 2,589,000 1,680,000 Gross profit $ 4,501,000 $ 80,000 $ 1,368,000 $ 1,615,000 $ 189,000 $ 209,000 $ 6,058,000 $ 1,904,000 Revenue Disaggregation The following table breaks out the revenue types for Sequire and BIGToken 2020 2019 Sequire platform revenue $ 5,781,000 $ 87,000 Conference revenue 503,000 - Sequire revenues 6,284,000 87,000 Consumer Media / Data 2,168,000 3,228,000 BIGToken revenues 2,168,000 3,228,000 Other revenues 195,000 269,000 Total revenues $ 8,647,000 $ 3,584,000 As of December 31, 2020 and 2019, revenue contract liabilities were approximately $4,842,000 and $0, respectively.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 22 – SUBSEQUENT EVENTS The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The Management of the Company determined the following reportable events: Share Exchange Agreement On February 4, 2021, the Company completed the share exchange (“Share Exchange”) with Force Protection Video Equipment Corporation (“FPVD”) initially disclosed on the Company’s Current Report on Form 8-K filed with the Securities Exchange Commission on October 5, 2020. Pursuant to the Share Exchange, the Company divested its ownership in BIG Token, Inc. (“BIG Token”), the Company’s wholly owned subsidiary. As a result of the Share Exchange, BIG Token became the wholly owned subsidiary of FPVD. The transaction was accounted for as a reverse acquisition; therefore, the Company will account for this transaction as a purchase of the assets and liabilities of FPVD. The Company is deemed to be the purchaser and surviving company for accounting purposes. Accordingly, due to acquisition, BIGToken’s net assets will be included in the balance sheet at their historical book values and the results of operations will be presented for the comparative prior periods. As consideration for the Share Exchange, the Company received 149,562,566,584 shares of FPVD’s common stock and 5,000,000 shares of FPVD’s Series A Preferred Stock for 100% of the issued and outstanding common stock of BIGToken. BIGToken’s statement of changes in stockholders’ equity were restated to reflect the 149,562,566,584 common stock and 5,000,000 shares of Series A Preferred Stock received as a result of the Share Exchange. Amendment to Share Exchange Agreement The Company entered into an Amendment to the Exchange Agreement on January 27, 2021. The Exchange Amendment amended the amount of securities each party thereto would receive in the Share Exchange and included anti-dilution protection for the Company should FPVD sell equity securities at a pre-money valuation of less than $10,000,000 resulting in the Company owning less than 70% of the voting power of FPVD. Transition Services Agreement On January 27, 2021 BIG Token and FPVD entered into the TSA with the Company. Pursuant to the TSA, the Company agreed to FPVD us with certain operational and administrative services as needed. Master Separation Agreement On January 27, 2021, BIG Token and FPVD entered into the MSA with the Company. The MSA describes FPVD’s separation from the Company. Warrant offering On February 21, 2021, SRAX, Inc. (the “Company”) entered into letter agreements (the “Letter Agreements”) with certain existing institutional and accredited investors to exercise certain outstanding warrants (the “Existing Warrants”) to purchase up to an aggregate of 4,545,550 shares of the Company’s Class A common stock (“Common Stock”) at their original exercise price of $2.50 per share (the “Exercise”). The shares of Common Stock underlying the Existing Warrants were previously registered pursuant to a registration statement on Form S-3 (File No. 333-240270). In consideration for the exercise of the Existing Warrants for cash, the exercising holders will receive new registered warrants to purchase up to an aggregate of 4,545,440 shares of Common Stock (the “New Warrants”) at an exercise price of $7.50 per share and will expire on January 31, 2022. The New Warrants will be issued pursuant to the existing shelf registration statement on Form S-3 (File No.333-235298). Each investor has agreed to pay $0.125 for each New Warrant received. Pursuant to the Letter Agreements, the New Warrants shall be substantially in the form of the Existing Warrants, will be exercisable immediately, and will have a term that ends on January 31, 2022. The Special Equities Group, a division of Bradley Woods & Co. Ltd., acted as warrant solicitation agent and will receive a cash fee of $909,088. Prior to deducting solicitation agent fees, the Company expects to receive gross proceeds from the Exercise of $11,932,000. The Company currently intends to use the net proceeds from the Exercise for general working capital. The closing of the Exercise is expected to take place on or about February 23, 2022. Option Issuance to CEO As of February 2021, FPVD is required to issue to its newly appointed CEO an option to purchase an aggregate of 13,951,066,447 shares of Common Stock, of FPVD, at a weighted average exercise price of $0.000062719 per share, subject to certain vesting conditions. FPVD Equity Offering On March 12, 2021, our consolidated subsidiary, FPVD entered into a Securities Purchase Agreements (“SPA”) and Registration Rights Agreements (“RRA”) with accredited investors pursuant to which investors purchased 47,248.27 shares of Series B preferred Stock (“Series B Stock”) for an aggregate of $4,724,827 or $100 per share (the “Offering”). The Offering closed on March 12, 2021. FPVD had previously closed on 10,500 shares of Series B Preferred stock or $1,050,000 in October of 2020. As a result, on March 12, 2021, there were 57,748.27 shares of Series B Stock outstanding. OID Convertible Debenture conversions During the period subsequent December 31, 2020 and through March 28, 2021 the Company has issued approximately 2,000,000 shares of common stock through the conversions of convertible debentures. At the Market Offering issuances From January 1, 2021 through March 25, 2021, we have sold 53,626 shares under such agreement at an average per share price of $5.47 resulting in gross proceeds of $293,000 and net proceeds of $284,000 after deducting Sales Agent commissions of up to 5% and other costs and expenses associated with such sales. Future sales under our at-the-market sales agreement are limited to $2,832,000, the remaining amount left pursuant to the takedown from our shelf registration statement.

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization We are a technology firm focused on enhancing communications between public companies and their shareholders and investors. We currently have two distinct business units: ● Our unique SaaS platform, Sequire provides users many features which allow issuers to track their shareholders’ behaviors and trends, then use data-driven insights to engage with shareholders across marketing channels. ● Through LD Micro, we organize and host investor conferences within the micro and small- cap space, and plan to create several more niche events for the investor community. Our endeavor provides our clients an integrated investor and shareholder analytics platform drove us to develop this platform, acquire LD Micro, and begin cultivating the Sequire Community. Each SRAX business unit delivers valuable insights that assist our clients with their investor relations and communications initiatives. We are headquartered in Westlake Village, California but work as a distributed virtual Company.
Liquidity and Going Concern	Liquidity and Going Concern The Company has incurred significant losses since its inception and has not demonstrated an ability to generate sufficient revenues from the sales of its goods and services to achieve profitable operations. In addition, the Company’s operations and specifically, the continued operation of BIGToken will require significant additional financing. As of December 31, 2020, the Company had cash and cash equivalents of $451,000 which is not sufficient to fund the Company’s planned operations through one year after the date the consolidated financial statements are issued, and accordingly, these factors create substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. The consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. Accordingly, the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of business. In making this assessment we performed a comprehensive analysis of our current circumstances including: our financial position, our cash flow and cash usage forecasts, and obligations and debts. Although management has a long history of successful capital raises, the analysis used to determine the Company’s ability as a going concern does not include cash sources outside the Company’s direct control that management expects to be available within the next 12 months. We expect that our existing cash and cash equivalents as of December 31, 2020, will not be sufficient to enable us to fund our anticipated level of operations through 2021. As discussed in Note 22 Subsequent events, the Company has raised approximately $16 million in net proceeds through the sale of equity securities and the exercise of warrants. We anticipate raising additional capital through the private and public sales of our equity or debt securities and selling our marketable securities or a combination thereof. Although management believes that such capital sources will be available, there can be no assurance that financing will be available to us when needed in order to allow us to continue our operations, or if available, on terms acceptable to us. If we do not raise sufficient capital in a timely manner, among other things, we may be forced to scale back our operations or cease operations altogether. During the year ended December 31, 2020, the Company was able to raise net cash proceeds (net of debt repayments, commissions, and fees) of approximately $7,900,000. The Company’s capital-raising efforts are ongoing and the Company has undertaken the following to raise capital and reduce its cash burn rate: (i) received a PPP Loan from the Small Business Administration for funding under the Payroll Protection Program, in the amount of $1,084,000 (ii) entered into an “At the Market” sales agreement for the sale of up to $3,125,000 of our equity securities, (iii) sold OID convertible debentures for proceeds of $13,268,000. Additionally, the Company sold its remaining position in TI Health (f/k/a SRAXmd) for a total of $8,000,000. Substantially, all of these proceeds were used to redeem a portion of our outstanding OID convertible debentures. The ultimate impact of the COVID-19 pandemic on the Company’s operations continues to be unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but may have a material impact on our business, financial condition and results of operations. The significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact. Management continues to monitor the business environment for any significant changes that could impact the Company’s operations. The Company has taken proactive steps to manage costs and discretionary spending, such as remote working and reducing facility related expenses.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. The consolidated financial statements include the accounts of the Company and its subsidiaries from the acquisition date of majority voting control of the subsidiary.
Business Segments	Business Segments The Company uses the “management approach” to identify its reportable segments. The management approach designates the internal organization used by management for making operating decisions and assessing performance as the basis for identifying the Company’s reportable segments. Using the management approach, the Company determined that it has two operating segments BIGToken and Sequire.
Business Combinations	Business Combinations For all business combinations (whether partial, full or step acquisitions), the Company records 100% of all assets and liabilities of the acquired business, including goodwill, generally at their fair values; contingent consideration, if any, is recognized at its fair value on the acquisition date and, for certain arrangements, changes in fair value are recognized in earnings until settlement and acquisition-related transaction and restructuring costs are expensed rather than treated as part of the cost of the acquisition.
Use of Estimates	Use of Estimates The consolidated financial statements have been prepared in conformity with generally accepted accounting principles accepted in the United States of America (“GAAP”) and requires management of the Company to make estimates and assumptions in the preparation of these consolidated financial statements that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from these estimates and assumptions. The most significant areas that require management judgment and which are susceptible to possible change in the near term include the Company’s revenue recognition, allowance for doubtful accounts and sales credits, stock-based compensation, income taxes, borrowing rate considered for operating lease right-of-use asset and related operating lease liability, purchase price for acquisition, goodwill, other intangible assets, put rights and valuation of other assets and liabilities.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The accounting standard for fair value measurements provides a framework for measuring fair value and requires disclosures regarding fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, based on the Company’s principal or, in absence of a principal, most advantageous market for the specific asset or liability. The Company uses a three-tier fair value hierarchy to classify and disclose all assets and liabilities measured at fair value on a recurring basis, as well as assets and liabilities measured at fair value on a non-recurring basis, in periods subsequent to their initial measurement. The hierarchy requires the Company to use observable inputs when available, and to minimize the use of unobservable inputs, when determining fair value. The three tiers are defined as follows: ● Level 1—Observable inputs that reflect quoted market prices (unadjusted) for identical assets or liabilities in active markets; ● Level 2—Observable inputs other than quoted prices in active markets that are observable either directly or indirectly in the marketplace for identical or similar assets and liabilities; and ● Level 3—Unobservable inputs that are supported by little or no market data, which require the Company to develop its own assumptions. The determination of fair value and the assessment of a measurement’s placement within the hierarchy requires judgment. Level 3 valuations often involve a higher degree of judgment and complexity. Level 3 valuations may require the use of various cost, market, or income valuation methodologies applied to unobservable management estimates and assumptions. Management’s assumptions could vary depending on the asset or liability valued and the valuation method used. Such assumptions could include: estimates of prices, earnings, costs, actions of market participants, market factors, or the weighting of various valuation methods. The Company may also engage external advisors to assist us in determining fair value, as appropriate. Although the Company believes that the recorded fair value of our financial instruments is appropriate, these fair values may not be indicative of net realizable value or reflective of future fair values. The Company’s financial instruments, including cash and cash equivalents, net accounts receivable, accounts payable and accrued expenses, are carried at historical cost. At December 31, 2020 and 2019, the carrying amounts of these instruments approximated their fair values because of the short-term nature of these instruments. The Company measures certain non-financial assets, liabilities, and equity issuances at fair value on a non-recurring basis. These non-recurring valuations include evaluating assets such as long-lived assets and goodwill for impairment; allocating value to assets in an acquired asset group; and applying accounting for business combinations.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term highly liquid investments with a remaining maturity at the date of purchase of three months or less to be cash equivalents.
Accounts Receivable	Accounts Receivable Credit is extended to customers based on an evaluation of their financial condition and other factors. Management periodically assesses the Company’s accounts receivable and, if necessary, establishes an allowance for estimated uncollectible amounts. Accounts determined to be uncollectible are charged to operations when that determination is made. The Company usually does not require collateral. Allowance for doubtful accounts was approximately $491,000 and $530,000 as of December 31, 2020 and 2019, respectively.
Concentration of Credit and Significant Customer Risk	Concentration of Credit and Significant Customer Risk Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents and accounts receivable. Cash and cash equivalents are deposited with financial institutions within the United States. The balances maintained at these financial institutions are generally more than the Federal Deposit Insurance Corporation insurance limits. The Company has not experienced any loss on these accounts. As of December 31, 2020, the Company had two customers with accounts receivable balances of approximately 20.0% and 10.4%. As of December 31, 2019, the Company had three customers with accounts receivable balances of approximately 23.7%, 15.0%, and 13.7%. For the year ended December 31, 2020, the Company had one customer that account for approximately 18.1% of total revenue. For the year ended December 31, 2019, the Company had two customers that accounted for 17.7% and 12.9%.
Long-lived Assets	Long-lived Assets Management evaluates the recoverability of the Company’s identifiable intangible assets and other long-lived assets when events or circumstances indicate a potential impairment exists. Events and circumstances considered by the Company in determining whether the carrying value of identifiable intangible assets and other long-lived assets may not be recoverable include, but are not limited to: significant changes in performance relative to expected operating results; significant changes in the use of the assets; significant negative industry or economic trends; a significant decline in the Company’s stock price for a sustained period of time; and changes in the Company’s business strategy. In determining if impairment exists, the Company estimates the undiscounted cash flows to be generated from the use and ultimate disposition of these assets. If impairment is indicated based on a comparison of the assets’ carrying values and the undiscounted cash flows, the impairment loss is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairments have been recorded regarding its identifiable intangible assets or other long-lived assets during the years ended December 31, 2020 or 2019, respectively.
Property and Equipment	Property and equipment Property and equipment is stated at cost less accumulated depreciation. Depreciation is provided on the straight-line basis over the estimated useful lives of the assets of three to seven years. Expenditures for repair and maintenance which do not materially extend the useful lives of property and equipment are charged to operations. When property or equipment is sold or otherwise disposed of, the cost and related accumulated depreciation are removed from the respective accounts with the resulting gain or loss reflected in operations. Management periodically reviews the carrying value of its property and equipment for impairment.
Intangible Assets	Intangible assets Intangible assets consist of intellectual property, a non-compete agreement, and internally developed software and are stated at cost less accumulated amortization. Amortization is provided for on the straight-line basis over the estimated useful lives of the assets of five to six years. Costs incurred to develop computer software for internal use are capitalized once: (1) the preliminary project stage is completed, (2) management authorizes and commits to funding a specific software project, and (3) it is probable that the project will be completed and the software will be used to perform the function intended. Costs incurred prior to meeting the qualifications are expensed as incurred. Capitalization of costs ceases when the project is substantially complete and ready for its intended use. Post-implementation costs related to the internal use computer software, are expensed as incurred. Internal use software development costs are amortized using the straight-line method over its estimated useful life which ranges up to three years. Software development costs may become impaired in situations where development efforts are abandoned due to the viability of the planned project becoming doubtful or due to technological obsolescence of the planned software product. For the years ended December 31, 2020, and 2019 there has been no impairment associated with internal use software. For the years ended December 31, 2020, and 2019, the Company capitalized software development costs of $1,172,000 and $1,292,000, respectively. During 2016, the Company began capitalizing the costs of developing internal-use computer software, including directly related payroll costs. The Company amortizes costs associated with its internally developed software over periods up to three years, beginning when the software is ready for its intended use. The Company capitalizes costs incurred during the application development stage of internal-use software and amortize these costs over the estimated useful life. Upgrades and enhancements are capitalized if they result in added functionality which enable the software to perform tasks it was previously incapable of performing. Software maintenance, training, data conversion, and business process reengineering costs are expensed in the period in which they are incurred.
Right of Use Assets and Lease Obligations	Right of Use Assets and Lease Obligations The Right of Use Asset and Lease Liability reflect the present value of the Company’s estimated future minimum lease payments over the lease term, which may include options that are reasonably assured of being exercised, discounted using a collateralized incremental borrowing rate. Typically, renewal options are considered reasonably assured of being exercised if the associated asset lives of the building or leasehold improvements exceed that of the initial lease term, and the sales performance of the restaurant remains strong. Therefore, the Right of Use Asset and Lease Liability may include an assumption on renewal options that have not yet been exercised by the Company. As the rate implicit in leases are not readily determinable, the Company uses an incremental borrowing rate to calculate the lease liability that represents an estimate of the interest rate the Company would incur to borrow on a collateralized basis over the term of a lease within a particular currency environment.
Goodwill	Goodwill Goodwill is comprised of the purchase price of business combinations in excess of the fair value assigned at acquisition to the net tangible and identifiable intangible assets acquired. Goodwill is not amortized. The Company tests goodwill for impairment for its reporting units on an annual basis, or when events occur or circumstances indicate the fair value of a reporting unit is below its carrying value. If the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that implied fair value of the goodwill within the reporting unit is less than its carrying value. The Company performed its most recent annual goodwill impairment test as of December 31, 2020 using market data and discounted cash flow analysis. Based on this analysis, it was determined that the fair value exceeded the carrying value of its reporting units. The Company concluded the fair value of the goodwill exceeded the carrying value accordingly there were no indicators of impairment for the years ended December 31, 2020 and 2019. The Company had historically performed its annual goodwill and impairment assessment on December 31 st When evaluating the potential impairment of goodwill, management first assess a range of qualitative factors, including but not limited to, macroeconomic conditions, industry conditions, the competitive environment, changes in the market for the Company’s products and services, regulatory and political developments, entity specific factors such as strategy and changes in key personnel, and the overall financial performance for each of the Company’s reporting units. If, after completing this assessment, it is determined that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then proceed to the impairment testing methodology primarily using the income approach (discounted cash flow method). We compare the carrying value of the reporting unit, including goodwill, with its fair value, as determined by its estimated discounted cash flows. If the carrying value of a reporting unit exceeds its fair value, then the amount of impairment to be recognized. When required, we arrive at our estimates of fair value using a discounted cash flow methodology which includes estimates of future cash flows to be generated by specifically identified assets, as well as selecting a discount rate to measure the present value of those anticipated cash flows. Estimating future cash flows requires significant judgment and includes making assumptions about projected growth rates, industry-specific factors, working capital requirements, weighted average cost of capital, and current and anticipated operating conditions. The use of different assumptions or estimates for future cash flows could produce different results.
Derivatives	Derivatives The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic No. 480, Distinguishing Liabilities From Equity Derivatives and Hedging The Company has adopted ASU 2017-11, Earnings per share (Topic 260), provided that when determining whether certain financial instruments should be classified as liability or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. If a down round feature on the conversion option embedded in the note is triggered, the Company will evaluate whether a beneficial conversion feature exists, the Company will record the amount as a debt discount and will amortize it over the remaining term of the debt. If the down round feature in the warrants that are classified as equity is triggered, the Company will recognize the effect of the down round as a deemed dividend, which will reduce the income available to common stockholders.
Warrant Liability	Warrant Liability The Company accounts for certain common stock warrants outstanding as a liability at fair value and adjusts the instruments to fair value at each reporting period. This liability is subject to re-measurement at each balance sheet date until exercised, and any change in fair value is recognized in the Company’s consolidated statements of operations. The fair value of the warrants issued by the Company has been estimated using a Black-Scholes option pricing model, at each measurement date.
Debt Discounts	Debt Discounts The Company accounts for debt discounts originating in connection with conversion features that remain embedded in the related notes in accordance with ASC 470-20, Debt with Conversion and Other Options
Revenue Recognition	Revenue Recognition The Company adopted Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers ASC Topic 606 is a comprehensive revenue recognition model that requires revenue to be recognized when control of the promised goods or services are transferred to our customers at an amount that reflects the consideration that we expect to receive. Application of ASC Topic 606 requires us to use more judgment and make more estimates than under former guidance. Application of ASC Topic 606 requires a five-step model applicable to all product offering revenue streams as follows: Identification of the contract, or contracts, with a customer A contract with a customer exists when (i) we enter into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) we determine that collection of substantially all consideration for goods or services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience or, in the case of a new customer, published credit or financial information pertaining to the customer. Identification of the performance obligations in the contract Performance obligations promised in a contract are identified based on the goods or services that will be transferred to the customer that are both capable of being distinct, whereby the customer can benefit from the goods or service either on its own or together with other resources that are readily available from third parties or from us, and are distinct in the context of the contract, whereby the transfer of the goods or services is separately identifiable from other promises in the contract. When a contract includes multiple promised goods or services, we apply judgment to determine whether the promised goods or services are capable of being distinct and are distinct within the context of the contract. If these criteria are not met, the promised goods or services are accounted for as a combined performance obligation. Determination of the transaction price The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods or services to our customer. We estimate any variable consideration included in the transaction price using the expected value method that requires the use of significant estimates for discounts, cancellation periods, refunds and returns. Variable consideration is described in detail below. Allocation of the transaction price to the performance obligations in the contract If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price to each performance obligation based on a relative Stand-Alone Selling Price (“SSP,”) basis. We determine SSP based on the price at which the performance obligation would be sold separately. If the SSP is not observable, we estimate the SSP based on available information, including market conditions and any applicable internally approved pricing guidelines. Recognition of revenue when, or as, we satisfy a performance obligation We recognize revenue at the point in time that the related performance obligation is satisfied by transferring the promised goods or services to our customer. Principal versus Agent Considerations When another party is involved in providing goods or services to our customer, we apply the principal versus agent guidance in ASC Topic 606 to determine if we are the principal or an agent to the transaction. When we control the specified goods or services before they are transferred to our customer, we report revenue gross, as principal. If we do not control the goods or services before they are transferred to our customer, revenue is reported net of the fees paid to the other party, as agent. Our evaluation to determine if we control the goods or services within ASC Topic 606 includes the following indicators: We are primarily responsible for fulfilling the promise to provide the specified good or service. When we are primarily responsible for providing the goods and services, such as when the other party is acting on our behalf, we have indication that we are the principal to the transaction. We consider if we may terminate our relationship with the other party at any time without penalty or without permission from our customer. We have risk before the specified good or service have been transferred to a customer or after transfer of control to the customer. We may commit to obtaining the services of another party with or without an existing contract with our customer. In these situations, we have risk of loss as principal for any amount due to the other party regardless of the amount(s) we earn as revenue from our customer. The entity has discretion in establishing the price for the specified good or service. We have discretion in establishing the price our customer pays for the specified goods or services. Contract Liabilities Contract liabilities consist of customer advance payments and billings in excess of revenue recognized. We may receive payments from our customers in advance of completing our performance obligations. We record contract liabilities equal to the amount of payments received in excess of revenue recognized, including payments that are refundable if the customer cancels the contract according to the contract terms. Contract liabilities have been historically low historically recorded as current liabilities on our consolidated financial statements when the time to fulfill the performance obligations under terms of our contracts is less than one year. We have no long-term contract liabilities which would represent the amount of payments received in excess of revenue earned, including those that are refundable, when the time to fulfill the performance obligation is greater than one year. Practical Expedients and Exemptions We have elected certain practical expedients and policy elections as permitted under ASC Topic 606 as follows: ● We applied the transitional guidance to contracts that were not complete at the date of our initial application of ASC Topic 606 on January 1, 2018. ● We adopted the practical expedient related to not adjusting the promised amount of consideration for the effects of a significant financing component if the period between transfer of product and customer payment is expected to be less than one year at the time of contract inception; ● We made the accounting policy election to not assess promised goods or services as performance obligations if they are immaterial in the context of the contract with the customer; ● We made the accounting policy election to exclude any sales and similar taxes from the transaction price; and ● We adopted the practical expedient not to disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.
Cost of Revenue	Cost of Revenue Cost of revenue consists of payments to media providers and website publishers that are directly related to a revenue-generating event and project and application design costs. The Company becomes obligated to make payments related to media providers and website publishers in the period the advertising impressions, click-throughs, actions or lead-based information are delivered or occur. Such expenses are classified as cost of revenue in the corresponding period in which the revenue is recognized in the accompanying consolidated statements of operations.
Stock-Based Compensation	Stock-Based Compensation We account for our stock-based compensation under ASC 718 “ Compensation – Stock Compensation We use the fair value method for equity instruments granted to non-employees and use the Black-Scholes model for measuring the fair value of options. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. Common stock awards The Company grants common stock awards to non-employees in exchange for services provided. The Company measures the fair value of these awards using the fair value of the services provided or the fair value of the awards granted, whichever is more reliably measurable. The fair value measurement date of these awards is generally the date the performance of services is complete. The fair value of the awards is recognized on a straight-line basis as services are rendered. The share-based payments related to common stock awards for the settlement of services provided by non-employees is recorded in accordance with ASC 718 on the consolidated statement of comprehensive loss in the same manner and charged to the same account as if such settlements had been made in cash. Warrants In connection with certain financing, consulting and collaboration arrangements, the Company has issued warrants to purchase shares of its common stock. The outstanding warrants are standalone instruments that are not puttable or mandatorily redeemable by the holder and are classified as equity awards. The Company measures the fair value of the awards using the Black-Scholes option pricing model as of the measurement date. Warrants issued in conjunction with the issuance of common stock are initially recorded at fair value as a reduction in additional paid-in capital of the common stock issued. All other warrants are recorded at fair value as expense over the requisite service period or at the date of issuance, if there is not a service period.
Income Taxes	Income Taxes We utilize ASC 740 “ Income Taxes The Company recognizes the impact of a tax position in the financial statements only if that position is more likely than not of being sustained upon examination by taxing authorities, based on the technical merits of the position. Our practice is to recognize interest and/or penalties related to income tax matters in income tax expense.
Earnings Per Share	Earnings Per Share We use ASC 260, “ Earnings Per Share There were 15,366,426 common share equivalents at December 31, 2020 and 7,429,949 at December 31, 2019. For the year ended December 31, 2020, these securities were not included in the computation of diluted net earnings per share as their effect would have been antidilutive.
Recently Issued Accounting Standards	Recently Issued Accounting Standards Changes to accounting principles are established by the FASB in the form of ASUs to the FASB’s Codification. We consider the applicability and impact of all ASUs on our financial position, results of operations, cash flows, or presentation thereof. Described below are ASUs that are not yet effective, but may be applicable to our financial position, results of operations, cash flows, or presentation thereof. ASUs not listed below were assessed and determined to not be applicable to our financial position, results of operations, cash flows, or presentation thereof. Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02 (with amendments issued in 2018), which changes the accounting for leases and requires expanded disclosures about leasing activities. This new guidance also requires lessees to recognize a ROU asset and a lease liability at the commencement date for all leases with terms greater than twelve months. Accounting by lessors is largely unchanged. ASU 2016-02 is effective for fiscal periods beginning after December 15, 2018. We adopted ASU 2016-02 on January 1, 2019 using the modified retrospective optional transition method. Thus, the standard was applied starting January 1, 2019 and prior periods were not restated. We applied the package of practical expedients permitted under the transition guidance. As a result, we did not reassess the identification, classification and initial direct costs of leases commencing before the effective date. We also applied the practical expedient to not separate lease and non-lease components to all new leases as well as leases commencing before the effective date. See Note 8 for additional information. In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments.” This guidance updates existing guidance for measuring and recording credit losses on financial assets measured at amortized cost by replacing the “incurred loss” model with an “expected loss” model. Accordingly, these financial assets will be presented at the net amount expected to be collected. ASU 2016-13 is effective for fiscal years beginning after December 15, 2019. Early adoption is permitted. The adoption of ASU 2016-13 did not have a material impact on our consolidated financial statements. In January 2017, the FASB issued ASU 2017-04, “Simplifying the Test for Goodwill Impairment.” This guidance simplifies how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. Instead, if the carrying amount of a reporting unit exceeds its fair value, an impairment loss will be recognized in an amount equal to that excess, limited to the total amount of goodwill allocated to the reporting unit. ASU 2017-04 is effective for fiscal periods beginning after December 31, 2019. Early adoption is permitted. The adoption of ASU 2017-04 did not have a material impact on our consolidated financial statements. In June 2018, the FASB issued ASU 2018-07, “Improvements to Non-employee Share-Based Payment Accounting.” This guidance expands the scope of Topic 718 “Compensation - Stock Compensation” to include share-based payment transactions for acquiring goods and services from non-employees, but excludes awards granted in conjunction with selling goods or services to a customer as part of a contract accounted for under ASC 606, “Revenue from Contracts with Customers.” The adoption of ASU 2018-07 did not have a material impact on our consolidated financial statements. In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract,” which amends ASC 350-40, “Intangibles - Goodwill and Other - Internal-Use Software.” The ASU aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software and requires the capitalized implementation costs to be expensed over the term of the hosting arrangement. The accounting for the service element of a hosting arrangement that is a service contract is not affected. ASU 2018-15 is effective for fiscal periods beginning after December 15, 2019, and interim periods within those fiscal years. The adoption of ASU 2018-15, effective January 1, 2019, did not have a material impact on our consolidated financial statements. Recent Accounting Updates Not Yet Effective In December 2019, the FASB issued ASU 2019-12, “Simplifying the Accounting for Income Taxes.” This guidance, among other provisions, eliminates certain exceptions to existing guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. This guidance also requires an entity to reflect the effect of an enacted change in tax laws or rates in its effective income tax rate in the first interim period that includes the enactment date of the new legislation, aligning the timing of recognition of the effects from enacted tax law changes on the effective income tax rate with the effects on deferred income tax assets and liabilities. Under existing guidance, an entity recognizes the effects of the enacted tax law change on the effective income tax rate in the period that includes the effective date of the tax law. ASU 2019-12 is effective for interim and annual periods beginning after December 15, 2020, with early adoption permitted. We are currently evaluating the impact of this guidance.

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combinations [Abstract]
Summary of Calculation of Purchase Price	The total consideration to be paid by the Company is $7,610,000, as adjusted, as follows: Calculation of the purchase price: Fair value of stock at closing $ 4,264,000 Cash at closing 1,000,000 Deferred payments 2,771,000 Less cash received (303,000 ) Transaction expenses 10,000 Working capital adjustment (132,000 ) Purchase price $ 7,610,000
Summary of Allocation of Purchase Price to Assets Acquired and Liabilities Assumed	The following table summarizes the allocation of the purchase price to the assets acquired and liabilities assumed: Accounts receivable, net $ 30,000 Intangibles 468,000 Goodwill 7,706,000 Accounts payable and accrued liabilities (324,000 ) Payroll protection loan (42,000 ) Other current liabilities (97,000 ) Deferred tax liability (131,000 ) Net assets acquired $ 7,610,000
Schedule of Intangible Assets Acquired as Part of Business Combination	Intangible assets consisted of the following: Fair Value Life in Years Trademark $ 271,000 Indefinite Domain name 3,000 Indefinite Noncompete 8,000 5 years Customer list 186,000 3 years $ 468,000
Summary of Amounts of Revenue and Earnings of Acquiree Since The Acquisition Date	The amounts of revenue and earnings of the Acquiree since the acquisition date included in the consolidated statements of operations for the year ended December 31, 2020 follows: Revenues $ - Net income (loss) (51,000 )
Schedule of Pro Forma Consolidated Statements of Operations	Pro Forma Consolidated Statements of Operations For the Year ended December 31,2020 SRAX, Inc. LD Micro, Inc. Pro Forma Adjustment Pro Forma Combined Revenues $ 8,647,000 $ 937,000 $ - $ 9,584,000 Cost of revenues (2,589,000 ) (98,000 ) - (2,687,000 ) Operating expenses (17,655,000 ) (858,000 ) 171,000 (18,342,000 ) Other expense (3,082,000 ) (1,000 ) - (3,083,000 ) Provision for income taxes (26,000 ) - - (26,000 ) Net loss $ (14,705,000 ) $ (20,000 ) $ 171,000 $ (14,554,000 ) Pro Forma Consolidated Statements of Operations For the Year ended December 31,2019 SRAX, Inc. LD Micro, Inc. Pro Forma Adjustment Pro Forma Combined Revenues $ 3,584,000 $ 1,142,000 $ - $ 4,726,000 Cost of revenues (1,680,000 ) (188,000 ) - (1,868,000 ) Operating expenses (19,762,000 ) (1,037,000 ) (58,000 ) (20,857,000 ) Other income 999,000 8,000 - 1,007,000 Net loss $ (16,859,000 ) $ (75,000 ) $ (58,000 ) $ (16,992,000 )
Summary of Pro Forma Adjustments	The following summarizes the pro forma adjustments made for the years ended December 31: 2020 2019 Amortization of intangibles acquired $ 64,000 64,000 Employee related costs (235,000 ) (235,000 ) Financing costs - 229,000 Net income (loss) $ (171,000 ) $ 58,000

Marketable Securities (Tables)

Marketable Securities (Tables)	12 Months Ended
	Dec. 31, 2020
Cash and Cash Equivalents [Abstract]
Schedule of Movement of Marketable Securities	The movement in this account is as follows: Balance as of December 31, Common Convertible 2020 Stock Debentures Balances at beginning of year $ 83,000 $ 83,000 $ — Additions 8,406,000 7,496,000 910,000 Sale of marketable securities (916,000 ) (916,000 ) — Change in fair value 874,000 1,101,000 (227,000 ) Balances at end of year $ 8,447,000 $ 7,764,000 $ 683,000 Balance as of December 31, Common Convertible 2019 Stock Debentures Balances at beginning of year $ 39,000 $ 39,000 $ — Additions 50,000 50,000 — Sale of marketable securities — — — Change in fair value (6,000 ) (6,000 ) — Balances at end of year $ 83,000 $ 83,000 $ —
Schedule of Component of Other Income (Expense) Realized and Unrealized Gain (Loss) on Marketable Securities	The Company recorded as a component of other income (expense) the realized and unrealized gain (loss) on marketable securities as follows: 2020 2019 Unrealized gain (loss) $ 261,000 $ (6,000 ) Realized gain 613,000 - Change in fair value of marketable securities $ 874,000 $ (6,000 )

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consist of the following as of December 31: 2020 2019 Office equipment $ 406,000 $ 406,000 Accumulated depreciation (288,000 ) (215,000 ) Property and equipment, net $ 118,000 $ 191,000

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following as of December 31: 2020 2019 Internally developed software $ 4,028,000 $ 2,856,000 Non-compete agreement 1,258,000 1,250,000 Intellectual property 756,000 756,000 Acquired Software 617,000 617,000 Trademark 271,000 - Customer list 186,000 - Domain name 36,000 - Total cost 7,152,000 5,479,000 Accumulated amortization (4,743,000 ) (3,513,000 ) Intangible assets, net $ 2,409,000 $ 1,966,000
Schedule of Estimated Future Amortization Expense	The estimated future amortization expense for the years ended December 31, are as follows: 2021 $ 1,180,000 2022 666,000 2023 247,000 2024 6,000 2025 and thereafter 3,000 $ 2,102,000
Summary of Carrying Amount of Intangible Assets Not Subject to Amortization	The following table summarizes the carrying amount of intangible assets not subject to amortization as of December 31, 2020: Trademark $ 271,000 Domain name 36,000 $ 307,000
Schedule of Goodwill	The following table summarizes the carrying amount of goodwill as of December 31, 2020: Segment Sequire BigToken Total Balance as of January 1, 2020 $ 10,200,000 $ 5,445,000 $ 15,645,000 Goodwill acquired during the year (LD Micro) 7,706,000 7,706,000 Balance as of December 31, 2020 $ 17,906,000 $ 5,445,000 $ 23,351,000

Right to Use Asset (Tables)

Right to Use Asset (Tables)	12 Months Ended
	Dec. 31, 2020
Leases [Abstract]
Schedule of Component of Lease Expense	The following tables summarize the lease expense for the year ended December 31: 2020 2019 Operating lease expense $ 163,000 $ 150,000 Short-term lease expense 29,000 154,000 Total lease expense $ 192,000 $ 304,000
Schedule of Operating Lease Assets and Liabilities	The below table summarizes these lease asset and liability accounts presented on our accompanying Consolidated Balance Sheets for the year ended December 31: Operating Leases* Consolidated Balance Sheet Caption 2020 2019 Operating lease right-of-use assets - non-current Right of use asset $ 366,000 $ 456,000 Operating lease liabilities - current Other current liabilities $ 109,000 $ 91,000 Operating lease liabilities - non-current Right to use liability - long term 243,000 352,000 Total operating lease liabilities $ 352,000 $ 443,000
Schedule of Weighted Average Remaining Lease Term and Applied Discount Rate	Weighted Average Remaining Lease Term Weighted Average Discount Rate Operating leases as of December 31, 2020 2.75 years 18 %
Schedule of Future Minimum Contractual Lease Payments	The below table summarizes our (i) minimum lease payments over the next five years, (ii) lease arrangement implied interest, and (iii) present value of future lease payments for the years ending December 31: Operating Leases - future payments 2021 163,000 2022 163,000 2023 123,000 Total future lease payments, undiscounted 449,000 Less: Implied interest (97,000 ) Present value of operating lease payments 352,000

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses as of December 31, are comprised of the following: 2020 2019 Accounts payable, trade $ 2,631,000 $ 1,708,000 Accrued expenses 605,000 335,000 Accrued compensation 238,000 270,000 Accrued commissions 80,000 129,000 Accrued interest 7,000 - Accounts payable and accrued expenses $ 3,561,000 $ 2,442,000

Derivative Liability (Tables)

Derivative Liability (Tables)	12 Months Ended
	Dec. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Warrant Instruments	Series Number of Warrants Series A warrants 267,535 Series A1 warrants 471,667 Series A2 warrants 813,364 Series B1 warrants 1,090,863 Leapfrog warrants 350,000 Total 2,993,429
Schedule of Warrant Derivative Liabilities	The Warrant liabilities are comprised of the following at December 31: Debenture Warrant Liabilities Leapfrog Warrant Liability Derivative Total Balance December 31, 2018 $ 4,324,000 $ 622,000 $ 496,000 $ 5,442,000 Adjustment to fair value (775,000 ) (142,000 ) (128,000 ) (1,045,000 ) Balance December 31, 2019 $ 3,549,000 $ 480,000 $ 368,000 $ 4,397,000 Debenture Warrant Liabilities Leapfrog Warrant Liability Derivative Total Balance December 31, 2019 $ 3,549,000 $ 480,000 $ 368,000 $ 4,397,000 Adjustment to fair value (245,000 ) (42,000 ) (34,000 ) (321,000 ) Transfer to Equity (3,304,000 ) (438,000 ) (334,000 ) (4,076,000 ) Balance December 31, 2020 $ − $ − $ − $ −

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2020
Other Liabilities Disclosure [Abstract]
Schedule of Other Current Liabilities	The following table summarizes the composition of other current liabilities presented on our accompanying Consolidated Balance Sheets: December 31, 2020 December 31, 2019 Contract liabilities $ 4,842,000 $ - BIGToken point liability 452,000 446,000 Operating lease liabilities - current 109,000 91,000 Other current liabilities 3,308,000 - Total other current liabilities $ 8,711,000 $ 537,000

OID Convertible Debentures (Tab

OID Convertible Debentures (Tables)	12 Months Ended
	Dec. 31, 2020
Debt Disclosure [Abstract]
Schedule of OID Convertible Debentures	The table below summarizes the transactions during the year: Principal Debt discount Net book value Issuance during the year $ 16,101,000 $ (12,731,000 ) $ 3,370,000 Extension 472,000 - 472,000 Redemption (6,069,000 ) 3,037,000 (3,032,000 ) Conversion (1,118,000 ) 685,000 (433,000 ) Amortization - 5,639,000 5,639,000 Total $ 9,386,000 $ (3,370,000 ) $ 6,016,000

Stock Options, Awards and War_2

Stock Options, Awards and Warrants (Tables)	12 Months Ended
	Dec. 31, 2020
Schedule of Vested and Nonvested Stock Option	Number of Shares Weighted Average Strike Price/Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Weighted Average Grant Date Fair Value Outstanding — December 31, 2018 547,662 $ 5.94 2.73 $ — $ — Granted 696,252 3.45 2.34 — 2.25 Exercised — — — — — Forfeited (51,395 ) 6.92 — — 3.37 Outstanding — December 31, 2019 1,192,519 4.14 2.17 — — Vested and exercisable — December 31, 2019 355,083 5.63 2.22 — 3.98 Unvested and non-exercisable - December 31, 2019 837,436 3.49 2.15 — 2.29 Outstanding — December 31, 2019 1,192,519 4.14 2.17 — — Granted 766,172 2.77 3.00 521,000 2.72 Exercised — — — — — Forfeited (316,367 ) 5.14 — — 3.14 Outstanding — December 31, 2020 1,642,324 3.30 2.81 — — Vested and exercisable — December 31, 2020 844,742 3.54 2.62 333,000 3.54 Unvested and non-exercisable - December 31, 2020 797,582 $ 2.81 3.00 $ 207,000 $ 2.09
BIGToken [Member]
Schedule of Vested and Nonvested Stock Option	Number of Shares Weighted Average Strike Price/Share Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value Weighted Average Grant Date Fair Value Outstanding — December 31, 2018 4,325,423 $ 5.05 2.85 $ — $ - Granted 3,885,442 3.99 2.21 94,910 1.60 Exercised (342,000 ) 3.50 — — 4.79 Forfeited (1,631,435 ) 5.14 — — 1.97 Outstanding — December 31, 2019 6,237,430 3.57 2.68 — — Vested and exercisable — December 31, 2019 5,937,430 3.51 2.60 — 2.34 Unvested and non-exercisable - December 31, 2019 300,000 4.75 4.43 — 3.88 Outstanding — December 31, 2019 6,237,430 3.57 2.68 — — Granted 7,421,054 2.63 1.82 3,929,000 1.38 Exercised — — — — — Forfeited (1,073,201 ) — — — — Outstanding — December 31, 2020 12,585,283 2.98 1.78 4,460,000 1.38 Vested and exercisable — December 31, 2020 12,285,283 2.94 1.74 4,460,000 1.38 Unvested and non-exercisable - December 31, 2020 300,000 $ 4.75 3.37 $ — $ —

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Schedule of Income Tax (Benefit) Expense	Income tax expense from continuing operations for the year ended December 31, 2020 consisted of the following: Current Deferred Total Federal $ — $ — State 26,000 — 26,000 Subtotal 26,000 — 26,000 Valuation allowance — — — Total $ 26,000 $ — $ 26,000 Income tax (benefit) expense from continuing operations for the year ended December 31, 2019 consisted of the following: Current Deferred Total Federal $ — $ (3,198,000 ) $ (3,198,000 ) State — (920,000 ) (920,000 ) Subtotal — (4,118,000 ) (4,118,000 ) Valuation allowance — 4,118,000 4,118,000 Total $ — $ — $ —
Schedule of Effective Tax Rate	A reconciliation of the federal statutory income tax rate to the Company’s effective income tax rate is as follows: 2020 2019 Taxes calculated at federal rate 21.0 % 21.0 % Stock based compensation (2.7 )% (1.4 )% Permanent Differences (13.1 )% - % Change in Valuation Allowance (2.5 )% (23.7 )% Fair market adjustment derivatives 0.5 % 1.3 % Prior year True-ups (3.3 )% 3.0 % Other adjustments (0.1 )% (0.2 )% Provision for income taxes (0.2 )% — %
Schedule of Deferred Tax Assets and Liabilities	The tax effects, rounded to thousands, of temporary differences that give rise to significant portions of the deferred tax assets and liabilities at December 31, are presented below: 2020 2019 Deferred Tax Assets Net operating loss carryforwards $ 9,040,000 $ 6,621,000 Bad debt expense 136,000 111,000 Fixed assets 9,000 - Accrued interest - 492,000 Stock based compensation 567,000 431,000 Interest expense limitation carryover 629,000 - Contribution carryover 5,000 - Lease liability 97,000 - Other accruals 192,000 84,000 Total Deferred Tax Assets 10,675,000 7,739,000 Deferred Tax Liabilities Fixed assets - (39,000 ) Right-of-use asset (101,000 ) - Unrealized gain on marketable securities (72,000 ) - Intangibles (690,000 ) (327,000 ) Prepaid expenses (17,000 ) (20,000 ) Total Deferred Tax Liabilities (880,000 ) (386,000 ) Net Deferred Tax Assets 9,795,000 7,353,000 Valuation Allowance (9,795,000 ) (7,353,000 ) Net deferred tax / (liabilities) $ — $ —

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value On Recurring Basis	The Company had the following financial assets and liabilities as of December 31, 2020 and 2019: Quoted Prices in Significant Other Significant Balance as of Active Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2020 (Level 1) (Level 2) (Level 3) Marketable securities $ 8,447,000 $ 7,764,000 $ 683,000 $ — Total assets $ 8,447,000 $ 7,764,000 $ 683,000 $ — Quoted Prices in Significant Other Significant Balance as of Active Markets for Observable Unobservable December 31, Identical Assets Inputs Inputs 2019 (Level 1) (Level 2) (Level 3) Marketable securities $ 83,000 $ 83,000 $ — $ — Total assets $ 83,000 $ 83,000 $ — $ — Debenture warrant liability $ 3,549,000 $ — $ — $ 3,549,000 Leapfrog warrant liability 480,000 — — 480,000 Derivative liability 368,000 — — 368,000 Total liabilities $ 4,397,000 $ — $ — $ 4,397,000
Schedule of Reconciliation of Derivative and Warrant Liability Measured at Fair Value on Level 3	A reconciliation of the beginning and ending balances for the derivative and warrant liability measured at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows for the years ended December 31: 2019 Outstanding, beginning of the period $ 5,442,000 Change in fair value (1,045,000 ) Warrant liabilities $ 4,397,000

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2020
Segment Reporting [Abstract]
Schedule of Revenue and Gross Profit by Reportable Segment	The following table presents revenues and gross profits by reportable segment. For the Years Ended December 31, SEQUIRE BIGToken Corporate and Other Consolidated 2020 2019 2020 2019 2020 2019 2020 2019 Sequire platform revenue $ 5,781,000 $ 87,000 $ - $ - $ - $ - $ 5,781,000 $ 87,000 Conference revenue 503,000 - - - - - 503,000 - BIGtoken revenue - - 2,168,000 3,228,000 - - 2,168,000 3,228,000 Other - - - - 195,000 269,000 195,000 269,000 Total Revenue 6,284,000 87,000 2,168,000 3,228,000 195,000 269,000 8,647,000 3,584,000 Cost of Revenue 1,783,000 7,000 800,000 1,613,000 6,000 60,000 2,589,000 1,680,000 Gross profit $ 4,501,000 $ 80,000 $ 1,368,000 $ 1,615,000 $ 189,000 $ 209,000 $ 6,058,000 $ 1,904,000
Schedule of Revenue Disaggregation	The following table breaks out the revenue types for Sequire and BIGToken 2020 2019 Sequire platform revenue $ 5,781,000 $ 87,000 Conference revenue 503,000 - Sequire revenues 6,284,000 87,000 Consumer Media / Data 2,168,000 3,228,000 BIGToken revenues 2,168,000 3,228,000 Other revenues 195,000 269,000 Total revenues $ 8,647,000 $ 3,584,000

Organization and Basis of Prese

Organization and Basis of Presentation (Details Narrative) - USD ($)	Jan. 02, 2021	Oct. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash and cash equivalents			$ 451,000	$ 32,000
Proceeds from Debt repayment , commissions and fees			7,900,000
Proceeds from debt			472,000
Allowance for doubtful accounts			491,000	530,000
Impairment of long-lived assets			0	0
Impairment for internal use software			0	0
Capitalized software development costs			$ 1,172,000	$ 1,292,000
Antidilutive common share equivalents			15,366,426	7,429,949
Maximum [Member]
Estimated useful lives for property and equipment			3 years
Estimated useful lives for intangible assets			5 years
Minimum [Member]
Estimated useful lives for property and equipment			5 years
Estimated useful lives for intangible assets			6 years
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration risk, percentage			20.00%	23.70%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Concentration risk, percentage			10.40%	15.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]
Concentration risk, percentage				13.70%
Customer Concentration Risk [Member] | Revenue [Member] | Customer One [Member]
Concentration risk, percentage			18.10%	17.70%
Customer Concentration Risk [Member] | Revenue [Member] | Customer Two [Member]
Concentration risk, percentage				12.90%
TI Health [Member]
Proceeds from debt		$ 7,000,000	$ 8,000,000
Convertible Debentures [Member]
Proceeds from debt			13,268,000
Payroll Protection Program [Member]
Proceeds from debt			1,084,000
Sales Agreement [Member]
Proceeds from debt			$ 3,125,000
Subsequent Event [Member]
Proceeds fro sale of equity security	$ 16,000,000

Acquisitions (Details Narrative

Acquisitions (Details Narrative) - USD ($)	Jul. 01, 2021	Apr. 01, 2021	Jan. 02, 2021	Sep. 15, 2020	Sep. 04, 2020	Dec. 31, 2020	Dec. 31, 2019
Deferred payments discounted under CCC rated corporate debt						$ 3,000,000
Amortization of the payments						2,000	$ 62,000
Employee related costs						235,000	$ 235,000
LD Micro, Inc. [Member]
Business acquisition, closing date of acquisition agreement				Sep. 15, 2020
Business combination, cash payable by entity				$ 1,000,000	$ 4,000,000	$ 7,610,000
Deferred payments discounted under CCC rated corporate debt				3,000,000
Amortization of the payments				$ 229,000
LD Micro, Inc. [Member] | Class A Common Stock [Member]
Number of shares issued in acquisition				1,600,000
LD Micro, Inc. [Member] | Forecast [Member]
Business combination, cash payable by entity	$ 1,000,000	$ 1,000,000
LD Micro, Inc. [Member] | Subsequent Event [Member]
Business combination, cash payable by entity			$ 1,000,000

Acquisitions - Summary of Calcu

Acquisitions - Summary of Calculation of Purchase Price (Details) - LD Micro, Inc. [Member] - USD ($)	Sep. 15, 2020	Sep. 04, 2020	Dec. 31, 2020
Fair value of stock at closing	$ 4,264,000
Cash at closing	1,000,000	$ 4,000,000	$ 7,610,000
Deferred payments	2,771,000
Less cash received	(303,000)
Transaction expenses	10,000
Working capital adjustment	(132,000)
Purchase price	$ 7,610,000

Acquisitions - Summary of Alloc

Acquisitions - Summary of Allocation of Purchase Price to Assets Acquired and Liabilities Assumed (Details) - USD ($)	Dec. 31, 2020	Sep. 15, 2020	Dec. 31, 2019
Goodwill	$ 23,351,000		$ 15,645,000
LD Micro, Inc. [Member]
Accounts receivable, net		$ 30,000
Intangibles		468,000
Goodwill		7,706,000
Accounts payable and accrued liabilities		(324,000)
Payroll protection loan		(42,000)
Other current liabilities		(97,000)
Deferred tax liability		(131,000)
Net assets acquired		$ 7,610,000

Acquisitions - Schedule of Inta

Acquisitions - Schedule of Intangible Assets Acquired as Part of Business Combination (Details) - LD Micro, Inc. [Member]	Sep. 15, 2020USD ($)
Fair value	$ 468,000
Noncompete Agreements [Member]
Fair value	$ 8,000
Life in Years	5 years
Customer List [Member]
Fair value	$ 186,000
Life in Years	3 years
Trademarks [Member]
Fair value	$ 271,000
Life in years, description	Indefinite
Domain Name [Member]
Fair value	$ 3,000
Life in years, description	Indefinite

Acquisitions - Summary of Amoun

Acquisitions - Summary of Amounts of Revenue and Earnings of Acquiree Since The Acquisition Date (Details) - USD ($)	Sep. 15, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenues		$ 8,647,000	$ 3,584,000
Net income (loss)		$ (14,705,000)	$ (16,859,000)
LD Micro, Inc. [Member]
Revenues
Net income (loss)	$ (51,000)

Acquisitions - Schedule of Pro

Acquisitions - Schedule of Pro Forma Consolidated Statements of Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenues	$ 8,647,000	$ 3,584,000
Cost of revenues	(2,589,000)	(1,680,000)
Operating expenses	(17,655,000)	(19,762,000)
Other expense	(3,082,000)	999,000
Provision for income taxes	(26,000)
Net loss	(14,705,000)	(16,859,000)
Pro Forma Adjustment [Member]
Revenues
Cost of revenues
Operating expenses	(171,000)	(58,000)
Other expense
Provision for income taxes
Net loss	(171,000)	(58,000)
Pro Forma Combined [Member]
Revenues	9,584,000	4,726,000
Cost of revenues	(2,687,000)	(1,868,000)
Operating expenses	(18,342,000)	(20,857,000)
Other expense	3,083,000	1,007,000
Provision for income taxes	(26,000)
Net loss	(14,554,000)	(16,992,000)
LD Micro, Inc. [Member]
Revenues	937,000	1,142,000
Cost of revenues	(98,000)	(188,000)
Operating expenses	(858,000)	(1,037,000)
Other expense	(1,000)	8,000
Provision for income taxes
Net loss	$ (20,000)	$ (75,000)

Acquisitions - Summary of Pro F

Acquisitions - Summary of Pro Forma Adjustments (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Net income (loss)	$ (14,705,000)	$ (16,859,000)
Pro Forma Adjustment [Member]
Amortization of intangibles acquired	64,000	64,000
Employee related costs	(235,000)	(235,000)
Financing costs		229,000
Net income (loss)	$ (171,000)	$ (58,000)

Sale of Accounts Receivable (De

Sale of Accounts Receivable (Details Narrative) - USD ($)	Jun. 30, 2020	Mar. 24, 2020	Jan. 30, 2020	Jan. 22, 2020	Aug. 12, 2019	Dec. 31, 2020	Dec. 31, 2019
Accounts receivable			$ 75,000	$ 454,000
Accounts receivable, purchase			56,000	$ 454,000
Description of sale of accounts receivable						Upon the occurrence of a payment made on the applicable receivables, the Company is required to pay a true up amount as follows: a) ten percent (10%) of the portion of the receivables which are paid on or before the 30th day following the effective date of the agreement; b) twenty percent (20%) of the portion of the receivables which are paid after the 30th day but on or before the 60th day following the effective date of the agreement; and d) thirty six percent (36%) of the portion of the receivables which are paid after the 60th day following the effective date of the agreement.
Converted debt						$ 1,118,000
Loss on extinguishment						(1,103,000)
Difference between face value and fair value			$ 95,000
Fair value of warrants						(321,000)	(1,045,000)
Right to future subscription revenues						570,000
Proceeds from net of subscription revenues						528,000
Borrowings outstanding						$ 570,000	$ 570,000
Payable [Member]
Converted debt	$ 510,000
Accrued Interest [Member]
Converted debt	184,000
Debentures [Member]
Convertible debt	788,000
Fair value of debenture	815,000
Loss on extinguishment	(546,000)
Difference between face value and fair value	27,000
Fair value of warrants	424,000
Conversion premium	$ 27,000
Class A Common Stock [Member]
Sale of stock, number of shares issued in transaction			29,519	239,029	1,525,000
Agreements to Sell Accounts Receivable [Member]
Percentage of receivables upon exercise of put option		136.00%
Agreements to Sell Accounts Receivable Ammended [Member]
Description of sale of accounts receivable						On April 9, 2020 the Company entered into an agreement to amend the January 22 and 30 accounts receivable agreements. The purchaser agreed to amend the put option date as described above to June 23, 2020 and June 30, 2020 for the sale of receivables originating on January 22, 2020 and January 30, 2020, respectively. As consideration for the extension the Company agreed to issue the purchaser 32,668 and 4,032 shares of Class A common stock for the receivable sale originating on January 22, 2020 and January 30, 2020, respectively.
Agreements to Sell Accounts Receivable Ammended [Member] | Class A Common Stock [Member]
Sale of stock, number of shares issued in transaction			4,032	32,668

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Proceeds from sale of marketable securities	$ 916,000
Gain on marketable securities	303,000
Marketable securities	$ 613,000

Marketable Securities - Schedul

Marketable Securities - Schedule of Movement of Marketable Securities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balances at beginning of year	$ 83,000	$ 39,000
Additions	8,406,000	50,000
Sale of marketable securities	(916,000)
Change in fair value	874,000	(6,000)
Balances at end of year	8,447,000	83,000
Convertible Debentures [Member]
Balances at beginning of year
Additions	910,000
Sale of marketable securities
Change in fair value	(227,000)
Balances at end of year	683,000
Common Stock [Member]
Balances at beginning of year	83,000	39,000
Additions	7,496,000	50,000
Sale of marketable securities	(916,000)
Change in fair value	1,101,000	(6,000)
Balances at end of year	$ 7,764,000	$ 83,000

Marketable Securities - Sched_2

Marketable Securities - Schedule of Component of Other Income (Expense) Realized and Unrealized Gain (Loss) on Marketable Securities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash and Cash Equivalents [Abstract]
Unrealized loss	$ 874,000	$ (6,000)
Realized gain	613,000
Loss from marketable securities	$ 874,000	$ (6,000)

Notes Receivable (Details Narra

Notes Receivable (Details Narrative) - USD ($)	Oct. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Notes receivable		$ 893,000
CCC Rated Corporate debt [Member]
Deferred payments of notes receivable		960,000
Discount on notes receivable		$ 40,000
Debt maturity term		3 years
Implied discount		$ 107,000
Notes receivable		$ 893,000
Maximum [Member] | CCC Rated Corporate debt [Member]
Amortization of debt discount term		3 years
Haylard MD, LLC [Member]
Redemption of class A units	10,000,000
Price to be paid for all of the Units	$ 6,718,000
Price to be paid upon earliar	960,000
Total consideration	$ 7,678,000
Haylard MD, LLC [Member] | Maximum [Member]
Excess amount for each unit	$ 0.7677543
MD CoInvest, LLC [Member]
Redemption of class A units	420,000
Price to be paid for all of the Units	$ 282,000
Price to be paid upon earliar	40,000
Total consideration	$ 322,000
MD CoInvest, LLC [Member] | Maximum [Member]
Excess amount for each unit	$ 0.7677543

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 73,000	$ 74,000

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Property and equipment, net	$ 118,000	$ 191,000
Office Equipment [Member]
Property and equipment, gross	406,000	406,000
Accumulated depreciation	(288,000)	(215,000)
Property and equipment, net	$ 118,000	$ 191,000

Intangible Assets (Details Narr

Intangible Assets (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Amortization expense	$ 1,230,000	$ 1,089,000
Internally Developed Software [Member]
Amortization expense	1,024,000
Acquired Software [Member]
Amortization expense	206,000
Intellectual Property [Member]
Amortization expense	151,000
Internally Developed Software [Member]
Amortization expense	732,000
Acquired Software [Member]
Amortization expense	$ 206,000

Intangible Assets - Schedule of

Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Total cost	$ 7,152,000	$ 5,479,000
Accumulated amortization	(4,743,000)	(3,513,000)
Intangible assets, net	2,409,000	1,966,000
Internally Developed Software [Member]
Total cost	4,028,000	2,856,000
Non-compete Agreement [Member]
Total cost	1,258,000	1,250,000
Intellectual Property [Member]
Total cost	756,000	756,000
Acquired Software [Member]
Total cost	617,000	617,000
Trademarks [Member]
Total cost	271,000
Customer List [Member]
Total cost	186,000
Domain Name [Member]
Total cost	$ 36,000

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Estimated Future Amortization Expense (Details)	Dec. 31, 2020USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 1,180,000
2022	666,000
2023	247,000
2024	6,000
2025 and thereafter	3,000
Intangible assets, net	$ 2,102,000

Intangible Assets - Summary of

Intangible Assets - Summary of Carrying Amount of Intangible Assets Not Subject to Amortization (Details)	Dec. 31, 2020USD ($)
Intangible assets not subject to amortization	$ 307,000
Trademarks [Member]
Intangible assets not subject to amortization	271,000
Domain name [Member]
Intangible assets not subject to amortization	$ 36,000

Intangible Assets - Schedule _3

Intangible Assets - Schedule of Goodwill (Details)	12 Months Ended
	Dec. 31, 2020USD ($)
Begginning balance	$ 15,645,000
Goodwill acquired during the year (LD Micro)	7,706,000
Ending balance	23,351,000
Sequire [Member]
Begginning balance	10,200,000
Goodwill acquired during the year (LD Micro)	7,706,000
Ending balance	17,906,000
BIG Token, Inc. [Member]
Begginning balance	5,445,000
Goodwill acquired during the year (LD Micro)
Ending balance	$ 5,445,000

Right to Use Asset (Details Nar

Right to Use Asset (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Remaining lease term	2 years 9 months
Variable lease costs
Sublease income
Lease expense	$ 192,000	$ 304,000

Right to Use Asset - Schedule o

Right to Use Asset - Schedule of Component of Lease Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease expense	$ 163,000	$ 150,000
Short-term lease expense	29,000	154,000
Total lease expense	$ 192,000	$ 304,000

Right to Use Asset - Schedule_2

Right to Use Asset - Schedule of Operating Lease Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
Operating lease right-of-use assets - non-current	$ 366,000	$ 456,000
Operating lease liabilities - current	$ 109,000	$ 91,000
Operating lease, liability, current, statement of financial position [extensible list]	Other current liabilities	Other current liabilities
Operating lease liabilities - non-current	$ 243,000	$ 352,000
Total operating lease liabilities	$ 352,000	$ 443,000

Right to Use Asset - Schedule_3

Right to Use Asset - Schedule of Weighted Average Remaining Lease Term and Applied Discount Rate (Details)	Dec. 31, 2020
Leases [Abstract]
Weighted Average Remaining Lease Term	2 years 9 months
Weighted Average Discount Rate	18.00%

Right to Use Assets - Schedule

Right to Use Assets - Schedule of Future Minimum Contractual Lease Payments (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Leases [Abstract]
2021	$ 163,000
2022	163,000
2023	123,000
Total future lease payments, undiscounted	449,000
Less: Implied interest	(97,000)
Present value of operating lease payments	$ 352,000	$ 443,000

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accounts payable, trade	$ 2,631,000	$ 1,708,000
Accrued expenses	605,000	335,000
Accrued compensation	238,000	270,000
Accrued commissions	80,000	129,000
Accrued interest	7,000
Accounts payable and accrued expenses	$ 3,561,000	$ 2,442,000

Derivative Liability (Details N

Derivative Liability (Details Narrative)	6 Months Ended	12 Months Ended
	Jun. 30, 2020USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares	Apr. 30, 2018$ / shares
Warrants exercise price | $ / shares		$ 3.60
Fair value of warrants		$ (321,000)	$ (1,045,000)
Right to purchase additional debenture		$ 9,386,000
Warrants to purchase shares of common stock | shares		2,993,429	2,993,429
Securities Purchaser Agreements [Member] | Series A1 Debentures [Member]
Right to purchase additional debenture		$ 3,000,000
Series A Warrants [Member]
Warrants percenatge		0.35%
Warrants acquired		$ 10,000,000
Warrants description		The Series A Warrants are exercisable for five years commencing 6 months from the date of closing. The exercise price of the Series A Warrants is subject to full ratchet adjustment in certain circumstances, subject to a floor price of $1.20 per share. The adjustment provisions under the terms of the Series A Warrants will be extinguished at such time as our Class A common stock trades at or above $10.00 per share for 20 consecutive trading days, subject to the satisfaction of certain equity conditions. In addition, if there is no effective registration statement covering the shares issuable upon the exercise of the Series A Warrants, the warrants are exercisable on a cashless basis.
Warrants exercise price | $ / shares		$ 1.20
Fair value of warrants	$ 334,000		$ 368,000
Warrants to purchase shares of common stock | shares		267,535
Series A Warrants [Member] | Risk Free Interest Rate [Member]
Fair value measurement input, warrant liability percentage		1.62
Series A Warrants [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Fair value measurement input, warrant liability percentage	1.62
Series A Warrants [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Fair value measurement input, warrant liability percentage	0.18
Series A Warrants [Member] | Expected Term [Member]
Fair value measurement input, warrant liability term	1 year 6 months	2 years
Series A Warrants [Member] | Expected Volatility [Member]
Fair value measurement input, warrant liability percentage	100	100
Series A Warrants [Member] | Expected Dividend Yield [Member]
Fair value measurement input, warrant liability percentage	0	0
Series A Warrants [Member] | Investors [Member]
Warrants exercise price | $ / shares				$ 2.245
Series A1 Warrants [Member]
Warrants description		The Series A1 Warrants are initially exercisable at $3.00 per share and, if at any time after the six-month anniversary of the issuance the underlying shares of our class A common stock are not covered by an effective resale registration statement, the Series A1 Warrants are exercisable on a cashless basis. The conversion price of the Debentures and the exercise price of the Series A1 Warrants are subject to adjustments upon certain events, including stock splits, stock dividends, subsequent equity transactions (other than specified exempt issuances), subsequent rights offerings, and fundamental transactions, subject to a floor of $1.40 per share. If we fail to timely deliver the shares of our class A common stock upon any conversion of the Series A1 Debentures or exercise of the Series A1 Warrants, we will be subject to certain buy-in provisions. Pursuant to the terms of the Series A1 Debentures and Series A1 Warrants, a holder will not have the right to convert any portion of the Series A1 Debentures or exercise any portion of the Series A1 Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% of the number of shares of class A common stock outstanding immediately after giving effect to such conversion or exercise, as such percentage ownership is determined in accordance with the terms of the Series A1 Debentures and the Series A1 Warrants; provided that after the Shareholder Approval Date, as defined below, at the election of a holder and notice to us such percentage ownership limitation may be increased or decreased to any other percentage, not to exceed 9.99%; provided that any increase will not be effective until the 61st day after such notice is delivered from the holder to us.
Warrants exercise price | $ / shares		$ 3
Fair value of warrants	$ 555,700		618,000
Number of common stock shares outstanding percentage		4.99%
Debenture warrants description		The Securities Purchase Agreements and the transactions thereunder (the "Shareholder Approval Date"), we were not obligated to issue any shares of our class A common stock upon any conversion of the Series A1 Debentures and/or exercise of the Series A1 Warrants, and the holders had no right to receive upon conversion and/or exercise thereof any shares of our Class A common stock, to the extent the issuance of such shares of Class A common stock would exceed 20% of our outstanding Class A common stock prior to the transaction.
Change in fair value of derivative liability			284,000
Warrants to purchase shares of common stock | shares		471,667
Series A1 Warrants [Member] | Minimum [Member]
Number of common stock shares outstanding percentage		20.00%
Series A1 Warrants [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Fair value measurement input, warrant liability percentage	1.62	2.46
Series A1 Warrants [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Fair value measurement input, warrant liability percentage	0.18	1.62
Series A1 Warrants [Member] | Expected Term [Member]
Fair value measurement input, warrant liability term	1 year 105 months
Series A1 Warrants [Member] | Expected Term [Member] | Maximum [Member]
Fair value measurement input, warrant liability term		3 years 4 months 17 days
Series A1 Warrants [Member] | Expected Term [Member] | Minimum [Member]
Fair value measurement input, warrant liability term		2 years 4 months 17 days
Series A1 Warrants [Member] | Expected Volatility [Member]
Fair value measurement input, warrant liability percentage	100
Series A1 Warrants [Member] | Expected Volatility [Member] | Maximum [Member]
Fair value measurement input, warrant liability percentage		164
Series A1 Warrants [Member] | Expected Volatility [Member] | Minimum [Member]
Fair value measurement input, warrant liability percentage		100
Series A1 Warrants [Member] | Expected Dividend Yield [Member]
Fair value measurement input, warrant liability percentage	0	0
Series A2 Warrants [Member]
Warrants description		The Series A2 Warrants have an exercise price of $3.00 per share, subject to adjustment and contain anti-dilution protection for subsequent financings and have an exercise price floor of $1.40 per share.
Warrants exercise price | $ / shares		$ 3
Fair value of warrants	$ 555,570		1,142,000
Change in fair value of derivative liability	$ 303,000		303,000
Warrants to purchase shares of common stock | shares		813,364
Series A2 Warrants [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Fair value measurement input, warrant liability percentage	0.18	2.46
Series A2 Warrants [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Fair value measurement input, warrant liability percentage	1.62	1.62
Series A2 Warrants [Member] | Expected Term [Member] | Maximum [Member]
Fair value measurement input, warrant liability term	1 year 105 months	3 years 10 months 17 days
Series A2 Warrants [Member] | Expected Term [Member] | Minimum [Member]
Fair value measurement input, warrant liability term	2 years 4 months 17 days	2 years 10 months 17 days
Series A2 Warrants [Member] | Expected Volatility [Member]
Fair value measurement input, warrant liability percentage	100
Series A2 Warrants [Member] | Expected Volatility [Member] | Maximum [Member]
Fair value measurement input, warrant liability percentage		158
Series A2 Warrants [Member] | Expected Volatility [Member] | Minimum [Member]
Fair value measurement input, warrant liability percentage		100
Series A2 Warrants [Member] | Expected Dividend Yield [Member]
Fair value measurement input, warrant liability percentage	0	0
Series B1 Warrants One [Member] | Redeemed Debenture [Member]
Fair value measurement input, warrant liability term		5 years
Warrants to purchase shares of common stock | shares		277,500
Warrants expiration date		Apr. 21, 2022
Series B1 Warrants Two [Member] | Redeemed Debenture [Member]
Fair value measurement input, warrant liability term		5 years
Warrants to purchase shares of common stock | shares		813,362
Warrants expiration date		Oct. 27, 2022
Series B1 Warrants [Member]
Warrants exercise price | $ / shares		$ 3
Fair value of warrants	$ 1,700,445		1,786,000
Change in fair value of derivative liability			224,000
Warrants to purchase shares of common stock | shares		1,090,863
Issuance of warrant shares description		The Series B1 Warrants are initially exercisable at $3.00 per share and, are subject to cashless exercise after six (6) months from the issuance date if the shares underlying the warrants are not subject to an effective registration statement. The Series B Warrants also contain anti- dilution protection for subsequent equity sales for a price lower than the then applicable exercise price, with a floor of $1.40.
Series B1 Warrants [Member] | Risk Free Interest Rate [Member]
Fair value measurement input, warrant liability percentage		1.62
Series B1 Warrants [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Fair value measurement input, warrant liability percentage	1.62
Series B1 Warrants [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Fair value measurement input, warrant liability percentage	0.18
Series B1 Warrants [Member] | Expected Term [Member]
Fair value measurement input, warrant liability term		3 years 10 months 28 days
Series B1 Warrants [Member] | Expected Term [Member] | Maximum [Member]
Fair value measurement input, warrant liability term	2 years 4 months 17 days
Series B1 Warrants [Member] | Expected Term [Member] | Minimum [Member]
Fair value measurement input, warrant liability term	1 year 105 months
Series B1 Warrants [Member] | Expected Volatility [Member]
Fair value measurement input, warrant liability percentage	100	100
Series B1 Warrants [Member] | Expected Dividend Yield [Member]
Fair value measurement input, warrant liability percentage	0	0
Leapfrog Warrants [Member]
Fair value of warrants	$ 438,000		480,000
Change in fair value of derivative liability			$ 142,000
Warrants to purchase shares of common stock | shares		350,000
Leapfrog Warrants [Member] | Risk Free Interest Rate [Member]
Fair value measurement input, warrant liability percentage		1.62
Leapfrog Warrants [Member] | Risk Free Interest Rate [Member] | Maximum [Member]
Fair value measurement input, warrant liability percentage	1.62
Leapfrog Warrants [Member] | Risk Free Interest Rate [Member] | Minimum [Member]
Fair value measurement input, warrant liability percentage	0.18
Leapfrog Warrants [Member] | Expected Term [Member]
Fair value measurement input, warrant liability term		2 years 7 months 17 days
Leapfrog Warrants [Member] | Expected Term [Member] | Maximum [Member]
Fair value measurement input, warrant liability term	2 years 4 months 17 days
Leapfrog Warrants [Member] | Expected Term [Member] | Minimum [Member]
Fair value measurement input, warrant liability term	2 years 1 month 16 days
Leapfrog Warrants [Member] | Expected Volatility [Member]
Fair value measurement input, warrant liability percentage	100	100
Leapfrog Warrants [Member] | Expected Dividend Yield [Member]
Fair value measurement input, warrant liability percentage	0	0

Derivative Liability - Schedule

Derivative Liability - Schedule of Warrant Instruments (Details) - shares	Dec. 31, 2020	Dec. 31, 2019
Number of warrants issued	2,993,429	2,993,429
Series A Warrants [Member]
Number of warrants issued	267,535
Series A1 Warrants [Member]
Number of warrants issued	471,667
Series A2 Warrants [Member]
Number of warrants issued	813,364
Series B1 Warrants [Member]
Number of warrants issued	1,090,863
Leapfrog Warrants [Member]
Number of warrants issued	350,000

Derivative Liability - Schedu_2

Derivative Liability - Schedule of Warrant Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance as of beginning of period	$ 4,397,000	$ 5,442,000
Adjustment to fair value	(321,000)	(1,045,000)
Transfer to Equity	(4,076,000)
Balance as of end of period		4,397,000
Debenture Warrant Liabilities [Member]
Balance as of beginning of period	3,549,000	4,324,000
Adjustment to fair value	(245,000)	(775,000)
Transfer to Equity	(3,304,000)
Balance as of end of period		3,549,000
Leapfrog Warrant Liability [Member]
Balance as of beginning of period	480,000	622,000
Adjustment to fair value	(42,000)	(142,000)
Transfer to Equity	(438,000)
Balance as of end of period		480,000
Derivative Liability [Member]
Balance as of beginning of period	368,000	496,000
Adjustment to fair value	(34,000)	(128,000)
Transfer to Equity	(334,000)
Balance as of end of period		$ 368,000

Other Current Liabilities (Deta

Other Current Liabilities (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Contract liability	$ 4,842,000	$ 0
Estimated future liability	452,000	446,000
Other current liabilities	8,711,000	$ 537,000
Remaining balance of short term financing	573,000
LD Micro, Inc. [Member]
Other current liabilities	$ 2,735,000

Other Current Liabilities - Sch

Other Current Liabilities - Schedule of Other Current Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Other Liabilities Disclosure [Abstract]
Contract liabilities	$ 4,842,000
BIGToken point liability	452,000	446,000
Operating lease liabilities - current	109,000	91,000
Other current liabilities	3,308,000
Total other current liabilities	$ 8,711,000	$ 537,000

Paycheck Protection Program L_2

Paycheck Protection Program Loan (Details Narrative) - USD ($)	Apr. 17, 2020	Dec. 31, 2020	Sep. 15, 2020
LD Micro, Inc. [Member]
Payroll protection loan in connection with acquisition			$ 42,000
Paycheck Protection Program Loan [Member]
Unsecured loan	$ 1,084,000
Term loan	2 years
Interest rate	1.00%
Short term loan		$ 747,000
Long term loan		$ 379,000

Short Term Promissory Notes (De

Short Term Promissory Notes (Details Narrative) - USD ($)	Jun. 30, 2020	Jun. 30, 2020	Feb. 28, 2020	Dec. 31, 2020	Dec. 31, 2019	Jan. 30, 2020
Debt instrument, face amount				$ 9,386,000
Debt instrument, original issue discount				3,370,000
Fair value of the security shares				8,406,000	$ 50,000
Repayment of short-term note payable				2,130,000
Converted debt				1,118,000
Loss on extinguishment				(1,103,000)
Difference between face value and fair value						$ 95,000
Fair value of warrants				(321,000)	$ (1,045,000)
Notes payable
Accrued Interest [Member]
Converted debt		$ 184,000
Debentures [Member]
Convertible debt		788,000
Fair value of debenture	$ 815,000	815,000
Loss on extinguishment		(546,000)
Difference between face value and fair value	27,000	27,000
Fair value of warrants		424,000
Conversion premium	27,000	27,000
Short-Term Promissory Notes [Member]
Debt instrument, face amount			$ 450,000
Debt instrument, maturity date			May 12, 2020
Debt instrument, description				The notes are due and payable on May 12, 2020. The notes will accrue interest as follows: (i) on the origination date, ten percent (10%) of the principal amount was added to each note, (ii) on March 12, 2020, an additional ten percent (10%) of the principal amount was added to each note, and (iii) on April 12, 2020, an additional sixteen percent (16%) of the principal amount was added to each note.
Debt conversion, converted instrument, shares issued				450,000
Debt instrument, original issue discount				$ 45,000
Security shares				100,000
Fair value of the security shares				$ 181,000
Difference between face value and fair value	65,000	65,000		$ 65,000
Short-Term Promissory Notes [Member] | Accrued Interest [Member]
Converted debt	126,000
Short-Term Promissory Notes [Member] | Debentures [Member]
Convertible debt	541,000
Fair value of debenture	560,000	560,000
Loss on extinguishment	375,000
Difference between face value and fair value	19,000	19,000
Fair value of warrants	291,000
Conversion premium	18,000	$ 18,000
Short-Term Promissory Notes [Member] | Chief Financial Officer [Member]
Debt instrument, face amount			$ 100,000
Repayment of short-term note payable	$ 136,000

Term Loan Note (Details Narrati

Term Loan Note (Details Narrative) - USD ($)	May 02, 2020	Feb. 28, 2020	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Proceeds from notes payable				$ 2,130,000
Debt instrument, unused borrowing capacity, amount				$ 570,000	570,000
Exercise price of warrant				$ 3.60
Proceeds from issuance of warrant					$ 1,196,000
Warrants [Member]
Class of warrant issued		500,000
Exercise price of warrant		$ 3.60
Warrant expire date		Oct. 31, 2022
Proceeds from issuance of warrant		$ 83,000
Warrants [Member] | Maximum [Member]
Exercise price of warrant		$ 2.50
Warrants [Member] | Second Drawdown [Member]
Class of warrant issued		500,000
Term loan [Member]
Term loan, maximum borrowing capacity		$ 5,000,000
Proceeds from notes payable	$ 2,164,000	2,500,000
Debt instrument, unused borrowing capacity, amount		2,500,000
Debt instrument, additional borrowing capacity		$ 1,000,000
Debt instrument, interest rate		10.00%
Debt instrument, maturity date		Mar. 1, 2022
Debt instrument, payment term description		The Company will make monthly payments of principal and interest on an eighteen (18) month straight line amortization schedule, based on the principal outstanding on July 31, 2020. Additionally, the Company will have the option of a one (1) time payment-in-kind payment for a monthly required payment of principal and interest, which will defer such payments and result in a recalculation of the amortization schedule. In the event that the Company is late on any payments under the Loan, a late charge of three percent (3%) of the amount of the payment due will be assessed.
Debt instrument origination fee		$ 300,000
Attorneys fees		$ 35,000
Repayment of loan priciple and interest			$ 2,585,000
Outstanding loan

OID Convertible Debentures (Det

OID Convertible Debentures (Details Narrative)	Jun. 25, 2020USD ($)$ / sharesshares	Feb. 28, 2020USD ($)	Dec. 31, 2020USD ($)$ / sharesshares	Dec. 31, 2019USD ($)shares
Debt instrument, face amount			$ 9,386,000
Debt discount			3,370,000
Accounts receivable			2,608,000	$ 805,000
Accrued interest			$ 7,000
Warrants exercise price per share | $ / shares			$ 3.60
Repayment of short-term note payable			$ 2,130,000
Warrants to purchase common stock shares | shares			2,993,429	2,993,429
Proceeds from issuance of debt			$ 472,000
Amortization expenses			5,639,000
Debenture principal converted into common stock			1,118,000
Increase in additional paid in capital			$ 434,000
Class A Common Stock [Member]
Debt instrument, no. of shares issued upon conversion | shares			411,626
OID Convertible Debentures [Members]
Debt instrument, face amount	$ 16,101,000
Debt discount	$ 14,169,000
Original issue discount percentage	12.00%
Warrant to purchase common stock | shares	6,440,561
Purchase price	$ 13,000,000
Outstanding loan	1,169,000
Accounts receivable	510,000
Short term promissory notes	350,000
Accrued interest	$ 125,000
Debt instrument, interest rate	12.00%
Initial conversion price | $ / shares	$ 2.69
Warrants exercise price per share | $ / shares	$ 2.50
OID Convertible Debentures [Members]
Debt instrument, face amount			$ 15,313,000
Debt discount			1,237,000
Debt instrument, maturity date	Dec. 31, 2021
Debt instrument discription	Subject to the Company's compliance with certain equity conditions, upon ten trading days' notice to the Purchasers, the Company has the right to redeem the Debentures in cash at 115% of their outstanding principal, plus accrued interest. Additionally, in the event that (i) the Company sells or reprices any securities (each, a "Redemption Financing"), or (ii) the Company disposes of assets (except those sold or transferred in the ordinary course of business) (each, an "Asset Sale"), then the Purchasers shall have the right to cause the Company (a) in the event of a Redemption Financing at a price per Common Stock equivalent of $2.50 or less per share, the Purchasers may mandate that 100% of the proceeds be used to redeem the Debentures (b) in the event of a Redemption Financing at a price per Common Stock equivalent of greater than $2.50 per share, the Purchasers may mandate that up to 50% of the proceeds be used to redeem the Debentures, and (c) in the event of an Asset Sale, the Purchasers may mandate that up to 100% of the proceeds be used to redeem the Debentures.
Debt instrument, restrictive covenants	The Company is also subject to certain negative covenants (unless waived by 67% of the then outstanding Purchasers, and including the lead Purchaser) under the Debentures, including but not limited to, the creation of certain debt obligations, liens on Company assets, amending its charter documents, repayment or repurchase of securities or certain debt of the Company, or the payment of dividends.
Warrant or right, reason for issuance, description	Pursuant to the terms of the Debentures and Warrants, a Purchaser will not have the right to convert any portion of the Debentures or exercise any portion of the Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99% (at the Purchaser's option) of the number of shares of Common Stock outstanding immediately after giving effect to such conversion or exercise, as such percentage ownership is determined in accordance with the terms of the Debentures and the Warrants; provided that at the election of a holder and notice to us such percentage ownership limitation may be increased to 9.99%; provided that any increase will not be effective until the 61st day after such notice is delivered from the holder to the Company.
Payment of outstanding debt		$ 2,500,000
Repayment of short-term note payable		$ 136,000
Proceeds from issuance of debt			4,200,000
Proceeds from offering gross			13,000,000
Proceeds from offering, net			$ 9,100,000
OID Convertible Debentures [Members] | Securities Purchase Agreement [Member]
Warrant to purchase common stock | shares			478,854
Warrants exercise price per share | $ / shares			$ 3.3625
Estimated warrant issuance | shares			360,000
OID Convertible Debentures [Members] | Securities Purchase Agreement [Member] | Bradley Woods & Co. Ltd [Member]
Commission			$ 1,040,000
Warrants to purchase common stock shares | shares			478,854
OID Convertible Debentures [Members] | Securities Purchase Agreement [Member] | Risk Free Interest Rate [Member]
Fair value of warrant liability, measurement input, percentage			0.11
OID Convertible Debentures [Members] | Securities Purchase Agreement [Member] | Expected Term [Member]
Fair value assumption, warrant expected term			2 years 50 months 1 day
OID Convertible Debentures [Members] | Securities Purchase Agreement [Member] | Expected Volatility [Member]
Fair value of warrant liability, measurement input, percentage			96
OID Convertible Debentures [Members] | Securities Purchase Agreement [Member] | Expected Dividend Yield [Member]
Fair value of warrant liability, measurement input, percentage			0
OID Convertible Debentures [Members] | Prior to Closing date [Members]
Proceeds from issuance of debt			$ 3,800,000
OID Convertible Debentures [Members] | After the Closing date [Members]
Proceeds from issuance of debt			$ 5,000,000
OID Convertible Debentures [Members] | Accounts Receivable [Members]
Accrued interest	$ 184,000

OID Convertible Debentures - Sc

OID Convertible Debentures - Schedule of OID Convertible Debentures (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Principal	$ 9,386,000
Debt discount	(3,370,000)
Net book value	6,016,000
Issuance During the Year [Member]
Principal	16,101,000
Debt discount	(12,731,000)
Net book value	3,370,000
Extension [Member]
Principal	472,000
Debt discount
Net book value	472,000
Redemption [Member]
Principal	(6,069,000)
Debt discount	3,037,000
Net book value	(3,032,000)
Conversion [Member]
Principal	(1,118,000)
Debt discount	685,000
Net book value	(433,000)
Amortization [Member]
Principal
Debt discount	5,639,000
Net book value	$ 5,639,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)

Jul. 01, 2021

Apr. 01, 2021

Jan. 02, 2021

Sep. 15, 2020

Sep. 04, 2020

Jun. 30, 2020

Jan. 30, 2020

Jan. 22, 2020

Aug. 12, 2019

Feb. 29, 2020

Jan. 31, 2020

Aug. 31, 2019

Jul. 31, 2019

Apr. 30, 2019

Mar. 25, 2021

Dec. 31, 2020

Dec. 31, 2019

Class of Stock [Line Items]

Preferred stock shares authorized

50,000,000

50,000,000

Preferred stock par value

$ 0.001

$ 0.001

Common stock shares authorized

250,000,000

250,000,000

Common stock par value

$ 0.001

$ 0.001

Common stock shares issued

16,145,778

13,997,452

Common stock shares outstanding

16,145,778

13,997,452

Value of common stock shares issued for services

$ 374,000

Warrants to purchase common stock shares

2,993,429

2,993,429

Warrants exercise price per share

$ 3.60

Net proceeds from sales

$ 12,197,000

Compensation expense

1,852,000

$ 1,167,000

Debt owed original issue discount

3,370,000

Gross proceeds from placement agents and legal fees

$ 5,490,000

Net proceeds after cash payments placement agents and legal fees

4,968,000

Debenture principal converted into common stock

1,118,000

Increase in additional paid in capital

434,000

Subsequent Event [Member]

Class of Stock [Line Items]

Number of common stock shares sold

53,626

Proceeds from sale of stock

$ 2,832,000

Sale of stock price per share

$ 5.47

Proceeds from sale of securities

$ 16,000,000

LD Micro, Inc. [Member]

Class of Stock [Line Items]

Payment to acquire business

$ 1,000,000

$ 4,000,000

$ 7,610,000

LD Micro, Inc. [Member] | Forecast [Member]

Class of Stock [Line Items]

Payment to acquire business

$ 1,000,000

$ 1,000,000

LD Micro, Inc. [Member] | Subsequent Event [Member]

Class of Stock [Line Items]

Payment to acquire business

$ 1,000,000

Short-Term Notes [Member]

Class of Stock [Line Items]

Proceeds from sale of non-performing receivables

$ 450,000

Receivable description

The notes are redeemable by the Company at any time prior to maturity at face value plus a fee determined by the number of days the notes are outstanding. These fees range from 10% to 36% of the face value.

Non-Performing Receivables [Member]

Class of Stock [Line Items]

Proceeds from sale of non-performing receivables

$ 529,000

Purchase price of receivables

$ 510,000

Receivable description

we agreed to provide a true-up to the purchaser of the receivable of between 10% and 36% depending on the payment date. In the event of nonpayment of the receivables by March 24, 2020 and March 30, 2020, as applicable to the receivables, the purchaser may require us to purchase any outstanding portion of the receivables for 136% of its outstanding balance (“Payment Date”).

Placement Agent Agreement [Member]

Class of Stock [Line Items]

Warrants to purchase common stock shares

101,270

Warrants exercise price per share

$ 5

Cash fee percentage

7.00%

Reimbursement of offering related expense

$ 50,000

Settlement Agreement [Member] | Lender [Member[

Class of Stock [Line Items]

Number of common stock shares canceled, issued as collateral

220,000

Debt owed original issue discount

$ 150,000

Stock issued original issue discount, shares

58,101

Stock issued original issue discount

$ 219,000

PA Agreements [Member]

Class of Stock [Line Items]

Proceeds from sale of securities

$ 60,000

Percentage of sale of securities

6.00%

Description for registered direct offering and private placement

In connection with the Registered Direct Offering and the Private Placement, the Company entered into engagement agreements (the "PA Agreements") with The Special Equities Group, LLC, a division of Bradley Woods & Co. Ltd., and WestPark Capital, Inc. (the "Placement Agents") on August 11, 2019 and August 9, 2019, respectively. Pursuant to the PA Agreements, the Placement Agents received (i) aggregate cash fees of 7.0% for one Placement Agent or 8.0% for the other Placement Agent, of their respective portions of the gross proceeds received by the Company from the sale of the securities, (ii) approximately $60,000 for certain expenses, and (iii) warrants to purchase up to 59,668 shares of Common Stock (the "Placement Agent Warrants"), representing 6.0% of the Common Stock and Series B Warrants sold by one of the Placement Agents in the Registered Direct Offering. The Placement Agent Warrants have substantially the same terms as the Series B Warrants, except that the exercise price of the Placement Agent Warrants is $4.50 per share and has a four (4) year term beginning one (1) year after issuance. Additionally, upon the exercise of up to 1,027,778 Series A Warrants, 650,701 Series B Warrants, and 1,027,778 Series C Warrants sold Registered Direct Offering and Private Placement, we have agreed to pay one of the Placement Agents a cash fee of 8% of proceeds from the exercise of such warrants exercised within 120 days following the closing of this offering or a cash fee of 5% of the proceeds from the exercise of such warrants after such 120 day period following the closing of this offering. One of the Placement Agents will be entitled to the foregoing cash commission and fee in the previous sentence with respect to certain investors if such investors provide capital to us in any future private or public offering, or other financing or capital-raising transaction during the six (6) months following the expiration or termination of our engagement of such Placement Agent.

PA Agreements [Member] | One Placement Agent [Member]

Class of Stock [Line Items]

Cash fee percentage

7.00%

PA Agreements [Member] | Other Placement Agent [Member]

Class of Stock [Line Items]

Cash fee percentage

8.00%

PA Agreements [Member] | Placement Agent Warrants [Member]

Class of Stock [Line Items]

Warrants to purchase common stock shares

59,668

Warrants exercise price per share

$ 4.50

Warrants term

4 years

Common Stock [Member]

Class of Stock [Line Items]

Number of common stock shares issued for services

75,000

Value of common stock shares issued for services

Number of common stock shares sold

1,687,825

Proceeds from sale of stock

$ 6,751,300

Sale of stock price per share

$ 4

Net proceeds from sales

$ 6,229,000

Placement agent fees

$ 523,000

Common stock shares issued as compensation

75,000

Fair value of compensation shares issued

$ 374,000

Compensation expense

$ 235,000

Series 1 Preferred Stock [Member]

Class of Stock [Line Items]

Preferred stock shares authorized

200,000

Class A Common Stock [Member]

Class of Stock [Line Items]

Common stock shares authorized

250,000,000

Common stock par value

$ 0.001

Debt instrument, no. of shares issued upon conversion

411,626

Class A Common Stock [Member] | LD Micro, Inc. [Member]

Class of Stock [Line Items]

Number of shares issued in acquisition

1,600,000

Class B Common Stock [Member]

Class of Stock [Line Items]

Common stock shares authorized

9,000,000

Common stock par value

$ 0.001

Class A Common Stock [Member]

Class of Stock [Line Items]

Common stock par value

$ 0.001

Warrants to purchase common stock shares

1,525,000

Number of common stock shares sold

29,519

239,029

1,525,000

Debt instrument, no. of shares issued upon conversion

411,626

Class A Common Stock [Member] | Short-Term Notes [Member]

Class of Stock [Line Items]

Number of shares pledged for repurchase of receivables

100,000

450,000

Class A Common Stock [Member] | Non-Performing Receivables [Member]

Class of Stock [Line Items]

Number of shares pledged for repurchase of receivables

36,700

239,029

Series A Warrants [Member]

Class of Stock [Line Items]

Warrants to purchase common stock shares

965,500

Warrants exercise price per share

$ 3.60

Warrants term

90 months

Series A Warrants [Member] | PA Agreements [Member]

Class of Stock [Line Items]

Number of warrants exercised

1,027,778

Series B Warrants [Member] | Investors [Member] | Private Placement [Member]

Class of Stock [Line Items]

Warrants to purchase common stock shares

1,525,000

Series B Warrants [Member] | PA Agreements [Member]

Class of Stock [Line Items]

Number of warrants exercised

650,701

Series C Warrants [Member] | Investors [Member] | Private Placement [Member]

Class of Stock [Line Items]

Warrants to purchase common stock shares

965,500

Series C Warrants [Member] | PA Agreements [Member]

Class of Stock [Line Items]

Number of warrants exercised

1,027,778

Series B Warrants and Series C Warrants [Member]

Class of Stock [Line Items]

Warrants exercise price per share

$ 4

Warrants term

6 months

Warrants expiration date

Oct. 1, 2022

Stock Options, Awards and War_3

Stock Options, Awards and Warrants (Details Narrative) - USD ($)	Nov. 30, 2020	Aug. 31, 2020	May 13, 2020	Feb. 23, 2017	Apr. 30, 2020	Apr. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Feb. 28, 2020	Aug. 12, 2019	Nov. 05, 2015	Jan. 31, 2013
Warrants to purchase common stock shares								2,993,429	2,993,429
Warrants exercise price per share								$ 3.60
Number of options terminated								316,367	51,395
Share-based payment award, fair value of options					$ 60,000	$ 60,000
Option term					7 years	7 years
Implied volatility					100.00%	102.00%
Risk free equivalent yield					24.00%	2.46%
Stock price					$ 1.95	$ 5.49
Compensation expense								$ 1,852,000	$ 1,167,000
Unrecognized compensation cost								1,667,000
Weighted average period vested								$ 1,667,000
Weighted average vested term								3 years
Warrants [Member]
Warrants exercise price per share										$ 3.60
Consulting Agreement [Member]
Number of options terminated								1,073,201	1,631,435
Consulting Agreement [Member] | Warrants [Member]
Number of option vested			300,000
Share-based payment award, fair value of options			$ 1,138,332
Option term			5 years
Implied volatility			101.00%
Risk free equivalent yield			1.80%
Stock price			$ 4.99
Stock Option [Member]
Compensation expense								$ 1,852,000	$ 1,167,000
Employees and Members of Management Team [Member]
Warrants to purchase common stock shares	300,000	430,000					685,000
Warrants exercise price per share	$ 2.97	$ 2.70					$ 3.42
Fair value of warrant option grant date	$ 649,000	$ 859,000					$ 1,513,137
Option vesting period		5 years
Non-Executive Directors [Member]
Number of common shares option to purchase					36,172	11,252
Shares issued price per share					$ 1.95	$ 5.49
Number of option vested					9,043	2,813
Option expiration date					Apr. 15, 2027	Apr. 15, 2026
Class A Common Stock [Member]
Warrants to purchase common stock shares											1,525,000
2012 Equity Compensation Plan [Member] | Class A Common Stock [Member]
Number of shares authorized													600,000
2014 Equity Compensation Plan [Member] | Class A Common Stock [Member]
Number of shares authorized												600,000
2016 Equity Compensation Plan [Member] | Class A Common Stock [Member]
Number of shares authorized				600,000
Minimum percentage of fair market value				100.00%
Threshold of employee ownership for increase in fair market value and decrease in maximum life				10.00%
Minimum percentage of fair market value for eligible employee				110.00%
Maximum fair market value underlying options exercisable by any option holder during any calendar year				$ 100,000
Maximum option life				10 years
Maximum option life for 10% holder				5 years

Stock Options, Awards and War_4

Stock Options, Awards and Warrants - Schedule of Vested and Nonvested Stock Option (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Number of Shares, Outstanding Beginning balance	1,192,519	547,662
Number of Shares, Granted	766,172	696,252
Number of Shares, Exercised
Number of Shares, Forfeited	(316,367)	(51,395)
Number of Shares, Outstanding Ending balance	1,642,324	1,192,519
Number of Shares, Vested and exercisable Ending balance	844,742	355,083
Number of Shares, Unvested and non-exercisable Ending balance	797,582	837,436
Weighted Average Strike Price/Share, Outstanding Beginning balance	$ 4.14	$ 5.94
Weighted Average Strike Price/Share, Granted	2.77	3.45
Weighted Average Strike Price/Share, Exercised
Weighted Average Strike Price/Share, Forfeited	5.14	6.92
Weighted Average Strike Price/Share, Outstanding Ending balance	3.30	4.14
Weighted Average Strike Price/Share, Vested and exercisable Ending balance	3.54	5.63
Weighted Average Strike Price/Share, Unvested and non-exercisable Ending balance	$ 2.81	$ 3.49
Weighted Average Remaining Contractual Term (Years), Outstanding Beginning balance	2 years 2 months 1 day	2 years 8 months 23 days
Weighted Average Remaining Contractual Term (Years), Granted	3 years	2 years 4 months 2 days
Weighted Average Remaining Contractual Term (Years), Outstanding Ending balance	2 years 9 months 22 days	2 years 2 months 1 day
Weighted Average Remaining Contractual Term (Years), Vested and exercisable Ending balance	2 years 7 months 13 days	2 years 2 months 19 days
Weighted Average Remaining Contractual Term (Years), Unvested and non-exercisable Ending balance	3 years	2 years 1 month 24 days
Aggregate Intrinsic Value, Outstanding Beginning balance
Aggregate Intrinsic Value, Granted	$ 521,000
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited
Aggregate Intrinsic Value, Outstanding Ending balance
Aggregate Intrinsic Value, Vested and exercisable Ending balance	333,000
Aggregate Intrinsic Value, Unvested and non-exercisable Ending balance	$ 207,000
Weighted Average Grant Date Fair Value, Outstanding Beginning balance
Weighted Average Grant Date Fair Value, Granted	2.72	2.25
Weighted Average Grant Date Fair Value, Exercised
Weighted Average Grant Date Fair Value, Forfeited	3.14	3.37
Weighted Average Grant Date Fair Value, Outstanding Ending balance
Weighted Average Grant Date Fair Value, Vested and exercisable Ending balance	3.54	3.98
Weighted Average Grant Date Fair Value, Unvested and non-exercisable Ending balance	$ 2.09	$ 2.29
Consulting Agreement [Member]
Number of Shares, Outstanding Beginning balance	6,237,430	4,325,423
Number of Shares, Granted	7,421,054	3,885,442
Number of Shares, Exercised		(342,000)
Number of Shares, Forfeited	(1,073,201)	(1,631,435)
Number of Shares, Outstanding Ending balance	12,585,283	6,237,430
Number of Shares, Vested and exercisable Ending balance	12,285,283	5,937,430
Number of Shares, Unvested and non-exercisable Ending balance	300,000	300,000
Weighted Average Strike Price/Share, Outstanding Beginning balance	$ 3.57	$ 5.05
Weighted Average Strike Price/Share, Granted	2.63	3.99
Weighted Average Strike Price/Share, Exercised		3.50
Weighted Average Strike Price/Share, Forfeited		5.14
Weighted Average Strike Price/Share, Outstanding Ending balance	2.98	3.57
Weighted Average Strike Price/Share, Vested and exercisable Ending balance	2.94	3.51
Weighted Average Strike Price/Share, Unvested and non-exercisable Ending balance	$ 4.75	$ 4.75
Weighted Average Remaining Contractual Term (Years), Outstanding Beginning balance	2 years 8 months 5 days	2 years 10 months 6 days
Weighted Average Remaining Contractual Term (Years), Granted	1 year 9 months 25 days	2 years 2 months 16 days
Weighted Average Remaining Contractual Term (Years), Outstanding Ending balance	1 year 9 months 11 days	2 years 8 months 5 days
Weighted Average Remaining Contractual Term (Years), Vested and exercisable Ending balance	1 year 8 months 26 days	2 years 7 months 6 days
Weighted Average Remaining Contractual Term (Years), Unvested and non-exercisable Ending balance	3 years 4 months 13 days	4 years 5 months 5 days
Aggregate Intrinsic Value, Outstanding Beginning balance
Aggregate Intrinsic Value, Granted	$ 3,929,000	$ 94,910
Aggregate Intrinsic Value, Exercised
Aggregate Intrinsic Value, Forfeited
Aggregate Intrinsic Value, Outstanding Ending balance	$ 4,460,000
Aggregate Intrinsic Value, Vested and exercisable Ending balance	4,460,000
Aggregate Intrinsic Value, Unvested and non-exercisable Ending balance
Weighted Average Grant Date Fair Value, Outstanding Beginning balance
Weighted Average Grant Date Fair Value, Granted	1.38	1.60
Weighted Average Grant Date Fair Value, Exercised		4.79
Weighted Average Grant Date Fair Value, Forfeited		1.97
Weighted Average Grant Date Fair Value, Outstanding Ending balance	1.38
Weighted Average Grant Date Fair Value, Vested and exercisable Ending balance	1.38	2.34
Weighted Average Grant Date Fair Value, Unvested and non-exercisable Ending balance		$ 3.88

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Changes in valuation allowance	$ 2,442,000	$ 4,283,000
Federal net operating losses carryforwards	31,439,000
State net operating losses carryforwards	$ 36,679,000
Operating loss carry-forward expiration dates, federal	Dec. 31, 2032
Operating loss carryforwards expiration date, state	Dec. 31, 2032
Unrecognized tax benefits
Accruals for interest and penalties related to unrecognized tax benefits
NOL carryforwards, description	The Company is in the process of analyzing their NOL and has not determined if the company has had any change of control issues that could limit the future use of NOL. NOL carryforwards that were generated after 2017 of approximately $20.1 million may only be used to offset 80% of taxable income and are carried forward indefinitely.
NOL carryforwards	$ 20,100,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax (Benefit) Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Current Federal
Current State	26,000
Current Subtotal	26,000
Current Valuation allowance
Current Total	26,000
Deferred Federal		(3,198,000)
Deferred State		(920,000)
Deferred Subtotal		(4,118,000)
Deferred Valuation allowance		4,118,000
Deferred Total
Federal		(3,198,000)
State	26,000	(920,000)
Subtotal	26,000	(4,118,000)
Valuation allowance		4,118,000
Total	$ 26,000

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Tax Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Taxes calculated at federal rate	21.00%	21.00%
Stock based compensation	(2.70%)	(1.40%)
Permanent Differences	(13.41%)	0.00%
Change in Valuation Allowance	(2.50%)	(23.70%)
Fair market adjustment derivatives	0.50%	1.30%
Prior year True-ups	(3.30%)	3.00%
Other adjustments	(0.10%)	(0.20%)
Provision for income taxes	(0.20%)	0.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Deferred Tax Assets: Net operating loss carryforwards	$ 9,040,000	$ 6,621,000
Deferred Tax Assets: Bad debt expense	136,000	111,000
Deferred Tax Assets: Fixed assets	9,000
Deferred Tax Assets: Accrued interest		492,000
Deferred Tax Assets: Stock based compensation	567,000	431,000
Deferred Tax Assets: Interest expense limitation carryover	629,000
Deferred Tax Assets: Contribution carryover	5,000
Deferred Tax Assets: Lease liability	97,000
Deferred Tax Assets: Other accruals	192,000	84,000
Total Deferred Tax Assets	10,675,000	7,739,000
Deferred Tax Liabilities: Fixed assets		(39,000)
Deferred Tax Liabilities: Right-of-use asset	(101,000)
Deferred Tax Liabilities: Unrealized gain on marketable securities	(72,000)
Deferred Tax Liabilities: Intangibles	(690,000)	(327,000)
Deferred Tax Liabilities: Prepaid expenses	(17,000)	(20,000)
Total Deferred Tax Liabilities	(880,000)	(386,000)
Net Deferred Tax Assets	9,795,000	7,353,000
Valuation Allowance	(9,795,000)	(7,353,000)
Net deferred tax / (liabilities)

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Schedule of Assets and Liabilities Measured at Fair Value On Recurring Basis (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	$ 8,447,000	$ 83,000
Debenture warrant liability		3,549,000
Leapfrog warrant liability		480,000
Derivative liability		368,000
Total liabilities		4,397,000
Fair Value, Measurements, Recurring [Member] | Quoted Prices in Active Markets for Identical Assets (Level1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	7,764,000	83,000
Debenture warrant liability
Leapfrog warrant liability
Derivative liability
Total liabilities
Fair Value, Measurements, Recurring [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	683,000
Debenture warrant liability
Leapfrog warrant liability
Derivative liability
Total liabilities
Fair Value, Measurements, Recurring [Member] | Significant Unobservable Inputs (Level3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets
Debenture warrant liability		3,549,000
Leapfrog warrant liability		480,000
Derivative liability		368,000
Total liabilities		4,397,000
Fair Value, Measurements, Recurring [Member] | Marketable Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	8,447,000	83,000
Fair Value, Measurements, Recurring [Member] | Marketable Securities [Member] | Quoted Prices in Active Markets for Identical Assets (Level1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	7,764,000	83,000
Fair Value, Measurements, Recurring [Member] | Marketable Securities [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets	683,000
Fair Value, Measurements, Recurring [Member] | Marketable Securities [Member] | Significant Unobservable Inputs (Level3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Total assets

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Reconciliation of Derivative and Warrant Liability Measured at Fair Value on Level 3 (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Fair Value Disclosures [Abstract]
Outstanding, beginning of the period	$ 4,397,000	$ 5,442,000
Change in fair value	$ (321,000)	(1,045,000)
Warrant liabilities		$ 4,397,000

Segment Reporting - (Details Na

Segment Reporting - (Details Narrative)	12 Months Ended
	Dec. 31, 2020USD ($)segment	Dec. 31, 2019USD ($)
Number of operating segments | segment	2
Goodwill	$ 23,351,000	$ 15,645,000
Revenue contract liabilities	4,842,000	$ 0
SEQUIRE [Member]
Goodwill	10,200,000
BIGToken [Member]
Goodwill	$ 5,445,000

Segment Reporting - Schedule of

Segment Reporting - Schedule of Revenue and Gross Profit by Reportable Segment (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total Revenue	$ 8,647,000	$ 3,584,000
Cost of Revenue	2,589,000	1,680,000
Gross profit	6,058,000	1,904,000
Platform Revenue [Member]
Total Revenue	5,781,000	87,000
Conference Revenues [Member]
Total Revenue	503,000
BIGtoken Revenue [Member]
Total Revenue	2,168,000	3,228,000
Other [Member]
Total Revenue	195,000	269,000
SEQUIRE [Member]
Total Revenue	6,284,000	87,000
Cost of Revenue	1,783,000	7,000
Gross profit	4,501,000	80,000
SEQUIRE [Member] | Platform Revenue [Member]
Total Revenue	5,781,000	87,000
SEQUIRE [Member] | Conference Revenues [Member]
Total Revenue	503,000
SEQUIRE [Member] | BIGtoken Revenue [Member]
Total Revenue
SEQUIRE [Member] | Other [Member]
Total Revenue
BIGToken [Member]
Total Revenue	2,168,000	3,228,000
Cost of Revenue	800,000	1,613,000
Gross profit	1,368,000	1,615,000
BIGToken [Member] | Platform Revenue [Member]
Total Revenue
BIGToken [Member] | Conference Revenues [Member]
Total Revenue
BIGToken [Member] | BIGtoken Revenue [Member]
Total Revenue	2,168,000	3,228,000
BIGToken [Member] | Other [Member]
Total Revenue
Corporate and Other [Member]
Total Revenue	195,000	269,000
Cost of Revenue	6,000	60,000
Gross profit	189,000	209,000
Corporate and Other [Member] | Platform Revenue [Member]
Total Revenue
Corporate and Other [Member] | Conference Revenues [Member]
Total Revenue
Corporate and Other [Member] | BIGtoken Revenue [Member]
Total Revenue
Corporate and Other [Member] | Other [Member]
Total Revenue	$ 195,000	$ 269,000

Segment Reporting - Schedule _2

Segment Reporting - Schedule of Revenue Disaggregation (Details) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Total Revenue	$ 8,647,000	$ 3,584,000
Platform Revenue [Member]
Total Revenue	5,781,000	87,000
Conference Revenues [Member]
Total Revenue	503,000
Other [Member]
Total Revenue	195,000	269,000
SEQUIRE [Member]
Total Revenue	6,284,000	87,000
SEQUIRE [Member] | Platform Revenue [Member]
Total Revenue	5,781,000	87,000
SEQUIRE [Member] | Conference Revenues [Member]
Total Revenue	503,000
SEQUIRE [Member] | Other [Member]
Total Revenue
BIGToken [Member]
Total Revenue	2,168,000	3,228,000
BIGToken [Member] | Platform Revenue [Member]
Total Revenue
BIGToken [Member] | Conference Revenues [Member]
Total Revenue
BIGToken [Member] | Consumer Media / Data [Member]
Total Revenue	2,168,000	3,228,000
BIGToken [Member] | Other [Member]
Total Revenue

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)	Mar. 12, 2021	Feb. 28, 2021	Feb. 21, 2021	Feb. 04, 2021	Jan. 27, 2021	Oct. 31, 2020	Apr. 30, 2019	Mar. 31, 2021	Mar. 25, 2021	Dec. 31, 2020	Dec. 31, 2019
Warrants to purchase common stock shares										2,993,429	2,993,429
Warrants exercise price per share										$ 3.60
Gross proceeds from warrant exercises											$ 1,196,000
Preferred stock share outstanding
Common Stock [Member]
Number of common shares sold							1,687,825
Shares sold price per share							$ 4
Conversion of convertible securities										411,626
Sale of stock, value							$ 6,751,300
Subsequent Event [Member]
Number of common shares sold									53,626
Shares sold price per share									$ 5.47
Proceeds from sale of stock									$ 293,000
Sale of stock percenage									5.00%
Sale of stock, value									$ 2,832,000
Subsequent Event [Member] | OID Convertible Debenture Conversions [Member]
Conversion of convertible securities								2,000,000
Subsequent Event [Member] | Lou Kerner [Member]
Shares issued purchase plan		13,951,066,447
Weighted average exercise price subject to vesting		$ 0.000062719
Share Exchange Agreement [Member] | Force Video Protection Equipment Corp. [Member] | Subsequent Event [Member]
Equity ownership percentage				100.00%
Share Exchange Agreement [Member] | Force Video Protection Equipment Corp. [Member] | Subsequent Event [Member] | Series A Preferred Stock [Membe]
Number of common shares sold				5,000,000
Share Exchange Agreement [Member] | Force Video Protection Equipment Corp. [Member] | Subsequent Event [Member] | Common Stock [Member]
Number of common shares sold				149,562,566,584
Share Exchange Agreement [Member] | BIG Token, Inc. [Member] | Subsequent Event [Member] | Series A Preferred Stock [Membe]
Number of common shares sold				5,000,000
Share Exchange Agreement [Member] | BIG Token, Inc. [Member] | Subsequent Event [Member] | Common Stock [Member]
Number of common shares sold				149,562,566,584
Amendment to Share Exchange Agreement [Member] | Force Video Protection Equipment Corp. [Member] | Subsequent Event [Member]
Equity ownership percentage					70.00%
Amendment to Share Exchange Agreement [Member] | Force Video Protection Equipment Corp. [Member] | Subsequent Event [Member] | Maximum [Member]
Number of common shares sold					10,000,000
Letter Agreements [Member] | Subsequent Event [Member] | Bradely Woods & Co. Ltd [Member]
Cash fee payable			$ 909,088
Gross proceeds from warrant exercises			$ 11,932,000
Letter Agreements [Member] | Subsequent Event [Member] | Existing Warrants [Member]
Warrants exercise price per share			$ 2.50
Letter Agreements [Member] | Subsequent Event [Member] | Existing Warrants [Member] | Class A Common Stock [Member] | Maximum [Member]
Warrants to purchase common stock shares			4,545,550
Letter Agreements [Member] | Subsequent Event [Member] | New Warrants [Member]
Warrants exercise price per share			$ 7.50
Warrants expiration date			Jan. 31, 2022
Letter Agreements [Member] | Subsequent Event [Member] | New Warrants [Member] | Each Investor [Member]
Warrants exercise price per share			$ 0.125
Letter Agreements [Member] | Subsequent Event [Member] | New Warrants [Member] | Maximum [Member]
Warrants to purchase common stock shares			4,545,440
Securities Purchaser Agreements and Registration Rights Agreements [Member] | Force Video Protection Equipment Corp. [Member] | Series B preferred Stock [Member] | Investors [Member]
Number of common shares sold						10,500
Share sold value						$ 1,050,000
Securities Purchaser Agreements and Registration Rights Agreements [Member] | Force Video Protection Equipment Corp. [Member] | Subsequent Event [Member] | Series B preferred Stock [Member] | Investors [Member]
Number of common shares sold	47,248.27
Share sold value	$ 4,724,827
Shares sold price per share	$ 100
Preferred stock share outstanding	57,748.27
Sales Agent Commissions [Member] | Subsequent Event [Member]
Proceeds from sale of stock									$ 284,000